array:24 [
  "pii" => "S0001731023006397"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2023.08.002"
  "estado" => "S300"
  "fechaPublicacion" => "2023-10-01"
  "aid" => "3623"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2023"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "rev"
  "cita" => "Actas Dermosifiliogr. 2023;114:T784-T801"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731023003976"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.05.016"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3506"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "pgl"
    "cita" => "Actas Dermosifiliogr. 2023;114:802-11"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">DOCUMENTO DE CONSENSO</span>"
      "titulo" => "Recomendaciones del Grupo de Psoriasis de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a sobre el manejo del paciente de edad avanzada con psoriasis en placas moderada-grave"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "802"
          "paginaFinal" => "811"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Moderate to Severe Psoriasis in Older Adults&#58; Recommendations on Management from the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology &#40;AEDV&#41;"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46; Mataix, L&#46; Garc&#237;a, I&#46; Belinch&#243;n, J&#46;C&#46; Ruiz Carrascosa, P&#46; de la Cueva, J&#46;M&#46; Carrascosa"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Mataix"
            ]
            1 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Garc&#237;a"
            ]
            2 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Belinch&#243;n"
            ]
            3 => array:2 [
              "nombre" => "J&#46;C&#46;"
              "apellidos" => "Ruiz Carrascosa"
            ]
            4 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "de la Cueva"
            ]
            5 => array:2 [
              "nombre" => "J&#46;M&#46;"
              "apellidos" => "Carrascosa"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023003976?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023003976/v1_202310020456/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731023004969"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.06.012"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3553"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "rev"
    "cita" => "Actas Dermosifiliogr. 2023;114:784-801"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
      "titulo" => "Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:3 [
        0 => "en"
        1 => "en"
        2 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "784"
          "paginaFinal" => "801"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Perfil de seguridad a largo plazo y usos fuera de indicaci&#243;n de los inhibidores de JAK en dermatolog&#237;a"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0005"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 1085
              "Ancho" => 832
              "Tamanyo" => 133126
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "L&#46; Corbella-Bagot, C&#46; Riquelme-McLoughlin, D&#46; Morgado-Carrasco"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Corbella-Bagot"
            ]
            1 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Riquelme-McLoughlin"
            ]
            2 => array:2 [
              "nombre" => "D&#46;"
              "apellidos" => "Morgado-Carrasco"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0005"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004969?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023004969/v1_202310020456/en/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731023004969"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2023.06.012"
      "estado" => "S300"
      "fechaPublicacion" => "2023-10-01"
      "aid" => "3553"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "rev"
      "cita" => "Actas Dermosifiliogr. 2023;114:784-801"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:14 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
        "titulo" => "Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:3 [
          0 => "en"
          1 => "en"
          2 => "es"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "784"
            "paginaFinal" => "801"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Perfil de seguridad a largo plazo y usos fuera de indicaci&#243;n de los inhibidores de JAK en dermatolog&#237;a"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "es" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 1
          "multimedia" => array:5 [
            "identificador" => "fig0005"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => false
            "mostrarDisplay" => true
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "fx1.jpeg"
                "Alto" => 1085
                "Ancho" => 832
                "Tamanyo" => 133126
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "L&#46; Corbella-Bagot, C&#46; Riquelme-McLoughlin, D&#46; Morgado-Carrasco"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "L&#46;"
                "apellidos" => "Corbella-Bagot"
              ]
              1 => array:2 [
                "nombre" => "C&#46;"
                "apellidos" => "Riquelme-McLoughlin"
              ]
              2 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Morgado-Carrasco"
              ]
            ]
          ]
        ]
        "resumen" => array:1 [
          0 => array:3 [
            "titulo" => "Graphical abstract"
            "clase" => "graphical"
            "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0005"></elsevierMultimedia></p></span>"
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004969?idApp=UINPBA000044"
      "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023004969/v1_202310020456/en/main.assets"
    ]
  ]
  "es" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">REVISI&#211;N</span>"
    "titulo" => " Perfil de seguridad a largo plazo y usos fuera de indicaci&#243;n de los inhibidores de JAK en dermatolog&#237;a"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "T784"
        "paginaFinal" => "T801"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "L&#46; Corbella-Bagot, C&#46; Riquelme-McLoughlin, D&#46; Morgado-Carrasco"
        "autores" => array:3 [
          0 => array:3 [
            "nombre" => "L&#46;"
            "apellidos" => "Corbella-Bagot"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "C&#46;"
            "apellidos" => "Riquelme-McLoughlin"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          2 => array:4 [
            "nombre" => "D&#46;"
            "apellidos" => "Morgado-Carrasco"
            "email" => array:1 [
              0 => "morgadodaniel8@gmail.com"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital Cl&#237;nic de Barcelona&#44; Universitat de Barcelona&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital de Figueres&#44; Fundaci&#243; Salut Empord&#224;&#44; Figueres&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 1
      "multimedia" => array:5 [
        "identificador" => "fig0005"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 1085
            "Ancho" => 857
            "Tamanyo" => 134049
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Introducci&#243;n</span><p id="par0005" class="elsevierStylePara elsevierViewall">En los &#250;ltimos a&#241;os&#44; el campo de la dermatolog&#237;a ha experimentado avances significativos con el desarrollo de m&#250;ltiples f&#225;rmacos biol&#243;gicos y peque&#241;as mol&#233;culas que act&#250;an selectivamente sobre mol&#233;culas espec&#237;ficas del sistema inmunitario&#46; Una v&#237;a de se&#241;alizaci&#243;n especialmente notable&#44; implicada tanto en la inmunidad innata como en la adaptativa&#44; es la v&#237;a Janus quinasa&#47;transductor de se&#241;al y activador de la transcripci&#243;n &#40;JAK-STAT&#41;&#46; Esta &#250;ltima implica tirosina quinasas intracelulares denominadas Janus quinasas &#40;JAK&#41;&#44; que se componen de cuatro isoformas&#58; JAK1&#44; JAK2&#44; JAK3 y TYK2&#46; Los inhibidores de JAK act&#250;an suprimiendo de forma reversible la fosforilaci&#243;n de las JAK mediante la ocupaci&#243;n del sitio catal&#237;tico de uni&#243;n al ATP<a class="elsevierStyleCrossRef" href="#bib0525"><span class="elsevierStyleSup">1</span></a>&#46; Aunque los inhibidores de JAK m&#225;s selectivos pueden evitar los efectos adversos asociados a las isoformas JAK no bloqueadas&#44; las implicaciones de esta selectividad para la seguridad a largo plazo siguen sin estar claras<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">2</span></a>&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">El upadacitinib y el abrocitinib orales &#40;inhibidores selectivos de JAK 1&#41;&#44; as&#237; como el baricitinib oral y el ruxolitinib t&#243;pico &#40;inhibidores de JAK1&#47;2&#41; han sido aprobados por la Administraci&#243;n de Alimentos y Medicamentos de EE&#46; UU&#46; &#40;FDA&#41; y&#47;o la Agencia Europea de Medicamentos &#40;EMA&#41; para varias indicaciones dermatol&#243;gicas &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41;&#46; En este estudio&#44; pretendemos revisar el perfil de seguridad a largo plazo de estos inhibidores de JAK en dermatolog&#237;a y describir su uso fuera de ficha t&#233;cnica en diversos trastornos cut&#225;neos&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">M&#233;todos</span><p id="par0015" class="elsevierStylePara elsevierViewall">Se realiz&#243; una revisi&#243;n narrativa de la literatura&#46; Se efectuaron b&#250;squedas bibliogr&#225;ficas en PubMed y Google Scholar desde enero de 2000 hasta enero de 2023 utilizando las palabras clave &#171;<span class="elsevierStyleItalic">Janus kinase inhibitors</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">JAK inhibitors</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">off-label</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">dermatology</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">safety</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">adverse events</span>&#187;&#44; &#171;ruxolitinib&#187;&#44; &#171;upadacitinib&#187;&#44; &#171;abrocitinib&#187; y &#171;baricitinib&#187;&#46; Tambi&#233;n se incluyeron las enfermedades inflamatorias cut&#225;neas en la estrategia de b&#250;squeda&#58; &#171;<span class="elsevierStyleItalic">granuloma annulare</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">histiocytosis</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">sarcoidosis</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">morphea</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">livedoid vasculopathy</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">Sweet syndrome</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">VEXAS syndrome</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">hypereosinophilic syndrome</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">Kimura disease</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">acrodermatitis continua of Hallopeau</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">erythema multiforme</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">DRESS syndrome</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">Steven Johnson syndrome</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">toxic epidermal necrolysis</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">autoinflammatory diseases</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">panniculitis</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">cutaneous vasculitis</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">cutaneous lupus</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">lichen planus</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">graft versushost disease</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">Still disease</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">necrobiosis lipoidica</span>&#187; y &#171;<span class="elsevierStyleItalic">chronic nodular prurigo</span>&#187;&#46; La estrategia de b&#250;squeda incluy&#243; ensayos cl&#237;nicos&#44; metaan&#225;lisis&#44; estudios observacionales&#44; series y reportes de casos&#44; y se restringi&#243; a art&#237;culos en ingl&#233;s y espa&#241;ol&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Resultados</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Perfil de seguridad a largo plazo</span><p id="par0020" class="elsevierStylePara elsevierViewall">Los inhibidores de JAK suelen asociarse a diversos acontecimientos adversos&#46; Entre ellos&#44; se incluyen citopenias&#44; infecciones urinarias y del tracto respiratorio superior&#44; reactivaci&#243;n del virus del herpes&#44; n&#225;useas&#44; diarrea&#44; cefalea&#44; alteraci&#243;n de las pruebas de funci&#243;n hep&#225;tica&#44; hipercolesterolemia y aumento de la creatinfosfoquinasa &#40;CPK&#41;<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">3</span></a>&#46; Los acontecimientos adversos m&#225;s graves y poco frecuentes incluyen los eventos tromboemb&#243;licos&#44; la reactivaci&#243;n del virus de la hepatitis B &#40;VHB&#41;&#44; la tuberculosis diseminada&#44; la perforaci&#243;n gastrointestinal &#40;en particular el tofacitinib<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">4</span></a>&#41; y a los c&#225;nceres s&#243;lidos<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">3</span></a>&#46; Entre las reacciones adversas dermatol&#243;gicas poco comunes est&#225;n el c&#225;ncer de piel no melanoma&#44; el molusco contagioso diseminado y las reacciones cut&#225;neas adversas<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">5</span></a>&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">El primero de septiembre de 2021&#44; la FDA revis&#243; los resultados del ensayo de seguridad poscomercializaci&#243;n que comparaba el tofacitinib con los inhibidores del factor de necrosis tumoral alfa &#40;TNF-&#945;&#41; en la artritis reumatoide&#46; En el estudio participaron pacientes de &#8805; 50 a&#241;os tratados simult&#225;neamente con metotrexato y con factores de riesgo cardiovascular preexistentes&#46; Se concluy&#243; que el tofacitinib planteaba un mayor riesgo de eventos cardiovasculares mayores &#40;MACE&#41;&#44; acontecimientos tromboemb&#243;licos&#44; neoplasias malignas y la muerte&#46; Bas&#225;ndose en estos resultados&#44; la FDA emiti&#243; una advertencia &#40;<span class="elsevierStyleItalic">Boxed Warning</span>&#41;&#44; que tambi&#233;n se extendi&#243; a otros inhibidores de JAK que no hab&#237;an sido evaluados en ensayos cl&#237;nicos similares<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">6</span></a>&#46; Sin embargo&#44; un estudio que analiz&#243; un amplio conjunto de datos en 126&#46;815 informes de eventos adversos asociados al uso de inhibidores de JAK no logr&#243; identificar ning&#250;n aumento estad&#237;sticamente significativo de acontecimientos cardiovasculares graves<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">4</span></a>&#46; Adem&#225;s&#44; dos metaan&#225;lisis que investigaron los inhibidores de JAK en enfermedades inflamatorias y dermatitis at&#243;pica informaron de una incidencia similar de tromboembolismo venoso en comparaci&#243;n con los controles<a class="elsevierStyleCrossRefs" href="#bib0555"><span class="elsevierStyleSup">7&#44;8</span></a>&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Los datos procedentes de ensayos controlados aleatorizados &#40;ECA&#41; sugieren que ciertos eventos adversos pueden actuar de forma dependiente de la dosis&#44; debido al bloqueo de otras isoformas de JAK m&#225;s all&#225; de las diana<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">9</span></a>&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Abrocitinib</span><p id="par0035" class="elsevierStylePara elsevierViewall">En un estudio en el que se evaluaron las tasas de incidencia a largo plazo de los eventos adversos graves de una cohorte del estudio de an&#225;lisis integrado de seguridad para abrocitinib con 2&#46;856 pacientes y 1&#46;614 persona-a&#241;os &#40;pa&#41;&#44; el abrocitinib a dosis de 100 mg y 200 mg mostr&#243; 0&#44;6 y 0&#44;4 c&#225;nceres de piel no melanoma&#47;100 pa&#59; 0&#44;6 y 0&#44;2 eventos MACE&#47;100 pa&#44; y 0&#44;0 y 0&#44;4 acontecimientos tromboemb&#243;licos venosos &#40;TEV&#41;&#47;100 pa&#44; respectivamente&#46; Se produjeron otras neoplasias malignas &#40;excluido el c&#225;ncer de piel no melanoma&#41; a una tasa de 0&#44;2&#47;100 pa<a class="elsevierStyleCrossRefs" href="#bib0550"><span class="elsevierStyleSup">6&#44;10</span></a>&#46; Los eventos adversos relacionados con la dosis incluyeron principalmente n&#225;useas&#44; cefalea&#44; acn&#233; y trombocitopenia&#46; Las tasas de incidencia fueron de 2&#44;65&#47;100 pa y 2&#44;33&#47;100 pa para las infecciones graves&#44; 2&#44;04&#47;100 pa y 4&#44;34&#47;100 pa para el herpes z&#243;ster y 8&#44;73&#47;100 pa y 11&#44;83&#47;100 pa para el herpes simple en los grupos de 100 y 200 mg&#44; respectivamente&#46; Se notificaron tres muertes&#44; atribuidas a carcinoma g&#225;strico&#44; muerte s&#250;bita y COVID-19<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">10</span></a>&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">En adolescentes con dermatitis at&#243;pica&#44; la seguridad del abrocitinib oral se ha evaluado en un ECA de fase 3 controlado con placebo&#44; demostrando una menor incidencia de acontecimientos adversos graves en comparaci&#243;n con el grupo placebo<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">11</span></a>&#46; Un metan&#225;lisis en dermatitis at&#243;pica mostr&#243; que el abrocitinib a 100 mg estaba relacionado con m&#225;s efectos adversos graves que el dupilumab &#40;<span class="elsevierStyleItalic">odds ratio</span> &#91;OR&#93; 2&#44;6&#41;<a class="elsevierStyleCrossRef" href="#bib0580"><span class="elsevierStyleSup">12</span></a>&#46; Un an&#225;lisis de los recuentos plaquetarios a partir de datos obtenidos en cinco ensayos cl&#237;nicos de abrocitinib inform&#243; de un mayor riesgo de trombocitopenia en las primeras cuatro semanas de tratamiento en pacientes con recuentos plaquetarios basales bajos<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">13</span></a>&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Baricitinib</span><p id="par0045" class="elsevierStylePara elsevierViewall">La incidencia de los eventos adversos graves asociados al baricitinib est&#225; en consonancia con el riesgo inherente que plantea la poblaci&#243;n de la enfermedad espec&#237;fica que se est&#225; tratando&#46; Las enfermedades reumatol&#243;gicas suelen asociarse a una mayor prevalencia de MACE&#44; TEV&#44; neoplasias malignas&#44; infecciones graves y herpes z&#243;ster&#46; Por el contrario&#44; los casos de herpes simples son m&#225;s frecuentes entre los pacientes con dermatitis at&#243;pica<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">14</span></a>&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">En un an&#225;lisis de seguridad combinado de 8 ECA de baricitinib en 2&#46;531 sujetos con dermatitis at&#243;pica&#44; la tasa global de acontecimientos adversos emergentes del tratamiento &#40;EAET&#41; fue mayor en los pacientes tratados con baricitinib que en los que se manejaron con placebo&#46; La tasa de incidencia ajustada de infecciones graves fue de 3&#44;0&#47;100 pa y de 1&#44;5&#47;100 pa para baricitinib a 4 mg y 2 mg diarios&#44; respectivamente&#46; Se notificaron dos casos de MACE en personas que recibieron baricitinib 2 mg y se observaron dos casos de TEV en los que obtuvieron la dosis de 4 mg&#46; Hubo una muerte en el grupo de baricitinib a 4 mg&#44; debida a hemorragia gastrointestinal&#46; Los acontecimientos adversos comunes relacionados con alteraciones en la anal&#237;tica fueron el aumento de la CPK&#44; la hiperlipidemia y alteraciones hematol&#243;gicas&#44; hep&#225;ticas y renales leves<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">15</span></a>&#46; El an&#225;lisis de seguridad ampliado de baricitinib a 2 mg mostr&#243; resultados similares<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">16</span></a>&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Entre los 1&#46;303 pacientes con alopecia areata &#40;AA&#41; incluidos en un an&#225;lisis integrado de seguridad&#44; los EAET m&#225;s frecuentes fueron la infecci&#243;n de las v&#237;as respiratorias superiores&#44; la nasofaringitis&#44; la cefalea&#44; el acn&#233; y la elevaci&#243;n de la CPK&#46; El an&#225;lisis identific&#243; 34 casos de herpes z&#243;ster&#44; tres neoplasias malignas &#40;excluido el c&#225;ncer de piel no melanoma&#41;&#44; una infecci&#243;n oportunista&#44; un infarto de miocardio&#44; una embolia pulmonar y una perforaci&#243;n gastrointestinal<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">17</span></a>&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">En cuanto a la psoriasis&#44; el baricitinib se someti&#243; a un ensayo cl&#237;nico de fase 2 b &#40;n &#61; 271&#41;&#44; con informes de seguridad comparables<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">18</span></a>&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Upadacitinib</span><p id="par0065" class="elsevierStylePara elsevierViewall">Se realiz&#243; un metaan&#225;lisis de 2 ECA para evaluar las tasas de incidencia a largo plazo de acontecimientos adversos en pacientes con dermatitis at&#243;pica&#46; Los resultados indicaron que el upadacitinib en dosis de 15 mg y 30 mg presentaba tasas de neoplasias inferiores y similares&#44; respectivamente&#44; en comparaci&#243;n con la tasa de incidencia general de todas las neoplasias en la poblaci&#243;n de EE&#46; UU&#46; El upadacitinib tambi&#233;n mostr&#243; tasas bajas de c&#225;ncer de piel no melanoma &#40;0&#44;4 eventos&#47;100 a&#241;os&#41;&#44; MACE &#40;0&#44;0-0&#44;1 eventos&#47;100 a&#241;os&#41; y TEV &#40;0&#44;1 eventos&#47;100 a&#241;os&#41;<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">6</span></a>&#46; En ambos ECA&#44; la incidencia de eventos adversos graves fue similar entre los grupos&#46; Los EAET observados con mayor frecuencia incluyeron el acn&#233;&#44; una infecci&#243;n de las v&#237;as respiratorias superiores&#44; la elevaci&#243;n de los niveles de CPK y la dermatitis at&#243;pica<a class="elsevierStyleCrossRef" href="#bib0615"><span class="elsevierStyleSup">19</span></a>&#46; Otros ECA realizados en pacientes con dermatitis at&#243;pica informaron de un perfil de seguridad igualmente favorable<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">20</span></a>&#46; Un estudio revel&#243; tasas ligeramente superiores de infecciones graves &#40;1&#44;1 vs&#46; 0&#44;6&#37;&#41;&#44; eccema herp&#233;tico &#40;0&#44;3 vs&#46; 0&#37;&#41;&#44; herpes z&#243;ster &#40;2&#44;0 vs&#46; 0&#44;9&#37;&#41; y alteraciones anal&#237;ticas en sujetos que recibieron upadacitinib en comparaci&#243;n con los que obtuvieron dupilumab<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">20</span></a>&#46; Los ensayos controlados con placebo arrojaron resultados similares&#44; aunque el aumento del riesgo de herpes z&#243;ster e infecciones graves no fue constante en todos los estudios<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">21&#44;22</span></a>&#46; Un metaan&#225;lisis realizado en pacientes con artritis psori&#225;sica mostr&#243; que una dosis diaria de upadacitinib de 30 mg se asociaba a un riesgo relativo de acontecimientos adversos de 1&#44;20 en comparaci&#243;n con el placebo&#44; mientras que una dosis diaria de 15 mg no alcanz&#243; significaci&#243;n estad&#237;stica<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">23</span></a>&#46; Aunque otro metaan&#225;lisis sobre el perfil de seguridad del upadacitinib demostr&#243; tasas similares de eventos adversos emergentes con el tratamiento &#40;EAET&#41; en pacientes con dermatitis at&#243;pica y en aquellos con afecciones reumatol&#243;gicas&#44; los EAET graves&#44; el herpes z&#243;ster y las elevaciones de la creatinfosfoquinasa fueron menos frecuentes en personas con dermatitis at&#243;pica&#46; Sin embargo&#44; se observaron tasas m&#225;s elevadas de acn&#233; en aquellos con dermatitis at&#243;pica&#46; El mismo estudio concluy&#243; que el upadacitinib se vinculaba a un mayor riesgo de herpes z&#243;ster&#44; c&#225;ncer de piel no melanoma y elevaci&#243;n de la CPK en comparaci&#243;n con el metotrexato y el adalimumab<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">24</span></a>&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Ruxolitinib t&#243;pico</span><p id="par0070" class="elsevierStylePara elsevierViewall">En general&#44; el ruxolitinib t&#243;pico se tolera bien y sus efectos adversos se limitan principalmente a reacciones cut&#225;neas locales &#40;dolor en el lugar de aplicaci&#243;n&#44; eritema&#44; exfoliaci&#243;n&#44; foliculitis&#44; prurito&#41;<a class="elsevierStyleCrossRefs" href="#bib0645"><span class="elsevierStyleSup">25&#44;26</span></a>&#46; No se ha notificado toxicidad sist&#233;mica&#46; Curiosamente&#44; en un estudio doble ciego de ruxolitinib 0&#44;5 o 1&#44;0&#37; de crema diaria o 1&#44;5&#37; de crema dos veces al d&#237;a en la psoriasis&#44; no se observ&#243; inhibici&#243;n de transductor de se&#241;al y activador de la transcripci&#243;n 3 &#40;STAT3&#41; fosforilada en las c&#233;lulas sangu&#237;neas&#44; y se detectaron bajas concentraciones plasm&#225;ticas del f&#225;rmaco en estado estacionario<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">27</span></a>&#46; Un estudio en dermatitis at&#243;pica estim&#243; que la exposici&#243;n sist&#233;mica correspond&#237;a aproximadamente a 4-5&#37; de la dosis aplicada<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">28</span></a>&#46; En dos ECA de fase 3 en dermatitis at&#243;pica &#40;n &#61; 1&#46;251&#41;&#44; se notific&#243; una menor tasa de reacciones en el lugar de aplicaci&#243;n en comparaci&#243;n con el veh&#237;culo<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">29</span></a>&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Uso fuera de la ficha t&#233;cnica de los inhibidores de JAK en trastornos cut&#225;neos</span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Abrocitinib &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;</span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Alopecia areata</span><p id="par0075" class="elsevierStylePara elsevierViewall">Una adolescente con dermatitis at&#243;pica y AA <span class="elsevierStyleItalic">universalis</span> recibi&#243; abrocitinib 200 mg&#47;d&#237;a&#44; tras lo cual el cabello le volvi&#243; a crecer al cabo de 12 semanas&#46; Se observaron pelos terminales en varias zonas en la semana 52<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">30</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Dermatitis de contacto</span><p id="par0080" class="elsevierStylePara elsevierViewall">Un paciente adulto tratado con abrocitinib 100 mg&#47;d&#237;a para una dermatitis de contacto al&#233;rgica ocupacional transmitida por el aire alcanz&#243; la resoluci&#243;n completa despu&#233;s de ocho semanas<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">31</span></a>&#46;</p></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Baricitinib &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;</span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Trastornos autoinflamatorios con manifestaciones cut&#225;neas</span><p id="par0085" class="elsevierStylePara elsevierViewall">El baricitinib oral se ha probado en determinados trastornos autoinflamatorios&#46; Se observ&#243; mejor&#237;a cl&#237;nica en series y&#47;o reportes de pacientes con s&#237;ndrome de dermatosis neutrof&#237;lica at&#237;pica cr&#243;nica con lipodistrofia y elevaci&#243;n de la temperatura &#40;CANDLE&#41;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&#44; s&#237;ndrome de &#171;<span class="elsevierStyleItalic">CANDLE-like</span>&#187;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&#44; Aicardi-Gouti&#232;res<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&#44; vasculopat&#237;a asociada a la prote&#237;na STING de inicio en la infancia &#40;SAVI&#41;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&#44; mutaciones de ganancia de funci&#243;n &#40;GOF&#41; en STAT1<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&#44; s&#237;ndrome de Blau refractario<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">33</span></a> y artritis idiop&#225;tica juvenil sist&#233;mica<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">34</span></a>&#46; En el s&#237;ndrome de vacuolas&#44; enzima E-1&#44; ligado a x&#44; autoinflamatorio&#44; som&#225;tico &#40;VEXAS&#41;&#44; un estudio multic&#233;ntrico retrospectivo mostr&#243; que el baricitinib y el upadacitinib conduc&#237;an a peores resultados que el ruxolitinib oral<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">35</span></a>&#46; Dos series de casos &#40;n &#61; 3 y n &#61; 2&#41; de enfermedad de Still del adulto presentaron resoluci&#243;n completa &#40;40&#37;&#41; o parcial &#40;20&#37;&#41;<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">34</span></a> con el baricitinib 4 mg&#47;d&#237;a&#44; y se comunic&#243; un caso de remisi&#243;n cl&#237;nica tras asociar baricitinib a anakinra y corticoides<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">36</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Lupus eritematoso cut&#225;neo</span><p id="par0090" class="elsevierStylePara elsevierViewall">Encontramos una serie de casos y cuatro reportes de casos con baricitinib 4 mg&#47;d&#237;a&#46; En pacientes con lupus pernio familiar se observ&#243; una mejor&#237;a de las lesiones l&#250;picas cut&#225;neas al cabo de tres meses<a class="elsevierStyleCrossRef" href="#bib0705"><span class="elsevierStyleSup">37</span></a>&#46; En los reportes de casos se consigui&#243; una desaparici&#243;n completa con estabilizaci&#243;n concomitante de la alopecia frontal fibrosante<a class="elsevierStyleCrossRef" href="#bib0710"><span class="elsevierStyleSup">38</span></a>&#44; una mejor&#237;a de la alopecia asociada al lupus eritematoso sist&#233;mico<a class="elsevierStyleCrossRef" href="#bib0715"><span class="elsevierStyleSup">39</span></a> y una resoluci&#243;n casi completa de las lesiones de lupus eritematoso cut&#225;neo subagudo<a class="elsevierStyleCrossRefs" href="#bib0720"><span class="elsevierStyleSup">40&#44;41</span></a>&#46;</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Enfermedad cr&#243;nica de injerto contra hu&#233;sped &#40;EICHc&#41;</span><p id="par0095" class="elsevierStylePara elsevierViewall">Un ECA de fase 1&#47;2 de baricitinib en la enfermedad cr&#243;nica de injerto contra hu&#233;sped &#40;EICHc&#41; &#40;n &#61; 20&#41;&#44; que incluy&#243; 19 casos de EICHc escler&#243;tica&#44; demostr&#243; una respuesta global en el sexto mes de 63&#37;&#44; con 88&#37; de respuestas duraderas<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">42</span></a>&#46;</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Eccema cr&#243;nico de las manos</span><p id="par0100" class="elsevierStylePara elsevierViewall">Una serie de casos &#40;n &#61; 2&#41; con baricitinib 4 mg&#47;d&#237;a revel&#243; una resoluci&#243;n casi completa tras 16 semanas<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">43</span></a>&#46;</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Prurigo nodular cr&#243;nico</span><p id="par0105" class="elsevierStylePara elsevierViewall">Baricitinib 4 mg&#47;d&#237;a produjo una r&#225;pida mejor&#237;a del prurito y de las lesiones de prurigo en dos reportes de casos de pacientes con predisposici&#243;n at&#243;pica<a class="elsevierStyleCrossRefs" href="#bib0740"><span class="elsevierStyleSup">44&#44;45</span></a>&#44; y en uno con prurigo nodular cr&#243;nico no at&#243;pico<a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">46</span></a>&#46;</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Dermatomiositis &#40;forma adulta&#41;</span><p id="par0110" class="elsevierStylePara elsevierViewall">Un estudio abierto &#40;n &#61; 12&#41; demostr&#243; que baricitinib 2 mg&#47;12 h disminu&#237;a la actividad de la enfermedad y mejoraba la puntuaci&#243;n del &#205;ndice de Calidad de Vida en Dermatolog&#237;a &#40;DLQI&#41;<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">47</span></a>&#46; Una serie de casos &#40;n &#61; 3&#41;<a class="elsevierStyleCrossRef" href="#bib0760"><span class="elsevierStyleSup">48</span></a> y el reporte de un caso<a class="elsevierStyleCrossRef" href="#bib0765"><span class="elsevierStyleSup">49</span></a> de baricitinib 4 mg&#47;d&#237;a tambi&#233;n documentaron resultados prometedores&#46;</p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Fascitis eosinof&#237;lica</span><p id="par0115" class="elsevierStylePara elsevierViewall">En un var&#243;n adulto con fascitis eosinof&#237;lica refractaria&#44; el baricitinib redujo la induraci&#243;n cut&#225;nea y el uso de corticoides&#44; y mejor&#243; la elasticidad cut&#225;nea<a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">50</span></a>&#46;</p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Alopecia frontal fibrosante</span><p id="par0120" class="elsevierStylePara elsevierViewall">En un estudio retrospectivo &#40;n &#61; 5&#41;&#44; el baricitinib mejor&#243; a 60&#37; de los pacientes con alopecia fibrosante frontal<a class="elsevierStyleCrossRef" href="#bib0775"><span class="elsevierStyleSup">51</span></a>&#46;</p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Morfea generalizada</span><p id="par0125" class="elsevierStylePara elsevierViewall">Un var&#243;n con morfea generalizada refractaria fue tratado con baricitinib 2 mg&#47;d&#237;a&#44; con mejor&#237;a al cabo de seis meses<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">52</span></a>&#46;</p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Granuloma anular</span><p id="par0130" class="elsevierStylePara elsevierViewall">Todos los pacientes de una serie de casos &#40;n &#61; 2&#41; y dos informes de casos experimentaron mejor&#237;a o remisi&#243;n tras dos a ocho semanas de tratamiento con baricitinib 3-4 mg&#47;d&#237;a<a class="elsevierStyleCrossRefs" href="#bib0785"><span class="elsevierStyleSup">53&#8211;55</span></a>&#46;</p></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">S&#237;ndrome hipereosinof&#237;lico</span><p id="par0135" class="elsevierStylePara elsevierViewall">Una mujer de 39 a&#241;os con s&#237;ndrome hipereosinof&#237;lico que presentaba vasculitis eosinof&#237;lica en los dedos normaliz&#243; el recuento de eosin&#243;filos tras tres meses de baricitinib<a class="elsevierStyleCrossRef" href="#bib0800"><span class="elsevierStyleSup">56</span></a>&#46;</p></span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Enfermedades ampollosas inmunes</span><p id="par0140" class="elsevierStylePara elsevierViewall">Los reportes de casos han documentado el uso de baricitinib en el tratamiento de diversos trastornos&#44; como en la epiderm&#243;lisis bullosa pruriginosa&#44; en el penfigoide de la mucosa ocular&#44; el penfigoide ampolloso y en el liquen plano &#40;LP&#41; penfigoide&#46; Los resultados comunicados var&#237;an desde una mejor&#237;a significativa hasta la resoluci&#243;n completa<a class="elsevierStyleCrossRefs" href="#bib0805"><span class="elsevierStyleSup">57&#8211;59</span></a>&#46;</p></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Dermatomiositis juvenil</span><p id="par0145" class="elsevierStylePara elsevierViewall">El baricitinib &#40;4-8 mg&#47;d&#237;a&#41; redujo significativamente la actividad de la enfermedad en la dermatomiositis juvenil &#40;DMJ&#41; refractaria &#40;n &#61; 4&#41; a partir de la cuarta semana en un estudio prospectivo<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">60</span></a>&#46; Ensayos retrospectivos &#40;n &#61; 15 y n &#61; 3&#41; informaron de una mejor&#237;a cut&#225;nea en todos los pacientes con DMJ&#44; incluida la estabilizaci&#243;n de la calcinosis&#44; la regresi&#243;n parcial y la remisi&#243;n completa<a class="elsevierStyleCrossRefs" href="#bib0825"><span class="elsevierStyleSup">61&#44;62</span></a>&#46; Los reportes de casos demostraron una mejor&#237;a de los s&#237;ntomas cut&#225;neos y musculares<a class="elsevierStyleCrossRef" href="#bib0835"><span class="elsevierStyleSup">63</span></a>&#44; as&#237; como reducciones de la calcinosis<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">64</span></a>&#46;</p></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Liquen plano</span><p id="par0150" class="elsevierStylePara elsevierViewall">En un estudio retrospectivo &#40;n &#61; 7&#41;&#44; el uso de baricitinib demostr&#243; mejor&#237;a en 71&#37; de los pacientes con LP pilaris<a class="elsevierStyleCrossRef" href="#bib0775"><span class="elsevierStyleSup">51</span></a>&#46; Una mujer con LP ungueal grave<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">65</span></a> experiment&#243; una mejor&#237;a significativa y sostenida con el baricitinib&#46;</p></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Vasculopat&#237;a livedoide</span><p id="par0155" class="elsevierStylePara elsevierViewall">Una serie de casos &#40;n &#61; 8&#41; de baricitinib 2 mg&#47;d&#237;a para la vasculopat&#237;a livedoide refractaria hall&#243; una mejor&#237;a estad&#237;sticamente significativa de la actividad de la enfermedad&#46; Se alcanz&#243; la remisi&#243;n cl&#237;nica en seis casos<a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">66</span></a>&#46; Dos reportes de casos mostraron una mejor&#237;a r&#225;pida<a class="elsevierStyleCrossRef" href="#bib0855"><span class="elsevierStyleSup">67</span></a> y notable con el baricitinib 4 mg&#47;d&#237;a<a class="elsevierStyleCrossRef" href="#bib0860"><span class="elsevierStyleSup">68</span></a>&#46;</p></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Psoriasis</span><p id="par0160" class="elsevierStylePara elsevierViewall">En un ECA de fase 2 b de 12 semanas de duraci&#243;n &#40;n &#61; 271&#41;&#44; se logr&#243; una reducci&#243;n de 75&#37; en el &#237;ndice de &#225;rea y gravedad de la psoriasis &#40;PASI&#41; en 43-54&#37; de los pacientes tratados con baricitinib<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">18</span></a>&#46; Un metaan&#225;lisis mostr&#243; una menor eficacia de este f&#225;rmaco en comparaci&#243;n con el tofacitinib<a class="elsevierStyleCrossRef" href="#bib0865"><span class="elsevierStyleSup">69</span></a>&#46; Una mujer de 28 a&#241;os con acrodermatitis continua de Hallopeau present&#243; una remisi&#243;n r&#225;pida y mantenida de los s&#237;ntomas cut&#225;neos y articulares con baricitinib 2 mg&#47;d&#237;a<a class="elsevierStyleCrossRef" href="#bib0870"><span class="elsevierStyleSup">70</span></a>&#46;</p></span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Pioderma gangrenoso</span><p id="par0165" class="elsevierStylePara elsevierViewall">El baricitinib 4 mg&#47;d&#237;a condujo a una respuesta completa en una serie de casos &#40;n &#61; 2&#41; de pioderma gangrenoso refractario en la parte inferior de la pierna y el cuero cabelludo<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">71</span></a>&#46;</p></span><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0180">S&#237;ndrome de Sweet</span><p id="par0170" class="elsevierStylePara elsevierViewall">Una mujer de 59 a&#241;os con s&#237;ndrome de Sweet asociado a artritis reumatoide refractaria mejor&#243; sus s&#237;ntomas articulares y cut&#225;neos tras cuatro semanas con baricitinib<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">72</span></a>&#46;</p></span><span id="sec0165" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0185">Esclerosis sist&#233;mica</span><p id="par0175" class="elsevierStylePara elsevierViewall">Una serie de casos &#40;n &#61; 10&#41;<a class="elsevierStyleCrossRef" href="#bib0885"><span class="elsevierStyleSup">73</span></a> y dos reportes de casos investigaron el uso de baricitinib en la esclerosis sist&#233;mica<a class="elsevierStyleCrossRefs" href="#bib0890"><span class="elsevierStyleSup">74&#44;75</span></a>&#46; Se observ&#243; una respuesta cut&#225;nea significativa en nueve pacientes<a class="elsevierStyleCrossRef" href="#bib0900"><span class="elsevierStyleSup">76</span></a>&#46;</p></span><span id="sec0170" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0190">Vit&#237;ligo</span><p id="par0180" class="elsevierStylePara elsevierViewall">Un hombre de 67 a&#241;os con vit&#237;ligo en ambas manos y antebrazos recibi&#243; baricitinib 4 mg&#47;d&#237;a para la artritis reumatoide&#44; mostrando repigmentaci&#243;n al cabo de ocho meses<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">77</span></a>&#46;</p></span></span><span id="sec0175" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0195">Upadacitinib &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a>&#41;</span><span id="sec0180" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0200">Alopecia areata</span><p id="par0185" class="elsevierStylePara elsevierViewall">Cuatro informes de casos &#40;n &#61; 4&#41; demostraron que el cabello volv&#237;a a crecer con upadacitinib 15-30 mg&#47;d&#237;a&#46; En tres casos&#44; este r&#233;gimen tambi&#233;n mejor&#243; una dermatitis at&#243;pica grave concurrente<a class="elsevierStyleCrossRefs" href="#bib0910"><span class="elsevierStyleSup">78&#8211;81</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0185" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0205">Liquen plano oral erosivo</span><p id="par0190" class="elsevierStylePara elsevierViewall">Una mujer de 45 a&#241;os con LP erosivo oral y artritis psori&#225;sica<a class="elsevierStyleCrossRef" href="#bib0930"><span class="elsevierStyleSup">82</span></a>&#44; y otra de 59 a&#241;os con LP erosivo oral y esof&#225;gico refractario<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">83</span></a> recibieron upadacitinib 15 mg diarios&#46; En ambos casos se observ&#243; una mejor&#237;a dr&#225;stica y sostenida de las lesiones orales&#46;</p></span><span id="sec0190" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0210">Eritema multiforme</span><p id="par0195" class="elsevierStylePara elsevierViewall">Una mujer de 30 a&#241;os con eritema multiforme persistente mostr&#243; una mejor&#237;a significativa con upadacitinib 15 mg&#47;d&#237;a<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">84</span></a>&#46;</p></span><span id="sec0195" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0215">Granuloma anular</span><p id="par0200" class="elsevierStylePara elsevierViewall">Una mujer de 60 a&#241;os con granuloma anular refractario en placas present&#243; una remisi&#243;n casi completa con upadacitinib 15 mg&#47;d&#237;a<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">85</span></a>&#46;</p></span><span id="sec0200" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0220">Hidradenitis supurativa</span><p id="par0205" class="elsevierStylePara elsevierViewall">Un estudio retrospectivo &#40;n &#61; 20&#41; de hidradenitis supurativa de moderada a grave tratada con upadacitinib mostr&#243; una mejor&#237;a significativa de la respuesta cl&#237;nica de la hidradenitis supurativa &#40;HiSCR&#41;&#44; el DLQI y las puntuaciones de dolor a partir de la cuarta semana de tratamiento<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">86</span></a>&#46;</p></span></span><span id="sec0205" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0225">Ruxolitinib t&#243;pico &#40;<a class="elsevierStyleCrossRef" href="#tbl0025">tabla 5</a>&#41;</span><span id="sec0210" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0230">Alopecia areata</span><p id="par0210" class="elsevierStylePara elsevierViewall">En un ECA de fase 1 &#40;n &#61; 16&#41; en el que se compar&#243; pomada de ruxolitinib al 1&#37; con clobetasol 0&#44;05&#37; en individuos con AA <span class="elsevierStyleItalic">universalis</span>&#44; 31&#37; mostr&#243; un recrecimiento parcial del cabello en las zonas tratadas con ruxolitinib<a class="elsevierStyleCrossRef" href="#bib0955"><span class="elsevierStyleSup">87</span></a>&#46; Un estudio piloto abierto seguido de un ECA&#44; en el que participaron pacientes con 25-99&#37; de p&#233;rdida de cabello al inicio del estudio&#44; inform&#243; de que 50&#37; logr&#243; una reducci&#243;n &#62; 50&#37; en la <span class="elsevierStyleItalic">Severity of Alopecia Tool</span> &#40;SALT50&#41; en la semana 24 con crema de ruxolitinib al 1&#44;5&#37;&#46; Sin embargo&#44; el ECA no pudo demostrar una eficacia superior en comparaci&#243;n con el veh&#237;culo<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">26</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0025">tabla 5</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><p id="par0215" class="elsevierStylePara elsevierViewall">En una serie de casos pedi&#225;tricos &#40;n &#61; 2&#41;&#44; el ruxolitinib t&#243;pico al 1-2&#37; dos veces al d&#237;a hizo que volviera a crecer m&#225;s de 75&#37; del vello de las pesta&#241;as superiores en un paciente y en el otro no volvieron a salir las cejas<a class="elsevierStyleCrossRef" href="#bib0960"><span class="elsevierStyleSup">88</span></a>&#46; Dos informes de casos mostraron un crecimiento parcial del vello con ruxolitinib t&#243;pico<a class="elsevierStyleCrossRefs" href="#bib0965"><span class="elsevierStyleSup">89&#44;90</span></a>&#46; Otro caso no mostr&#243; eficacia con ruxolitinib al 0&#44;6&#37; dos veces al d&#237;a<a class="elsevierStyleCrossRef" href="#bib0975"><span class="elsevierStyleSup">91</span></a>&#46;</p></span><span id="sec0215" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0235">Enfermedad cr&#243;nica cut&#225;nea de injerto contra hu&#233;sped</span><p id="par0220" class="elsevierStylePara elsevierViewall">Un var&#243;n de 51 a&#241;os mostr&#243; una mejora de 6&#44;4&#37; en la superficie corporal total en las lesiones tratadas con ruxolitinib t&#243;pico al 1&#44;5&#37; en la sexta semana<a class="elsevierStyleCrossRef" href="#bib0980"><span class="elsevierStyleSup">92</span></a>&#46;</p></span><span id="sec0220" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0240">Lupus eritematoso cut&#225;neo</span><p id="par0225" class="elsevierStylePara elsevierViewall">Una mujer con lupus eritematoso discoide refractario present&#243; mejor&#237;a y le volvi&#243; a crecer pelo tras dos meses de crema de ruxolitinib al 1&#44;5&#37;<a class="elsevierStyleCrossRef" href="#bib0985"><span class="elsevierStyleSup">93</span></a>&#46;</p></span><span id="sec0225" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0245">Liquen plano</span><p id="par0230" class="elsevierStylePara elsevierViewall">Un estudio prospectivo de fase 2 abierto con ruxolitinib al 1&#44;5&#37; dos veces al d&#237;a en LP cut&#225;neo &#40;n &#61; 12&#41; mostr&#243; una reducci&#243;n estad&#237;sticamente significativa del n&#250;mero de lesiones y su gravedad al cabo de ocho semanas<a class="elsevierStyleCrossRef" href="#bib0990"><span class="elsevierStyleSup">94</span></a>&#46;</p></span><span id="sec0230" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0250">Necrobiosis lipoidea</span><p id="par0235" class="elsevierStylePara elsevierViewall">Una mujer con necrobiosis lipo&#237;dica refractaria observ&#243; una notable mejor&#237;a tras cambiar de crema de tofacitinib al 2&#37; a ruxolitinib al 1&#44;5&#37; dos veces al d&#237;a<a class="elsevierStyleCrossRef" href="#bib0995"><span class="elsevierStyleSup">95</span></a>&#46;</p></span><span id="sec0235" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0255">Psoriasis</span><p id="par0240" class="elsevierStylePara elsevierViewall">En un ECA de fase 2 &#40;n &#61; 29&#41; se observ&#243; que el ruxolitinib al 1 y al 1&#44;5&#37; reduc&#237;a las placas en 53 y 54&#37;<a class="elsevierStyleCrossRef" href="#bib1000"><span class="elsevierStyleSup">96</span></a>&#46; En un ensayo abierto de fase IIb se hall&#243; una mejora media del PASI de 40&#37; tras tres meses de tratamiento con crema de ruxolitinib al 1&#37;<a class="elsevierStyleCrossRef" href="#bib1005"><span class="elsevierStyleSup">97</span></a>&#46; Otro ensayo abierto en el que se compar&#243; la crema de ruxolitinib al 1&#37; y 1&#44;5&#37; aplicada una o dos veces al d&#237;a durante cuatro semanas mostr&#243; una reducci&#243;n media de la puntuaci&#243;n del eritema &#40;42-55&#37;&#41;&#44; la descamaci&#243;n &#40;46-78&#37;&#41; y el grosor &#40;50-65&#37;&#41; en todos los grupos<a class="elsevierStyleCrossRef" href="#bib1010"><span class="elsevierStyleSup">98</span></a>&#46; Un estudio abierto de fase 2 &#40;n &#61; 25&#41; de ruxolitinib al 1&#44;5&#37; dos veces al d&#237;a revel&#243; una mejora estad&#237;sticamente significativa en el d&#237;a 28<a class="elsevierStyleCrossRef" href="#bib1015"><span class="elsevierStyleSup">99</span></a>&#46;</p></span><span id="sec0240" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0260">Dermatitis seborreica</span><p id="par0245" class="elsevierStylePara elsevierViewall">Un hombre de 74 a&#241;os con ros&#225;cea concomitante mostr&#243; una resoluci&#243;n completa de la dermatitis seborreica y una mejor&#237;a parcial de la ros&#225;cea despu&#233;s de dos semanas con ruxolitinib al 1&#44;5&#37; dos veces al d&#237;a<a class="elsevierStyleCrossRef" href="#bib1020"><span class="elsevierStyleSup">100</span></a>&#46;</p></span></span></span></span><span id="sec0245" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0265">Discusi&#243;n</span><p id="par0250" class="elsevierStylePara elsevierViewall">La inclusi&#243;n de una advertencia &#40;<span class="elsevierStyleItalic">Boxed Warning</span>&#41; para los inhibidores de JAK ha suscitado preocupaci&#243;n entre los dermat&#243;logos en relaci&#243;n con la seguridad de estos medicamentos&#46; Sin embargo&#44; no debe sobrestimarse la magnitud de estas preocupaciones&#46; Los efectos secundarios a largo plazo que motivaron la advertencia se observaron en pacientes &#8805; 50 a&#241;os con artritis reumatoide&#44; en tratamiento concomitante con metotrexato y con factores de riesgo cardiovascular preexistentes<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">9</span></a>&#46; En las indicaciones dermatol&#243;gicas&#44; las poblaciones de pacientes suelen diferir en gran medida seg&#250;n el contexto cl&#237;nico en el que se realiz&#243; este estudio&#44; lo que puede influir en el perfil de seguridad&#46; Adem&#225;s&#44; un ensayo que comparaba la incidencia de efectos adversos entre las terapias sist&#233;micas tradicionales &#40;metotrexato&#44; ciclosporina y corticoesteroides sist&#233;micos&#41; y los inhibidores de JAK &#40;upadacitinib y abrocitinib&#41; hall&#243; tasas similares o superiores de malignidad&#44; MACE y TEV con los abordajes tradicionales<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">6</span></a>&#46; Esto sugiere que los inhibidores de JAK podr&#237;an ofrecer una alternativa m&#225;s segura en t&#233;rminos de efectos secundarios a largo plazo&#46; Para mitigar el riesgo de efectos graves&#44; un grupo de trabajo multidisciplinar public&#243; en 2021 unas recomendaciones consensuadas para el tratamiento de los pacientes manejados con inhibidores de JAK<a class="elsevierStyleCrossRef" href="#bib1025"><span class="elsevierStyleSup">101</span></a>&#46; En 2022&#44; la EMA respald&#243; las medidas recomendadas por el Comit&#233; de Evaluaci&#243;n de Riesgos en Farmacovigilancia elaboradas con el mismo fin<a class="elsevierStyleCrossRef" href="#bib1030"><span class="elsevierStyleSup">102</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0030">tabla 6</a>&#41;&#46; Antes de iniciar el tratamiento con inhibidores de JAK&#44; debe realizarse una anamnesis completa&#44; centr&#225;ndose en factores como antecedentes de MACE y TEV&#44; trombosis familiar y neoplasias malignas previas&#46; Debe efectuarse un examen f&#237;sico completo y an&#225;lisis de sangre&#44; incluyendo un hemograma&#44; pruebas de funci&#243;n hep&#225;tica y renal&#44; lipidograma&#44; CPK y cribado serol&#243;gico de virus de la inmunodeficiencia humana &#40;VIH&#41;&#44; VHB&#44; virus de la hepatitis C &#40;VHC&#41; y virus de la varicela zoster &#40;VVZ&#41;&#46; Tambi&#233;n debe llevarse a cabo un cribado de la tuberculosis&#46; Dado el elevado riesgo de herpes z&#243;ster&#44; debe ofrecerse a todos los pacientes la vacunaci&#243;n en funci&#243;n de su estado serol&#243;gico&#46; Shingrix&#44; una vacuna adyuvada recombinante contra el herpes z&#243;ster&#44; ha mostrado resultados prometedores en los datos iniciales de sujetos con artritis reumatoide&#44; con tan solo 0&#44;7&#37; de desarrollo de herpes z&#243;ster&#46; Sin embargo&#44; se necesitan m&#225;s estudios para confirmar su eficacia en prevenci&#243;n<a class="elsevierStyleCrossRef" href="#bib1035"><span class="elsevierStyleSup">103</span></a>&#46; El seguimiento y la monitorizaci&#243;n estrechos son vitales durante todo el tratamiento con inhibidores de JAK&#46; Los pacientes deben ser seguidos por profesionales expertos en estos medicamentos&#44; y deben realizarse an&#225;lisis de sangre peri&#243;dicos para controlar los posibles efectos adversos&#46; Las revisiones dermatol&#243;gicas son especialmente importantes en los sujetos de alto riesgo para detectar signos precoces de c&#225;ncer de piel&#46;</p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia><p id="par0255" class="elsevierStylePara elsevierViewall">Dado que los estudios cl&#237;nicos tienden a infrarrepresentar a los pacientes pedi&#225;tricos o mayores de 65 a&#241;os&#44; a los individuos con comorbilidades o en riesgo de malignidad o de eventos tromboemb&#243;licos y cardiovasculares&#44; es necesario que los ensayos cl&#237;nicos incluyan a estas poblaciones para evaluar de forma exhaustiva la seguridad de los inhibidores de JAK&#46; Se necesitan m&#225;s investigaciones para determinar si los riesgos pueden mitigarse mediante una cuidadosa selecci&#243;n de las dosis&#46;</p><p id="par0260" class="elsevierStylePara elsevierViewall">Nuestra revisi&#243;n incluye datos preliminares sobre la eficacia de los inhibidores de JAK en varias entidades dermatol&#243;gicas &#40;<a class="elsevierStyleCrossRef" href="#tbl0035">tabla 7</a>&#41;&#46; Sobre la base de los prometedores hallazgos examinados&#44; es razonable considerar a los inhibidores de JAK como una opci&#243;n terap&#233;utica potencial para enfermedades como la vasculopat&#237;a livedoide&#44; la EICHc&#44; las enfermedades autoinflamatorias&#44; el lupus eritematoso cut&#225;neo&#44; la dermatomiositis y la esclerosis sist&#233;mica&#46; Estas enfermedades suelen ser refractarias a los tratamientos convencionales o dependen en gran medida de los corticoesteroides&#44; por lo que urge encontrar terapias alternativas&#46;</p><elsevierMultimedia ident="tbl0035"></elsevierMultimedia><p id="par0265" class="elsevierStylePara elsevierViewall">La accesibilidad de los inhibidores de JAK como medicamentos fuera de ficha t&#233;cnica plantea preocupaciones&#46; Un estudio de cohorte prospectivo en cl&#237;nicas dermatol&#243;gicas alemanas revel&#243; tasas de aprobaci&#243;n m&#225;s bajas de inhibidores de JAK en comparaci&#243;n con los biol&#243;gicos &#40;OR 0&#44;16&#41;<a class="elsevierStyleCrossRef" href="#bib1040"><span class="elsevierStyleSup">104</span></a>&#46; Adem&#225;s&#44; considerando su alto coste&#44; un an&#225;lisis de coste-beneficio es esencial&#44; especialmente para afecciones que no amenazan la vida&#46;</p><p id="par0270" class="elsevierStylePara elsevierViewall">Nuestro estudio tiene varias limitaciones&#46; Es una revisi&#243;n narrativa y no sistem&#225;tica&#46; Los tama&#241;os de muestra eran en su mayor&#237;a peque&#241;os&#44; faltaban estudios prospectivos en muchas indicaciones fuera de ficha t&#233;cnica y hubo periodos de seguimiento cortos con metodolog&#237;as heterog&#233;neas&#44; lo que limit&#243; la generalizaci&#243;n de los hallazgos&#46; Muchos informes de casos y series que evaluaron la eficacia de los inhibidores de JAK enfrentaron desaf&#237;os al atribuir resultados positivos &#250;nicamente a estos medicamentos&#44; ya que numerosos casos involucraron tratamientos concomitantes que podr&#237;an haber influido en los hallazgos&#46;</p></span><span id="sec0250" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0270">Conclusi&#243;n</span><p id="par0275" class="elsevierStylePara elsevierViewall">Los inhibidores de JAK suponen un importante paso hacia la medicina de precisi&#243;n&#46; Su seguridad depende en gran medida de las caracter&#237;sticas del paciente&#44; la enfermedad que se est&#225; tratando&#44; la v&#237;a de administraci&#243;n&#44; el inhibidor espec&#237;fico de JAK y la dosis&#46; En comparaci&#243;n con las terapias inmunosupresoras tradicionales&#44; en general&#44; estos f&#225;rmacos demuestran mejores perfiles de seguridad&#46; Estos agentes son prometedores como tratamientos para diversas dermatosis inflamatorias que tienen un gran impacto en la calidad de vida&#46;</p></span><span id="sec0260" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0275">Financiaci&#243;n</span><p id="par0285" class="elsevierStylePara elsevierViewall">Ninguna&#46;</p></span><span id="sec0265" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0280">Conflicto de intereses</span><p id="par0280" class="elsevierStylePara elsevierViewall">Los autores declaran no tener conflicto de intereses&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:13 [
        0 => array:3 [
          "identificador" => "xres1979640"
          "titulo" => "Graphical abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:3 [
          "identificador" => "xres1979638"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        2 => array:2 [
          "identificador" => "xpalclavsec1702492"
          "titulo" => "Palabras clave"
        ]
        3 => array:3 [
          "identificador" => "xres1979639"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0015"
            ]
          ]
        ]
        4 => array:2 [
          "identificador" => "xpalclavsec1702491"
          "titulo" => "Keywords"
        ]
        5 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introducci&#243;n"
        ]
        6 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "M&#233;todos"
        ]
        7 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "Resultados"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Perfil de seguridad a largo plazo"
            ]
            1 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Abrocitinib"
            ]
            2 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Baricitinib"
            ]
            3 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Upadacitinib"
            ]
            4 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Ruxolitinib t&#243;pico"
            ]
            5 => array:3 [
              "identificador" => "sec0045"
              "titulo" => "Uso fuera de la ficha t&#233;cnica de los inhibidores de JAK en trastornos cut&#225;neos"
              "secciones" => array:4 [
                0 => array:3 [
                  "identificador" => "sec0050"
                  "titulo" => "Abrocitinib &#40;tabla 2&#41;"
                  "secciones" => array:2 [
                    0 => array:2 [
                      "identificador" => "sec0055"
                      "titulo" => "Alopecia areata"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0065"
                      "titulo" => "Dermatitis de contacto"
                    ]
                  ]
                ]
                1 => array:3 [
                  "identificador" => "sec0070"
                  "titulo" => "Baricitinib &#40;tabla 3&#41;"
                  "secciones" => array:20 [
                    0 => array:2 [
                      "identificador" => "sec0075"
                      "titulo" => "Trastornos autoinflamatorios con manifestaciones cut&#225;neas"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0080"
                      "titulo" => "Lupus eritematoso cut&#225;neo"
                    ]
                    2 => array:2 [
                      "identificador" => "sec0085"
                      "titulo" => "Enfermedad cr&#243;nica de injerto contra hu&#233;sped &#40;EICHc&#41;"
                    ]
                    3 => array:2 [
                      "identificador" => "sec0090"
                      "titulo" => "Eccema cr&#243;nico de las manos"
                    ]
                    4 => array:2 [
                      "identificador" => "sec0095"
                      "titulo" => "Prurigo nodular cr&#243;nico"
                    ]
                    5 => array:2 [
                      "identificador" => "sec0100"
                      "titulo" => "Dermatomiositis &#40;forma adulta&#41;"
                    ]
                    6 => array:2 [
                      "identificador" => "sec0105"
                      "titulo" => "Fascitis eosinof&#237;lica"
                    ]
                    7 => array:2 [
                      "identificador" => "sec0110"
                      "titulo" => "Alopecia frontal fibrosante"
                    ]
                    8 => array:2 [
                      "identificador" => "sec0115"
                      "titulo" => "Morfea generalizada"
                    ]
                    9 => array:2 [
                      "identificador" => "sec0120"
                      "titulo" => "Granuloma anular"
                    ]
                    10 => array:2 [
                      "identificador" => "sec0125"
                      "titulo" => "S&#237;ndrome hipereosinof&#237;lico"
                    ]
                    11 => array:2 [
                      "identificador" => "sec0130"
                      "titulo" => "Enfermedades ampollosas inmunes"
                    ]
                    12 => array:2 [
                      "identificador" => "sec0135"
                      "titulo" => "Dermatomiositis juvenil"
                    ]
                    13 => array:2 [
                      "identificador" => "sec0140"
                      "titulo" => "Liquen plano"
                    ]
                    14 => array:2 [
                      "identificador" => "sec0145"
                      "titulo" => "Vasculopat&#237;a livedoide"
                    ]
                    15 => array:2 [
                      "identificador" => "sec0150"
                      "titulo" => "Psoriasis"
                    ]
                    16 => array:2 [
                      "identificador" => "sec0155"
                      "titulo" => "Pioderma gangrenoso"
                    ]
                    17 => array:2 [
                      "identificador" => "sec0160"
                      "titulo" => "S&#237;ndrome de Sweet"
                    ]
                    18 => array:2 [
                      "identificador" => "sec0165"
                      "titulo" => "Esclerosis sist&#233;mica"
                    ]
                    19 => array:2 [
                      "identificador" => "sec0170"
                      "titulo" => "Vit&#237;ligo"
                    ]
                  ]
                ]
                2 => array:3 [
                  "identificador" => "sec0175"
                  "titulo" => "Upadacitinib &#40;tabla 4&#41;"
                  "secciones" => array:5 [
                    0 => array:2 [
                      "identificador" => "sec0180"
                      "titulo" => "Alopecia areata"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0185"
                      "titulo" => "Liquen plano oral erosivo"
                    ]
                    2 => array:2 [
                      "identificador" => "sec0190"
                      "titulo" => "Eritema multiforme"
                    ]
                    3 => array:2 [
                      "identificador" => "sec0195"
                      "titulo" => "Granuloma anular"
                    ]
                    4 => array:2 [
                      "identificador" => "sec0200"
                      "titulo" => "Hidradenitis supurativa"
                    ]
                  ]
                ]
                3 => array:3 [
                  "identificador" => "sec0205"
                  "titulo" => "Ruxolitinib t&#243;pico &#40;tabla 5&#41;"
                  "secciones" => array:7 [
                    0 => array:2 [
                      "identificador" => "sec0210"
                      "titulo" => "Alopecia areata"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0215"
                      "titulo" => "Enfermedad cr&#243;nica cut&#225;nea de injerto contra hu&#233;sped"
                    ]
                    2 => array:2 [
                      "identificador" => "sec0220"
                      "titulo" => "Lupus eritematoso cut&#225;neo"
                    ]
                    3 => array:2 [
                      "identificador" => "sec0225"
                      "titulo" => "Liquen plano"
                    ]
                    4 => array:2 [
                      "identificador" => "sec0230"
                      "titulo" => "Necrobiosis lipoidea"
                    ]
                    5 => array:2 [
                      "identificador" => "sec0235"
                      "titulo" => "Psoriasis"
                    ]
                    6 => array:2 [
                      "identificador" => "sec0240"
                      "titulo" => "Dermatitis seborreica"
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
        8 => array:2 [
          "identificador" => "sec0245"
          "titulo" => "Discusi&#243;n"
        ]
        9 => array:2 [
          "identificador" => "sec0250"
          "titulo" => "Conclusi&#243;n"
        ]
        10 => array:2 [
          "identificador" => "sec0260"
          "titulo" => "Financiaci&#243;n"
        ]
        11 => array:2 [
          "identificador" => "sec0265"
          "titulo" => "Conflicto de intereses"
        ]
        12 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2023-04-07"
    "fechaAceptado" => "2023-06-12"
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1702492"
          "palabras" => array:6 [
            0 => "Inhibidores de JAK"
            1 => "Inhibidores de Janus kinasa"
            2 => "Dermatolog&#237;a"
            3 => "Fuera de indicaci&#243;n"
            4 => "Seguridad"
            5 => "Eventos adversos"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1702491"
          "palabras" => array:6 [
            0 => "JAK inhibitors"
            1 => "Janus kinase inhibitors"
            2 => "Dermatology"
            3 => "Off-label"
            4 => "Safety"
            5 => "Adverse events"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Los inhibidores de Janus quinasa &#40;JAK&#41; act&#250;an bloqueando la acci&#243;n de ciertas citoquinas inflamatorias involucradas en varias enfermedades inflamatorias&#46; Cuatro mol&#233;culas han sido aprobadas para empleo en dermatolog&#237;a&#58; upadacitinib&#44; baricitinib&#44; abrocitinib y ruxolitinib t&#243;pico&#46; Se han reportado usos fuera de indicaci&#243;n para diferentes patolog&#237;as dermatol&#243;gicas&#46; Se realiz&#243; una revisi&#243;n narrativa de la literatura sobre la seguridad a largo plazo de los inhibidores de JAK aprobados y su utilizaci&#243;n fuera de indicaci&#243;n en enfermedades dermatol&#243;gicas&#44; mediante b&#250;squedas bibliogr&#225;ficas en PubMed y Google Scholar desde enero del 2000 hasta enero del 2023&#44; incluyendo las palabras clave&#58; &#171;<span class="elsevierStyleItalic">Janus kinase inhibitors</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">JAK inhibitors</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">off-label</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">dermatology</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">safety</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">adverse events</span>&#187;&#44; &#171;ruxolitinib&#187;&#44; &#171;upadacitinib&#187;&#44; &#171;abrocitinib&#187; y &#171;baricitinib&#187;&#46; Se encontraron un total de 37 trastornos cut&#225;neos con estudios que respaldan el uso de estos f&#225;rmacos&#46; Los ensayos preliminares indican que los inhibidores de JAK tienen un perfil de seguridad generalmente favorable y pueden considerarse una opci&#243;n en muchas enfermedades dermatol&#243;gicas&#46;</p></span>"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0015" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">JAK inhibitors target specific inflammatory cytokines involved in various inflammatory diseases&#46; Four molecules have been approved for dermatological use&#58; upadacitinib&#44; baricitinib&#44; abrocitinib and topical ruxolitinib&#46; Off-label prescriptions for other dermatological conditions have been reported&#46; We conducted a narrative review of the literature to assess the long-term safety profile of currently approved JAK inhibitors in dermatology&#44; and their off-label use in skin disorders&#46; We performed literature searches with PubMed and Google Scholar from January 2000 to January 2023&#44; using the keywords &#8220;Janus kinase inhibitors&#8221;&#44; &#8220;JAK inhibitors&#8221;&#44;&#8220;off-label&#8221;&#44; &#8220;dermatology&#8221;&#44; &#8220;safety&#8221;&#44; &#8220;adverse events&#8221;&#44; &#8220;ruxolitinib&#8221;&#44; &#8220;upadacitinib&#8221;&#44;&#8220;abrocitinib&#8221; and &#8220;baricitinib&#8221;&#46; Our search yielded a total of 37 dermatological disorders with studies supporting the use of these JAK inhibitors&#46; Preliminary studies indicate that JAK inhibitors generally have a favorable safety profile and can be considered as an option in many dermatological disorders&#46;</p></span>"
      ]
    ]
    "multimedia" => array:8 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">EMA&#58; <span class="elsevierStyleItalic">European Medicines Agency</span>&#59; FDA&#58; <span class="elsevierStyleItalic">Food and Drugs Administration</span>&#59; JAK&#58; Janus quinasa&#59; TYK2&#58; tirosina quinasa 2&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Droga&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mecanismo de acci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaciones aprobadas por la FDA en Dermatolog&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaciones aprobadas por la EMA en Dermatolog&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abrocitinib &#40;oral&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor selectivo JAK 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis at&#243;pica moderada a severa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis at&#243;pica moderada a severa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib &#40;oral&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor JAK 1 y JAK 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia areata&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia areataDermatitis at&#243;pica moderada a severa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib &#40;oral&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor reversible JAK con mayor potencia inhibitoria para JAK1 que JAK2&#44; JAK3&#44; o TYK2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis at&#243;pica moderada a severa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis at&#243;pica moderada a severa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib &#40;t&#243;pico&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor JAK 1 y JAK 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis at&#243;pica leve a moderadaVit&#237;ligo no segmentario&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295034.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Mecanismo de acci&#243;n e indicaciones aprobadas para los inhibidores de JAK 1 en Dermatolog&#237;a</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mayor nivel de evidencia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dosificaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mediciones&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultados cl&#237;nicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Efectos adversos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia areata<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">30</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abrocitinib 200 mg diario&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reaparici&#243;n del vello en todas las zonas afectadas del cuerpo despu&#233;s de 12 semanas&#46; Se observan pelos gruesos terminales en varias zonas en la semana 52&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis de contacto<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">31</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abrocitinib 100 mg diario&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n completa tras ocho semanas de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295031.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Uso fuera de ficha t&#233;cnica de abrocitinib en Dermatolog&#237;a</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabla 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">AIJ&#58; artritis idiop&#225;tica juvenil&#59; CDASI-A&#58; &#237;ndice de actividad del &#225;rea y gravedad de la enfermedad de dermatomiositis cut&#225;nea&#59; CDASI&#58; &#237;ndice de &#225;rea y gravedad de la enfermedad cut&#225;nea&#59; DDS&#58; puntuaci&#243;n diaria&#59; DLQI&#58; &#237;ndice de calidad de vida dermatol&#243;gica&#59; EASI&#58; &#237;ndice de &#225;rea y gravedad del eccema&#59; EVA&#58; escala visual anal&#243;gica&#59; ECA&#58; ensayo controlado aleatorizado&#59; EICH&#58; enfermedad de injerto contra hu&#233;sped&#59; HAQ II<span class="elsevierStyleSmallCaps">&#58;</span> cuestionario de evaluaci&#243;n de la salud II&#59; HECSI&#58; &#237;ndice de gravedad del eccema de manos&#59; IGA&#58; escala de evaluaci&#243;n global del investigador&#59; JAK&#58; Janus quinasa&#59; LP&#58; liquen plano&#59; LPPAI&#58; &#237;ndice de actividad del liquen plano pilaris&#59; mRSS&#58; puntuaci&#243;n cut&#225;nea de Rodnan modificada&#59; NRS&#58; escala de clasificaci&#243;n num&#233;rica&#59; PAS&#58; puntuaci&#243;n de actividad del prurigo&#59; PASI&#58; puntuaci&#243;n del &#237;ndice de &#225;rea y gravedad de la psoriasis&#59; PGA&#58; actividad global del m&#233;dico&#59; QOLHE&#58; cuestionario de calidad de vida en el eccema de manos&#59; SAVI&#58; vasculopat&#237;a asociada a STING de inicio en la infancia&#59; LECS&#58; lupus eritematoso cut&#225;neo subagudo&#59; RCT&#58; ensayo cl&#237;nico aleatorizado&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mayor nivel de evidencia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dosificaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mediciones&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultados cl&#237;nicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Efectos adversos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Trastornos autoinflamatorios</span><a class="elsevierStyleCrossRefs" href="#bib0680"><span class="elsevierStyleSup">32&#8211;36</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Enfermedad de Still del adulto<a class="elsevierStyleCrossRefs" href="#bib0690"><span class="elsevierStyleSup">34&#44;36</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dos series de casos &#40;n &#61; 3 y n &#61; 2&#41;<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">34</span></a> y el reporte de un caso &#40;n &#61; 1&#41;<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">36</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Se consigui&#243; una resoluci&#243;n completa en tres casos &#40;50&#37;&#41;&#44; una remisi&#243;n parcial en un caso &#40;16&#44;7&#37;&#41; y ninguna remisi&#243;n en dos casos &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se produjeron acontecimientos adversos que condujeran a la reducci&#243;n de la dosis o a una interrupci&#243;n de la mediaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Aicardi-Gouti&#232;res<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a de la piel tras el tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Blau<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">33</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estabilizaci&#243;n de las manifestaciones cut&#225;neas&#44; oculares y articulares tras el cambio de tofacitinib a baricitinib 4 mg diarios debido a una linfopenia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Linfopenia transitoria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de CANDLE<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 11&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 0&#44;1&#8211;10 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Criterios de reducci&#243;n de la DDS&#44; tiempo de remisi&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">De los pacientes&#44; 83&#37; mostraron mejor&#237;a cl&#237;nica y en la DDS y&#47;o reducci&#243;n del uso de prednisona&#46; De ellos&#44; 36&#37; presentaron un aumento del tiempo de remisi&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infecciones frecuentes &#40;viremia del virus BK o infecciones respiratorias&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de CANDLE-like<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 0&#44;5&#8211;9 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Criterios de reducci&#243;n de la DDS&#44; disminuci&#243;n de la dosis de corticosteroides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a de la DDS&#58; 25&#37;Disminuci&#243;n de la dosis de corticoides&#58; 50&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infecciones &#40;incluida la sepsis&#41;&#44; trastorno cerebrovascular&#44; osteonecrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de mutaciones de GOF en STAT1<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a cut&#225;nea tras el tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>SAVI &#40;<span class="elsevierStyleItalic">n</span> &#61; 4&#41;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2&#8211;10 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Criterios de reducci&#243;n de la DDS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Solo un caso de cuatro de mejor&#237;a en DDS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infecciones de las v&#237;as respiratorias&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>AIJ sist&#233;mica<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">34</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4&#8211;8 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a parcial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome VEXAS<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">35</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&#44; niveles de prote&#237;na C reactiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib y upadacitinib fueron menos eficaces que el ruxolitinib oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infecciones y tromboembolismos venosos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Lupus eritematoso cut&#225;neo</span><a class="elsevierStyleCrossRefs" href="#bib0705"><span class="elsevierStyleSup">37&#8211;41</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Lupus pernio familiar<a class="elsevierStyleCrossRef" href="#bib0705"><span class="elsevierStyleSup">37</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#205;ndice revisado de &#225;rea y gravedad del lupus cut&#225;neo &#40;R-CLASI&#41;&#44; dolor evaluado mediante EVA&#44; firma de IFN tipo I en sangre&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Se alcanz&#243; el R-CLASI100 en dos de tres pacientes&#46; La EVA media disminuy&#243; 72&#37; en el d&#237;a 30&#46; La puntuaci&#243;n de IFN tipo I logr&#243; una reducci&#243;n estad&#237;sticamente significativa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notificaron reacciones adversas graves&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Lupus eritematoso cut&#225;neo subagudo<a class="elsevierStyleCrossRefs" href="#bib0710"><span class="elsevierStyleSup">38&#44;40&#44;41</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de casos &#40;n &#61; 3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica &#40;3&#47;3&#41;&#44; &#237;ndice revisado de &#225;rea y gravedad del lupus cut&#225;neo &#40;R-CLASI&#41; &#40;1&#47;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n casi completa de las lesiones cut&#225;neas activas &#40;2&#47;3&#41; &#40;incluido un descenso del R-CLASI de 21 a 3&#41;&#44; resoluci&#243;n completa del LECS &#40;1&#47;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Alopecia difusa no cicatricial por lupus eritematoso sist&#233;mico<a class="elsevierStyleCrossRef" href="#bib0715"><span class="elsevierStyleSup">39</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Interrupci&#243;n de la ca&#237;da del cabello seguida de un prominente recrecimiento del cabello al cabo de ocho semanas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Prurigo nodular cr&#243;nico</span><a class="elsevierStyleCrossRefs" href="#bib0740"><span class="elsevierStyleSup">44&#8211;46</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Prurigo nodular cr&#243;nico at&#243;pico<a class="elsevierStyleCrossRefs" href="#bib0740"><span class="elsevierStyleSup">44&#44;45</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Puntuaci&#243;n del EASI&#44; NRS del prurito &#40;2&#47;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">R&#225;pida mejor&#237;a del prurito y de las lesiones cut&#225;neas&#46; Se alcanz&#243; el EASI50 en la semana ocho &#40;1&#47;1&#41;La NRS de picor disminuy&#243; 66&#44;7&#37; en la semana ocho y 75&#37; al cabo de tres meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sequedad &#40;50&#37;&#41;&#44; ros&#225;cea &#40;50&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Prurigo nodular cr&#243;nico no at&#243;pico<a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">46</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IGA&#44; Escala visual anal&#243;gica &#40;EVA&#41;&#44; NRS&#44; PAS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">En la semana 12&#44; la IGA disminuy&#243; de 3 a 2&#44; la VAS disminuy&#243; de 8 a 1&#44; la NRS disminuy&#243; de 9 a 2&#44; y la PAS disminuy&#243; de 4 a 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dermatomiositis</span><a class="elsevierStyleCrossRefs" href="#bib0755"><span class="elsevierStyleSup">47&#44;60</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dermatomiositis juvenil<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">60</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudio prospectivo &#40;n &#61; 4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4&#8211;8 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Puntuaci&#243;n del CDASI&#44; actividad global seg&#250;n paciente&#47;cuidador&#44; actividad global extramuscular y PGA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Se logr&#243; una disminuci&#243;n estad&#237;sticamente significativa de todas las puntuaciones en la cuarta semana&#46; Se redujeron o suspendieron los corticoides orales y otros inmunosupresores&#46; No hubo cambios notables en la calcinosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notificaron reacciones adversas graves&#46; Infecciones del tracto respiratorio superior&#44; reactivaci&#243;n del virus BK&#44; anomal&#237;as hematol&#243;gicas y niveles elevados de creatina cinasa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dermatomiositis &#40;adulto&#41;<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">47</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudio abierto &#40;n &#61; 12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CDASI-A y puntuaci&#243;n del DLQI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a significativa en la puntuaci&#243;n del CDASI-A y del DLQI en la semana cuatro y 12&#44; respectivamenteEl eritema facial y el prurito mostraron una mejor&#237;a significativa tras el tratamientoLa prednisona se redujo en cinco de seis pacientes y se suspendi&#243; en un paciente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aumento transitorio de las plaquetas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Enfermedades ampollosas autoinmunes</span><a class="elsevierStyleCrossRefs" href="#bib0805"><span class="elsevierStyleSup">57&#8211;59</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Epiderm&#243;lisis ampollosa pruriginosa<a class="elsevierStyleCrossRef" href="#bib0805"><span class="elsevierStyleSup">57</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a sustancial tras dos semanas de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Penfigoide de mucosas<a class="elsevierStyleCrossRef" href="#bib0805"><span class="elsevierStyleSup">57</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a ocular significativa dos meses despu&#233;s del tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span> Penfigoide ampolloso<a class="elsevierStyleCrossRef" href="#bib0810"><span class="elsevierStyleSup">58</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Un paciente con psoriasis concomitante mostr&#243; una remisi&#243;n completa de ambas dermatosis en la semana 24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Liquen plano pemfigoide<a class="elsevierStyleCrossRef" href="#bib0815"><span class="elsevierStyleSup">59</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 3&#44;4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n casi completa al cabo de seis meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Otras dermatosis</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>EICH cr&#243;nica<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">42</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">RCT &#40;n &#61; 20&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg&#44; con escalada a 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Criterios de respuesta 2014 NIH cEICH&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respuesta global de 63&#37; al sexto mes&#46; Todos los &#243;rganos excepto los pulmones mostraron una respuesta significativa&#46; No se especific&#243; la respuesta cut&#225;nea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infecciones respiratorias altas &#40;13&#41;&#44; neutropenia &#40;6&#41;&#44; hipofosfatemia &#40;12&#41;&#44; hipertrigliceridemia &#40;5&#41;&#44; reactivaci&#243;n de CMV&#44; EBV o BK &#40;18&#44; ninguna requiri&#243; tratamiento&#41;&#44; infecciones graves &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Eccema cr&#243;nico de manos4<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">43</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HECSI&#44; QOLHEQ&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n casi completa en ambos casos&#44; con una reducci&#243;n media del HECSI de 88&#44;7&#37; en la semana 16&#44; cuando ambos casos ten&#237;an una calidad de vida &#171;en absoluto deteriorada&#187;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#218;lcera corneal bacteriana &#40;1&#47;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fascitis eosinof&#237;lica<a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">50</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib &#40;dosificaci&#243;n no especificada&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica y ecogr&#225;fica&#44; puntuaci&#243;n del HAQ II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reducci&#243;n de la dosis de corticosteroides&#44; mejora de la puntuaci&#243;n HAQ II de 2&#44;5 a 1&#44;0&#44; reducci&#243;n de la induraci&#243;n cut&#225;nea&#44; mejora de la elasticidad&#44; reducci&#243;n del grosor de la fascia del gastrocnemio superficial de 2 mm a 1 mm&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Alopecia frontal fibrosante<a class="elsevierStyleCrossRefs" href="#bib0775"><span class="elsevierStyleSup">51&#44;65</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudios retrospectivos &#40;n &#61; 5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 3&#44;4&#8211;6&#44;8 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LPPAI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a en la puntuaci&#243;n de actividad de la enfermedad en 60&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Elevaci&#243;n de las enzimas hep&#225;ticas &#40;1&#47;13&#41;&#44; hipercolesterolemia &#40;1&#47;13&#41;&#44; neutropenia &#40;1&#47;13&#41;&#44; fatiga &#40;1&#47;13&#41;<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Morfea generalizada<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">52</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n del eritema a los dos meses y mejor&#237;a subjetiva a los seis meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Granuloma anular<a class="elsevierStyleCrossRefs" href="#bib0785"><span class="elsevierStyleSup">53&#8211;55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Los casos no recidivaron&#44; mejoraron o remitieron tras dos semanas a dos meses con baricitinib&#46; Un caso no recay&#243; tras la interrupci&#243;n de baricitinib &#40;1&#47;2&#41;&#44; pero otro caso s&#237; &#40;1&#47;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome hipereosinof&#237;lico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 5 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recuento de eosin&#243;filos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Normalizaci&#243;n del recuento de eosin&#243;filos despu&#233;s de tres meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Liquen plano<a class="elsevierStyleCrossRefs" href="#bib0775"><span class="elsevierStyleSup">51&#44;65</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudios retrospectivos y reporte de casos &#40;n &#61; 8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 3&#44;4&#8211;6&#44;8 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LPPAI&#46; Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejora de la puntuaci&#243;n de actividad de la enfermedad en 71&#37;&#46; Mejor&#237;a significativa y mantenida del LP ungueal &#40;1&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Elevaci&#243;n de las enzimas hep&#225;ticas &#40;1&#47;13&#41;&#44; hipercolesterolemia &#40;1&#47;13&#41;&#44; neutropenia &#40;1&#47;13&#41;&#44; fatiga &#40;1&#47;13&#41;<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Vasculopat&#237;a livedoide<a class="elsevierStyleCrossRef" href="#bib0860"><span class="elsevierStyleSup">68</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 8&#41;<a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">66</span></a> y dos reportes de casos &#40;n &#61; 2&#41;<a class="elsevierStyleCrossRefs" href="#bib0855"><span class="elsevierStyleSup">67&#44;68</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2&#8211;4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Evaluaci&#243;n de la puntuaci&#243;n cl&#237;nica compuesta por tres dominios&#58; dolor &#40;0-3&#41;&#44; ulceraci&#243;n &#40;0-2&#41; y eritema &#40;0-3&#41;&#46; Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejora de las puntuaciones cl&#237;nicas medias tras el tratamiento con baricitinib &#40;7&#44;0 &#177; 1&#44;6 y 1&#44;4 &#177; 1&#44;2 antes y despu&#233;s&#44; respectivamente&#41;&#46; De los pacientes&#44; 75&#37; alcanzaron la remisi&#243;n cl&#237;nica<a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">66</span></a>Mejor&#237;a r&#225;pida y notable con el tratamiento<a class="elsevierStyleCrossRefs" href="#bib0855"><span class="elsevierStyleSup">67&#44;68</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Psoriasis<a class="elsevierStyleCrossRefs" href="#bib0610"><span class="elsevierStyleSup">18&#44;70</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Un ECA &#40;n &#61; 271&#41; y un reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2&#8211;10 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PASIExploraci&#243;n cl&#237;nica y radiogr&#225;fica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">En la semana 12&#44; lograron una reducci&#243;n de 75&#37; del PASI 43&#37; y 54&#37; de los pacientes tratados con baricitinib 8 mg y 10 mg diarios&#44; respectivamente&#44; frente a 17&#37; en el grupo placebo&#46; La eficacia se mantuvo hasta la semana 24 en m&#225;s de 81&#37; de los pacientes que respondieron<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">18</span></a>Mejor&#237;a dermatol&#243;gica y articular desde el quinto d&#237;a de tratamiento en un paciente con acrodermatitis continua de Hallopeau<a class="elsevierStyleCrossRef" href="#bib0870"><span class="elsevierStyleSup">70</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Neutropenia y anemia leves&#44; peque&#241;os aumentos de la creatinina y las lipoprote&#237;nas&#46; Una muerte en el grupo de baricitinib 4 mg&#44; debida a un c&#225;ncer de es&#243;fago&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pioderma gangrenoso<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">71</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serie de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Remisi&#243;n completa en cinco semanas- tres meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Sweet<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">72</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a articular y remisi&#243;n cut&#225;nea tras cuatro semanas&#44; sin m&#225;s reagudizaciones tras 10 meses de seguimiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Esclerosis sist&#233;mica<a class="elsevierStyleCrossRef" href="#bib0900"><span class="elsevierStyleSup">76</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Una serie de casos y dos reportes de casos &#40;n &#61; 12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2&#8211;4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">mRSS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Se notific&#243; una respuesta cut&#225;nea significativa en 75&#37; de los pacientes&#44; con una reducci&#243;n media de la puntuaci&#243;n mRSS de 8&#44;75&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Herpes zoster &#40;1&#47;12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Vitiligo<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">77</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Repigmentaci&#243;n casi completa de sus extremidades superiores tras ocho meses de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295028.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Un paciente requiri&#243; un ajuste de la dosis a baricitinib 8 mg diarios debido a un brote leve en la semana nueve&#44; y posteriormente se redujo a 6 mg diarios&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">En uno o m&#225;s pacientes&#44; la dosis de baricitinib se redujo a la mitad durante el seguimiento&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Los acontecimientos adversos de la alopecia frontal fibrosante y el liquen plano pilar se obtuvieron del mismo estudio&#44; por lo que la columna representa la suma de los acontecimientos adversos de ambas enfermedades&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Uso en Dermatolog&#237;a del baricitinib fuera de ficha t&#233;cnica</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabla 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">CPK&#58; creatinfosfoquinasa&#59; DLQI&#58; &#237;ndice de calidad de vida dermatol&#243;gica&#59; HiSCR&#58; respuesta cl&#237;nica de la hidradenitis supurativa&#59; LP&#58; liquen plano&#59; SALT&#58; herramienta de puntuaci&#243;n de la severidad de la alopecia&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M&#225;ximo grado de evidencia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dosificaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Medidas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultado cl&#237;nico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Efectos adversos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia areata<a class="elsevierStyleCrossRefs" href="#bib0910"><span class="elsevierStyleSup">78&#8211;81</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de casos &#40;n &#61; 4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib 15&#8211;30 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica &#40;4&#47;4&#41;&#44; tricoscopia &#40;1&#47;4&#41;&#44; herramienta de puntuaci&#243;n de la severidad de la alopecia SALT &#40;1&#47;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">El cabello volvi&#243; a crecer &#40;4&#47;4&#41;Se alcanz&#243; SALT100 en todas las regiones con pelo en el cuarto mes &#40;1&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Elevaci&#243;n transitoria de la lipasa y la amilasa s&#233;ricas &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Liquen plano oral erosivo<a class="elsevierStyleCrossRefs" href="#bib0930"><span class="elsevierStyleSup">82&#44;83</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib 15 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica &#40;2&#47;2&#41;&#46; Esofagoscopia y ex&#225;menes histol&#243;gicos &#40;1&#47;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a completa y sostenida del LP oral &#40;2&#47;2&#41;&#46; Mejor&#237;a de la esofagitis en la semana 24 &#40;1&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Granuloma anular<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">85</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib 15 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n f&#237;sica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Marcada mejor&#237;a en la sexta semana&#46; Remisi&#243;n casi completa tras cuatro meses de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hidradenitis supurativa<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">86</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudio retrospectivo &#40;n &#61; 20&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib 15 mg diarios<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Proporci&#243;n de individuos que alcanzaron mejoras de 50&#44; 75 y 90&#37; en el criterio de valoraci&#243;n de la HiSCR&#46; DLQI y puntuaciones de dolor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Semana cuatro&#58;<span class="elsevierStyleHsp" style=""></span>- HiSCR50&#58; 75&#37;<span class="elsevierStyleHsp" style=""></span>- HiSCR75&#58; 30&#37;<span class="elsevierStyleHsp" style=""></span>- HiSCR90&#58; 20&#37;Semana 12&#58;<span class="elsevierStyleHsp" style=""></span>- HiSCR50&#58; 100&#37;<span class="elsevierStyleHsp" style=""></span>- HiSCR75&#58; 95&#37;<span class="elsevierStyleHsp" style=""></span>- HiSCR90&#58; 30&#37;El DLQI y el &#237;ndice de dolor se redujeron significativamente en la cuarta semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Elevaci&#243;n de CPK &#40;80&#37;&#41;&#44; COVID-19 &#40;15&#37;&#41;&#44; elevaci&#243;n transitoria de enzimas hep&#225;ticas &#40;10&#37;&#41;&#44; reactivaci&#243;n de herpes zoster &#40;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Eritema multiforme persistente<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">84</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib 15 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Examen f&#237;sico e informe del paciente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Marcada mejor&#237;a de las manifestaciones orales y cut&#225;neas y respuesta sostenida tras 25 meses de seguimiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295032.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Upadacitinib 30 mg diarios se administr&#243; en individuos refractarios en la semana cuatro&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Uso fuera de ficha t&#233;cnica del upadacitinib en Dermatolog&#237;a</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Tabla 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">ECA&#58; ensayo controlado aleatorizado&#59; EICHc&#58; enfermedad cr&#243;nica del injerto contra el hu&#233;sped&#59; LP&#58; liquen plano&#59; mCAILS&#58; puntuaci&#243;n de la evaluaci&#243;n compuesta modificada del &#237;ndice de gravedad de las lesiones&#59; SALT&#58; herramienta de puntuaci&#243;n de la severidad de la alopecia&#59; SC&#58; superficie corporal&#59; EVA&#58; escala visual anal&#243;gica&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M&#225;ximo grado de evidencia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dosificaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Medidas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultados&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Acontecimientos adversos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia areata<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">26&#44;87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dos ECA &#40;n &#61; 16 y n &#61; 78&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pomada de ruxolitinib al 1-1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SALT<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">24</span></a>&#59; evaluaci&#243;n global del investigador y del paciente<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">86</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">De los pacientes&#44; 50&#37; alcanzaron SALT50 en la semana 24&#44; pero el ECA no pudo demostrar ninguna diferencia significativa en SALT en comparaci&#243;n con el veh&#237;culo<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">24</span></a>De los pacientes&#44; 31&#37; mostraron un recrecimiento parcial del vello en las zonas tratadas frente a 63&#37; con clobetasol al 0&#44;05&#37;<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">86</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se informaron de hallazgos significativos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Psoriasis<a class="elsevierStyleCrossRef" href="#bib1000"><span class="elsevierStyleSup">96</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ECA &#40;n &#61; 29&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 0&#44;5&#37; diarios a 1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Puntuaci&#243;n total de la lesi&#243;n&#58; eritema &#40;0-3&#41;&#44; descamaci&#243;n &#40;0-3&#41; y grosor &#40;0-3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib al 1&#37; aplicado a diario y al 1&#44;5&#37; aplicado dos veces al d&#237;a produjo una disminuci&#243;n no estad&#237;sticamente significativa de 53-54&#37; en la puntuaci&#243;n total de la lesi&#243;n&#44; frente a 32&#37; con el veh&#237;culo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Efectos adversos locales &#40;escozor&#44; picor&#44; irritaci&#243;n&#44; dolor&#44; sequedad&#44; exfoliaci&#243;n&#44; enrojecimiento&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis seborreica<a class="elsevierStyleCrossRef" href="#bib1020"><span class="elsevierStyleSup">100</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n completa tras dos semanas de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LP<a class="elsevierStyleCrossRef" href="#bib0990"><span class="elsevierStyleSup">94</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudio abierto &#40;n &#61; 12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">mCAILS&#44; recuento total de lesiones&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">El recuento total de las lesiones disminuy&#243; en una mediana de 50 lesiones&#44; y el mCAILS disminuy&#243; en una diferencia media de 7&#44;6 entre las lesiones tratadas y las de control en la semana ocho&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notificaron acontecimientos adversos graves&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">EICHc cut&#225;neo<a class="elsevierStyleCrossRef" href="#bib0980"><span class="elsevierStyleSup">92</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N de un ensayo cl&#237;nico &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SC&#44; EVA del prurito&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejora de 6&#44;4&#37; en la SC de las lesiones tratadas&#44; frente a 3&#44;81&#37; de las lesiones tratadas con veh&#237;culo en la semana seis&#46; La mejor&#237;a del prurito no fue superior a la del placebo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ninguna atribuible a ruxolitinib t&#243;pico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lupus eritematoso cut&#225;neo<a class="elsevierStyleCrossRef" href="#bib0985"><span class="elsevierStyleSup">93</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 1&#44;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a en las placas tratadas y sutil recrecimiento del vello tras dos meses de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Necrobiosis lipoidica<a class="elsevierStyleCrossRef" href="#bib0995"><span class="elsevierStyleSup">95</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">El cambio de tofacitinib 2&#37; condujo a una marcada mejor&#237;a en el color y tama&#241;o despu&#233;s de tres meses de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295033.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Uso fuera de ficha t&#233;cnica del ruxolitinib t&#243;pico en dermatolog&#237;a</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0030"
        "etiqueta" => "Tabla 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at6"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">EMA&#58; Agencia Europea de Medicamentos&#59; JAK&#58; quinasa Janus&#59; PRAC&#58; Comit&#233; de Evaluaci&#243;n de Riesgos en Farmacovigilancia&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Propuesto por un grupo de trabajo multidisciplinar internacional de expertos en inhibidores de JAK en enfermedades inflamatorias<a class="elsevierStyleCrossRef" href="#bib1025"><span class="elsevierStyleSup">101</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Propuesto por el PRAC y aprobado por la EMA<a class="elsevierStyleCrossRef" href="#bib1030"><span class="elsevierStyleSup">102</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Ajustes de la dosis en situaciones especiales en pacientes tratados con inhibidores de JAK orales seg&#250;n el respectivo Resumen de las Caracter&#237;sticas del Producto de la EMA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Antes del tratamiento</span><span class="elsevierStyleHsp" style=""></span>&#8226; Historia cl&#237;nica completa<span class="elsevierStyleHsp" style=""></span>&#8226; Radiograf&#237;a de t&#243;rax<span class="elsevierStyleHsp" style=""></span>&#8226; Exploraci&#243;n basal de c&#225;ncer de piel<span class="elsevierStyleHsp" style=""></span>&#8226; An&#225;lisis de sangre completo &#40;hemograma&#44; enzimas hep&#225;ticas&#44; funci&#243;n renal&#44; niveles de l&#237;pidos y serolog&#237;as para VHB y VIH&#41;<span class="elsevierStyleHsp" style=""></span>&#8226; Detecci&#243;n de la tuberculosis<span class="elsevierStyleHsp" style=""></span>&#8226; Comprobaci&#243;n del estado vacunal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Restringir el uso de inhibidores de JAK a cuando no se disponga de otras opciones y preferiblemente a dosis m&#225;s bajas&#44; en pacientes con mayor riesgo de acontecimientos adversos graves&#58;<span class="elsevierStyleHsp" style=""></span>&#8226; Pacientes &#62; 65 a&#241;os<span class="elsevierStyleHsp" style=""></span>&#8226; Fumadores o exfumadores de larga duraci&#243;n<span class="elsevierStyleHsp" style=""></span>&#8226; Antecedentes de enfermedad cardiovascular<span class="elsevierStyleHsp" style=""></span>&#8226; Presencia de eventos tromboemb&#243;licos venosos o factores de riesgo de c&#225;ncer</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Baricitinib</span>La dosis recomendada para los trastornos dermatol&#243;gicos es de 4 mg diarios&#46; En pacientes de edad &#8805; 75 a&#241;os o con antecedentes de infecciones cr&#243;nicas o recurrentes&#44; debe considerarse una reducci&#243;n de la dosis a 2 mg diarios&#46; Baricitinib puede requerir ajustes de dosis en caso de insuficiencia renal<span class="elsevierStyleBold">Upadacitinib</span>La dosis recomendada para la dermatitis at&#243;pica es de 15-30 mg diarios&#46; La dosis de 15 mg diarios debe considerarse especialmente en adolescentes y pacientes de &#8805; 65 a&#241;os<span class="elsevierStyleBold">Abrocitinib</span>La dosis inicial recomendada para la dermatitis at&#243;pica es de 200 mg diarios&#46; Sin embargo&#44; la dosificaci&#243;n de 100 mg diarios debe considerarse especialmente en pacientes con insuficiencia renal moderada y pacientes de edad &#8805; 65 a&#241;os</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Durante el tratamiento</span><span class="elsevierStyleHsp" style=""></span>&#8226; Exploraci&#243;n peri&#243;dica de la piel<span class="elsevierStyleHsp" style=""></span>&#8226; Ex&#225;menes de sangre peri&#243;dicos &#40;primer y tercer mes&#44; luego peri&#243;dicamente como cada tres meses&#41;<span class="elsevierStyleHsp" style=""></span>&#8226; Vacunaci&#243;n antineumoc&#243;cica y antigripal<span class="elsevierStyleHsp" style=""></span>&#8226; Vacuna contra el virus del herpes z&#243;ster en caso de serolog&#237;a positiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295030.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Resumen de recomendaciones de pretratamiento y seguimiento del tratamiento en pacientes que reciben inhibidores de JAK</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0035"
        "etiqueta" => "Tabla 7"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at7"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">AIJ&#58; artitis idiop&#225;tica juvenil&#59; JAK&#58; Janus quinasa&#59; EICHc&#58; enfermedad cr&#243;nica del injerto contra el hu&#233;sped&#59; LP&#58; liquen plano&#59; SAVI&#58; vasculopat&#237;a asociada a STING de inicio en la infancia&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dermatosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No&#46; de estudios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No&#46; de pacientes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Inhibidores de JAK&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Acrodermatitis continua de Hallopeau</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0870"><span class="elsevierStyleSup">70</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Alopecia areata</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abrocitinib&#44;<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">30</span></a> upadacitinib<a class="elsevierStyleCrossRefs" href="#bib0910"><span class="elsevierStyleSup">78&#8211;81</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dermatitis de contacto</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abrocitinib<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">31</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dermatomiositis &#40;del adulto y juvenil&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0755"><span class="elsevierStyleSup">47&#8211;49&#44;60&#8211;64</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Fascitis eosinof&#237;lica</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">50</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Eritema multiforme</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">84</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Alopecia frontal fibrosante</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0710"><span class="elsevierStyleSup">38&#44;51</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Granuloma anular</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib&#44;<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">85</span></a> baricitinib<a class="elsevierStyleCrossRefs" href="#bib0785"><span class="elsevierStyleSup">53&#8211;55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">EICHc</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">42</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Eccema de manos &#40;cr&#243;nico&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">43</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hidradenitis supurativa</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">86</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">S&#237;ndrome hipereosinof&#237;lico</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0800"><span class="elsevierStyleSup">56</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">LP</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib&#44;<a class="elsevierStyleCrossRefs" href="#bib0930"><span class="elsevierStyleSup">82&#44;83</span></a> baricitinib<a class="elsevierStyleCrossRefs" href="#bib0775"><span class="elsevierStyleSup">51&#44;65</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Vasculopat&#237;a livedoide</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0850"><span class="elsevierStyleSup">66&#8211;68</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Lupus eritematoso &#40;cut&#225;neo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0705"><span class="elsevierStyleSup">37&#8211;41</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Morfea &#40;generalizada&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">52</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Trastornos autoinflamatorios</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib&#44;<a class="elsevierStyleCrossRefs" href="#bib0680"><span class="elsevierStyleSup">32&#8211;36</span></a> upadacitinib<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">34</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Enfermedad de Still del adulto&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Aicardi-Gouti&#232;res&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Blau&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Candle&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome CANDLE-like&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de mutaciones de GOF en STAT1&#8217;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome SAVI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>AIJ sist&#233;mica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome VEXAS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Enfermedades ampollosas autoinmunes</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0805"><span class="elsevierStyleSup">57&#8211;59</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Penfigoide ampolloso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Epiderm&#243;lisis ampollosa pruriginosa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>LP penfigoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Penfigoide de la mucosa ocular&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Prurigo nodular cr&#243;nico</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0740"><span class="elsevierStyleSup">44&#8211;46</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Psoriasis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">271&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">18</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pioderma gangrenoso</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">71</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">S&#237;ndrome de Sweet</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">72</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Esclerosis sist&#233;mica</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0885"><span class="elsevierStyleSup">73&#8211;76</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Vit&#237;ligo</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">77</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295029.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Uso fuera de ficha t&#233;cnica en Dermatolog&#237;a de los inhibidores de JAK orales &#40;abrocitinib&#44; baricitinib y upadacitinib&#41;</p>"
        ]
      ]
      7 => array:5 [
        "identificador" => "fig0005"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 1085
            "Ancho" => 857
            "Tamanyo" => 134049
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:104 [
            0 => array:3 [
              "identificador" => "bib0525"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primer&#58; signal transduction in rheumatic disease &#8211; a clinician&#39;s guide"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/ncprheum0631"
                      "Revista" => array:7 [
                        "tituloSerie" => "Nat Clin Pract Rheumatol&#46;"
                        "fecha" => "2007"
                        "volumen" => "3"
                        "paginaInicial" => "651"
                        "paginaFinal" => "660"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0530"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "New-generation JAK inhibitors&#58; how selective can they be&#63;"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(18)31325-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet&#46;"
                        "fecha" => "2018"
                        "volumen" => "391"
                        "paginaInicial" => "2477"
                        "paginaFinal" => "2478"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0535"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Emerging topical and systemic JAK inhibitors in dermatology"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fimmu.2019.02847"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Immunol&#46;"
                        "fecha" => "2019"
                        "volumen" => "10"
                        "paginaInicial" => "2847"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0540"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adverse events associated with JAK inhibitors in 126&#44;815 reports from the WHO pharmacovigilance database"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/s41598-022-10777-w"
                      "Revista" => array:5 [
                        "tituloSerie" => "Sci Rep&#46;"
                        "fecha" => "2022"
                        "volumen" => "12"
                        "paginaInicial" => "7140"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0545"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Janus kinase inhibitors in dermatology&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2016.12.004"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "76"
                        "paginaInicial" => "745"
                        "paginaFinal" => "753&#46;e19"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0550"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK inhibitor safety compared to traditional systemic immunosuppressive therapies"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.36849/JDD.7187"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Drugs Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "21"
                        "paginaInicial" => "1298"
                        "paginaFinal" => "1303"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0555"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Venous thromboembolism risk with JAK inhibitors&#58; a meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.41580"
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Rheumatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "73"
                        "paginaInicial" => "779"
                        "paginaFinal" => "788"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0560"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2022.3516"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "158"
                        "paginaInicial" => "1254"
                        "paginaFinal" => "1261"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0565"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK in the &#91;black&#93; box&#58; a dermatology perspective on systemic JAK inhibitor safety"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40257-022-00701-3"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "23"
                        "paginaInicial" => "427"
                        "paginaFinal" => "431"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0570"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40257-021-00618-3"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "22"
                        "paginaInicial" => "693"
                        "paginaFinal" => "707"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0575"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis&#58; the JADE TEEN randomized clinical trial"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.2830"
                      "Revista" => array:7 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "157"
                        "paginaInicial" => "1165"
                        "paginaFinal" => "1173"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0580"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systemic immunomodulatory treatments for atopic dermatitis&#58; update of a living systematic review and network meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2022.0455"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "158"
                        "paginaInicial" => "523"
                        "paginaFinal" => "532"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0585"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Population pharmacokinetic&#8211;pharmacodynamic modelling of platelet time-courses following administration of abrocitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bcp.15334"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Clin Pharmacol&#46;"
                        "fecha" => "2022"
                        "volumen" => "88"
                        "paginaInicial" => "3856"
                        "paginaFinal" => "3871"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0590"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A review of safety outcomes from clinical trials of baricitinib in rheumatology&#44; dermatology and COVID-19"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12325-022-02281-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Adv Ther&#46;"
                        "fecha" => "2022"
                        "volumen" => "39"
                        "paginaInicial" => "4910"
                        "paginaFinal" => "4960"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0595"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.16948"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2021"
                        "volumen" => "35"
                        "paginaInicial" => "476"
                        "paginaFinal" => "485"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0600"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis&#58; an integrated analysis from eight randomized clinical trials"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40257-021-00602-x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "22"
                        "paginaInicial" => "395"
                        "paginaFinal" => "405"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0605"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/bjd/ljac059"
                      "Revista" => array:5 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2023"
                        "volumen" => "188"
                        "paginaInicial" => "218"
                        "paginaFinal" => "227"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0610"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A randomized phase 2 b trial of baricitinib&#44; an oral Janus kinase &#40;JAK&#41; 1&#47;JAK2 inhibitor&#44; in patients with moderate-to-severe psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.14403"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2016"
                        "volumen" => "174"
                        "paginaInicial" => "1266"
                        "paginaFinal" => "1276"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0615"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis &#40;Measure Up 1 and Measure Up 2&#41;&#58; results from two replicate double-blind&#44; randomised controlled phase 3 trials"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(21)00588-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet&#46;"
                        "fecha" => "2021"
                        "volumen" => "397"
                        "paginaInicial" => "2151"
                        "paginaFinal" => "2168"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0620"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis&#58; a randomized clinical trial"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.3023"
                      "Revista" => array:7 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "157"
                        "paginaInicial" => "1047"
                        "paginaFinal" => "1055"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0625"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis &#40;AD Up&#41;&#58; results from a randomised&#44; double-blind&#44; placebo-controlled&#44; phase 3 trial"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(21)00589-4"
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet&#46;"
                        "fecha" => "2021"
                        "volumen" => "397"
                        "paginaInicial" => "2169"
                        "paginaFinal" => "2181"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0630"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Upadacitinib in adults with moderate to severe atopic dermatitis&#58; 16-week results from a randomized&#44; placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaci.2019.11.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "145"
                        "paginaInicial" => "877"
                        "paginaFinal" => "884"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0635"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis&#63; A systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/1756-185X.14447"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Rheum Dis&#46;"
                        "fecha" => "2023"
                        "volumen" => "26"
                        "paginaInicial" => "31"
                        "paginaFinal" => "42"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0640"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis&#44; psoriatic arthritis&#44; ankylosing spondylitis and atopic dermatitis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/rmdopen-2022-002735"
                      "Revista" => array:5 [
                        "tituloSerie" => "RMD Open&#46;"
                        "fecha" => "2023"
                        "volumen" => "9"
                        "paginaInicial" => "e002735"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0645"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical Janus kinase inhibitors&#58; a review of applications in dermatology"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2018.04.018"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "79"
                        "paginaInicial" => "535"
                        "paginaFinal" => "544"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0650"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ruxolitinib cream for the treatment of patients with alopecia areata&#58; a 2-part&#44; double-blind&#44; randomized&#44; vehicle-controlled phase 2 study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2019.10.016"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "82"
                        "paginaInicial" => "412"
                        "paginaFinal" => "419"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0655"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Role of Janus kinase inhibitors in therapy of psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/jcm10194307"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Clin Med&#46;"
                        "fecha" => "2021"
                        "volumen" => "10"
                        "paginaInicial" => "4307"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0660"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of atopic dermatitis with ruxolitinib cream &#40;JAK1&#47;JAK2 inhibitor&#41; or triamcinolone cream"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaci.2019.08.042"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "145"
                        "paginaInicial" => "572"
                        "paginaFinal" => "582"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0665"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis&#58; results from 2 phase 3&#44; randomized&#44; double-blind studies"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2021.04.085"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "85"
                        "paginaInicial" => "863"
                        "paginaFinal" => "872"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0670"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2022.02.027"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAAD Case Rep&#46;"
                        "fecha" => "2022"
                        "volumen" => "22"
                        "paginaInicial" => "99"
                        "paginaFinal" => "100"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0675"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Occupational airborne allergic contact dermatitis to invasive compositae species treated with abrocitinib&#58; a reporte de caso"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cod.14204"
                      "Revista" => array:5 [
                        "tituloSerie" => "Contact Dermat&#46;"
                        "fecha" => "2022"
                        "volumen" => "87"
                        "paginaInicial" => "542"
                        "paginaFinal" => "544"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0680"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of Janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders&#58; a scoping review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s13555-021-00517-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Ther &#40;Heidelb&#41;&#46;"
                        "fecha" => "2021"
                        "volumen" => "11"
                        "paginaInicial" => "733"
                        "paginaFinal" => "750"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0685"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome&#58; reporte de caso and literature review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1759720X221093211"
                      "Revista" => array:3 [
                        "tituloSerie" => "Ther Adv Musculoskelet Dis&#46;"
                        "fecha" => "2022"
                        "volumen" => "14"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0690"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness and safety of JAK inhibitors in autoinflammatory diseases&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fmed.2022.930071"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Med &#40;Lausanne&#41;&#46;"
                        "fecha" => "2022"
                        "volumen" => "9"
                        "paginaInicial" => "930071"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0695"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome&#58; a retrospective multicenter study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood.2022016642"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "2022"
                        "volumen" => "140"
                        "paginaInicial" => "927"
                        "paginaFinal" => "931"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0700"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of refractory adult onset Still&#39;s disease with combination anakinra and baricitinib therapy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/key414"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2019"
                        "volumen" => "58"
                        "paginaInicial" => "736"
                        "paginaFinal" => "737"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0705"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessment of clinical response to Janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2018.5077"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "155"
                        "paginaInicial" => "342"
                        "paginaFinal" => "346"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0710"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.15044"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "47"
                        "paginaInicial" => "787"
                        "paginaFinal" => "788"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0715"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of JAK 1&#47;2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2019-216571"
                      "Revista" => array:7 [
                        "tituloSerie" => "Ann Rheum Dis&#46;"
                        "fecha" => "2020"
                        "volumen" => "79"
                        "paginaInicial" => "674"
                        "paginaFinal" => "675"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0720"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.15005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "47"
                        "paginaInicial" => "748"
                        "paginaFinal" => "750"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0725"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/kez442"
                      "Revista" => array:4 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2019"
                        "volumen" => "59"
                        "paginaInicial" => "1792"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0730"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease &#40;cGVHD&#41;&#58; preliminary analysis results of a phase 1&#47;2 study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2020-140392"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "2020"
                        "volumen" => "136"
                        "numero" => "Suppl&#46; 1"
                        "paginaInicial" => "1"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0735"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Baricitinib treatment of severe chronic hand eczema&#58; two reporte de casos"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cod.14039"
                      "Revista" => array:6 [
                        "tituloSerie" => "Contact Dermat&#46;"
                        "fecha" => "2022"
                        "volumen" => "86"
                        "paginaInicial" => "419"
                        "paginaFinal" => "421"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0740"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness of baricitinib in prurigo-type atopic dermatitis&#58; a reporte de caso"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.14878"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2021"
                        "volumen" => "34"
                        "paginaInicial" => "e14878"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0745"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Improvement of chronic nodular prurigo with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.17991"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2022"
                        "volumen" => "36"
                        "paginaInicial" => "e486"
                        "paginaFinal" => "e488"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0750"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment of refractory prurigo nodularis with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15642"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Therapy&#46;"
                        "fecha" => "2022"
                        "volumen" => "35"
                        "paginaInicial" => "e15642"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0755"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Baricitinib for the treatment of cutaneous dermatomyositis&#58; a prospective&#44; open-label study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2022.08.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "87"
                        "paginaInicial" => "1374"
                        "paginaFinal" => "1376"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0760"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.21252"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "187"
                        "paginaInicial" => "432"
                        "paginaFinal" => "435"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0765"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/keaa377"
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2020"
                        "volumen" => "59"
                        "paginaInicial" => "4003"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0770"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment with baricitinib in a patient with refractory eosinophilic fasciitis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3899/jrheum.200998"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "48"
                        "paginaInicial" => "948"
                        "paginaFinal" => "949"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0775"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of lichen planopilaris with baricitinib&#58; a retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2022.02.027"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "87"
                        "paginaInicial" => "663"
                        "paginaFinal" => "666"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0780"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Jak inhibition prevents bleomycin-induced fibrosis in mice and is effective in patients with morphea"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jid.2019.12.019"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Invest Dermatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "140"
                        "paginaInicial" => "1446"
                        "paginaFinal" => "1449&#46;e4"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0785"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rapid improvement of refractory generalized granuloma annulare with the Janus kinase inhibitor baricitinib in two patients"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ced/llac110"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2023"
                        "volumen" => "48"
                        "paginaInicial" => "375"
                        "paginaFinal" => "376"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0790"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Recalcitrant granuloma annulare induced by two different biologic agents resolved after Janus kinase inhibitor treatment"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15641"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2022"
                        "volumen" => "35"
                        "paginaInicial" => "e15641"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0795"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment of generalized granuloma annulare with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.18031"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2022"
                        "volumen" => "36"
                        "paginaInicial" => "e500"
                        "paginaFinal" => "e502"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0800"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hypereosinophilic syndrome &#8211; a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s10067-020-05134-z"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Rheumatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "39"
                        "paginaInicial" => "3507"
                        "paginaFinal" => "3510"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0805"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A literature review on Janus kinase &#40;JAK&#41; inhibitors for the treatment of immunobullous disorders"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.intimp.2022.108923"
                      "Revista" => array:5 [
                        "tituloSerie" => "Int Immunopharmacol&#46;"
                        "fecha" => "2022"
                        "volumen" => "110"
                        "paginaInicial" => "108923"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0810"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15754"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2022"
                        "volumen" => "35"
                        "paginaInicial" => "e15754"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0815"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effective treatment of refractory lichen planus pemphigoides with a Janus kinase-1&#47;2 inhibitor"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.15344"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "47"
                        "paginaInicial" => "2040"
                        "paginaFinal" => "2041"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0820"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Janus kinase &#40;JAK&#41; inhibition with baricitinib in refractory juvenile dermatomyositis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2020-218690"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis&#46;"
                        "fecha" => "2021"
                        "volumen" => "80"
                        "paginaInicial" => "406"
                        "paginaFinal" => "408"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0825"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The efficacy of baricitinib in real-world patients with refractory or severe juvenile dermatomyositis&#58; a monocentric retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.21203/rs.3.rs-1226720/v1"
                      "Revista" => array:3 [
                        "tituloSerie" => "Research Square&#46;"
                        "fecha" => "2022"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0830"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis&#58; a monocentric retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/keab116"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2021"
                        "volumen" => "60"
                        "paginaInicial" => "5801"
                        "paginaFinal" => "5808"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib0835"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Janus kinase 1&#47;2 inhibition with baricitinib in the treatment of juvenile dermatomyositis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/brain/awz005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Brain&#46;"
                        "fecha" => "2019"
                        "volumen" => "142"
                        "paginaInicial" => "e8"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib0840"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive&#44; bisphosphonate&#44; oral baricitinib and physical therapy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15960"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2022"
                        "volumen" => "35"
                        "paginaInicial" => "e15960"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib0845"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of severe nail lichen planus with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.5082"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "158"
                        "paginaInicial" => "107"
                        "paginaFinal" => "108"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib0850"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fimmu.2022.1008392"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Immunol&#46;"
                        "fecha" => "2022"
                        "volumen" => "13"
                        "paginaInicial" => "1008392"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib0855"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Refractory livedoid vasculopathy in a child successfully treated with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15659"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2022"
                        "volumen" => "35"
                        "paginaInicial" => "e15659"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib0860"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Refractory livedoid vasculopathy successfully treated with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ijd.16467"
                      "Revista" => array:2 [
                        "tituloSerie" => "Int J Dermatol&#46;"
                        "fecha" => "2022"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib0865"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The efficacy and safety of tofacitinib&#44; peficitinib&#44; solcitinib&#44; baricitinib&#44; abrocitinib and deucravacitinib in plaque psoriasis &#8211; a network meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.18263"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2022"
                        "volumen" => "36"
                        "paginaInicial" => "1937"
                        "paginaFinal" => "1946"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib0870"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inhibition of progression of acrodermatitis continua of hallopeau with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.0045"
                      "Revista" => array:7 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "157"
                        "paginaInicial" => "466"
                        "paginaFinal" => "468"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            70 => array:3 [
              "identificador" => "bib0875"
              "etiqueta" => "71"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment of ulcerated pyoderma gangrenosum with baricitinib&#44; a novel JAK inhibitor"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jtauto.2021.100099"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Transl Autoimmun&#46;"
                        "fecha" => "2021"
                        "volumen" => "4"
                        "paginaInicial" => "100099"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            71 => array:3 [
              "identificador" => "bib0880"
              "etiqueta" => "72"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.14712"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "46"
                         …3
                      ]
                    ]
                  ]
                ]
              ]
            ]
            72 => array:3 [
              "identificador" => "bib0885"
              "etiqueta" => "73"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK1&#47;2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fmed.2022.859330"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            73 => array:3 [
              "identificador" => "bib0890"
              "etiqueta" => "74"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib&#58; A Novel Case Report"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1155/2019/5293981"
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            74 => array:3 [
              "identificador" => "bib0895"
              "etiqueta" => "75"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.55563/clinexprheumatol/gu1ac8"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            75 => array:3 [
              "identificador" => "bib0900"
              "etiqueta" => "76"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK inhibitors and systemic sclerosis&#58; A systematic review of the literature"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.autrev.2022.103168"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            76 => array:3 [
              "identificador" => "bib0905"
              "etiqueta" => "77"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Repigmentation of vitiligo with oral baricitinib"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ajd.13348"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            77 => array:3 [
              "identificador" => "bib0910"
              "etiqueta" => "78"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Upadacitinib improved alopecia areata in a patient with atopic dermatitis&#58; A case report"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15346"
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            78 => array:3 [
              "identificador" => "bib0915"
              "etiqueta" => "79"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient&#58; A case report"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/2050313X221138452"
                      "Revista" => array:3 [ …3]
                    ]
                  ]
                ]
              ]
            ]
            79 => array:3 [
              "identificador" => "bib0920"
              "etiqueta" => "80"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ijd.16316"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            80 => array:3 [
              "identificador" => "bib0925"
              "etiqueta" => "81"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effective treatment of alopecia universalis with oral upadacitinib"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2022.08.014"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            81 => array:3 [
              "identificador" => "bib0930"
              "etiqueta" => "82"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of Oral Erosive Lichen Planus With Upadacitinib"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2022.0147"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            82 => array:3 [
              "identificador" => "bib0935"
              "etiqueta" => "83"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK inhibitors in lichen planus&#58; a review of pathogenesis and treatments"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546634.2022.2116926"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            83 => array:3 [
              "identificador" => "bib0940"
              "etiqueta" => "84"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.4084"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            84 => array:3 [
              "identificador" => "bib0945"
              "etiqueta" => "85"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful therapy of disseminated patch-type granuloma annulare with upadacitinib in a patient with rheumatoid arthritis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15211"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            85 => array:3 [
              "identificador" => "bib0950"
              "etiqueta" => "86"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "AbbVie&#46; A phase 2&#44; multicenter&#44; randomized&#44; placebo-controlled&#44; double-blind study to evaluate upadacitinib in adult subjects with moderate to severe hidradenitis suppurativa&#46; clinicaltrials&#46;gov&#59; 2023&#46; &#91;Internet&#93;&#44; &#91;consultado 29 Mar 2023&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT04430855">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT04430855</a>"
                ]
              ]
            ]
            86 => array:3 [
              "identificador" => "bib0955"
              "etiqueta" => "87"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of alopecia universalis with topical Janus kinase inhibitors &#8211; a double blind&#44; placebo&#44; and active controlled pilot study"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ijd.14192"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            87 => array:3 [
              "identificador" => "bib0960"
              "etiqueta" => "88"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2017.03.024"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            88 => array:3 [
              "identificador" => "bib0965"
              "etiqueta" => "89"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.15383"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            89 => array:3 [
              "identificador" => "bib0970"
              "etiqueta" => "90"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical Ruxolitinib for the Treatment of Alopecia Universalis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2015.4445"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            90 => array:3 [
              "identificador" => "bib0975"
              "etiqueta" => "91"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A case of Topical Ruxolitinib Treatment Failure in Alopecia Areata"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1203475417716363"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            91 => array:3 [
              "identificador" => "bib0980"
              "etiqueta" => "92"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Cowen E&#44; Phase II study of topical ruxolitinib for cutaneous chronic graft versus host disease &#40;CGVHD&#41;&#46; clinicaltrials&#46;gov&#59; 2022&#46; &#91;Internet&#93;&#44; &#91;consultado 29 Mar 2023&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/study/NCT03395340">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;study&#47;NCT03395340</a>"
                ]
              ]
            ]
            92 => array:3 [
              "identificador" => "bib0985"
              "etiqueta" => "93"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of cutaneous lupus with topical ruxolitinib cream"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2022.08.038"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            93 => array:3 [
              "identificador" => "bib0990"
              "etiqueta" => "94"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus&#58; A Prospective&#44; Open-Label Study"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jid.2022.01.015"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            94 => array:3 [
              "identificador" => "bib0995"
              "etiqueta" => "95"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2022.08.028"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            95 => array:3 [
              "identificador" => "bib1000"
              "etiqueta" => "96"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Preliminary clinical activity of a topical JAK1&#47;2 inhibitor in the treatment of psoriasis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2011.12.018"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            96 => array:3 [
              "identificador" => "bib1005"
              "etiqueta" => "97"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Downmodulation of key inflammatory cell markers with a topical Janus kinase 1&#47;2 inhibitor"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.13994"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            97 => array:3 [
              "identificador" => "bib1010"
              "etiqueta" => "98"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Incyte Corporation&#46; A double-blind&#44; randomized&#44; vehicle-controlled dose ranging study of the effect of INCB018424 phosphate cream when applied to patients with plaque psoriasis&#46; clinicaltrials&#46;gov&#59; 2022&#46; &#91;Internet&#93;&#44; &#91;consultado 29 Mar 2023&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT00778700">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT00778700</a>"
                ]
              ]
            ]
            98 => array:3 [
              "identificador" => "bib1015"
              "etiqueta" => "99"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Incyte Corporation&#46; An open label&#44; safety&#44; tolerability&#44; pharmacokinetic &#40;PK&#41;&#44; pharmacodynamic &#40;PD&#41; and preliminary efficacy study of ruxolitinib when applied to patients with plaque psoriasis involving 2&#8211;20&#37; body surface area &#40;BSA&#41;&#46; clinicaltrials&#46;gov&#59; 2022&#46; &#91;Internet&#93;&#44; &#91;consultado 29 Mar 2023&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT00617994">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT00617994</a>"
                ]
              ]
            ]
            99 => array:3 [
              "identificador" => "bib1020"
              "etiqueta" => "100"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2022.04.003"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            100 => array:3 [
              "identificador" => "bib1025"
              "etiqueta" => "101"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors&#58; a consensus statement"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2020-218398"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            101 => array:3 [
              "identificador" => "bib1030"
              "etiqueta" => "102"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "EMA&#46; EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders&#46; European Medicines Agency&#46; &#91;Internet&#93;&#44; &#91;consultado 30 Mar 2023&#93;&#46; Disponible en&#58; <a target="_blank" href="https://www.ema.europa.eu/en/news/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic">https&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;en&#47;news&#47;ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic</a>"
                ]
              ]
            ]
            102 => array:3 [
              "identificador" => "bib1035"
              "etiqueta" => "103"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Herpes zoster subunit vaccine for patients initiating a Janus kinase inhibitor"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2022.08.040"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            103 => array:3 [
              "identificador" => "bib1040"
              "etiqueta" => "104"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impact of off-label use regulations on patient care in dermatology &#8211; a prospective study of cost-coverage applications filed by tertiary dermatology clinics throughout Germany"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.18357"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023006397/v1_202310020456/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6158"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Revisiones"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011400000009/v1_202310020456/S0001731023006397/v1_202310020456/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023006397?idApp=UINPBA000044"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

REVISIÓN
Perfil de seguridad a largo plazo y usos fuera de indicación de los inhibidores de JAK en dermatología
Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders
L. Corbella-Bagota, C. Riquelme-McLoughlina, D. Morgado-Carrascoa,b,
Autor para correspondencia
morgadodaniel8@gmail.com

Autor para correspondencia.
a Departamento de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, España
b Departamento de Dermatología, Hospital de Figueres, Fundació Salut Empordà, Figueres, España
Leído
6393
Veces
se ha leído el artículo
1470
Total PDF
4923
Total HTML
Compartir estadísticas
 array:24 [
  "pii" => "S0001731023006397"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2023.08.002"
  "estado" => "S300"
  "fechaPublicacion" => "2023-10-01"
  "aid" => "3623"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2023"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "rev"
  "cita" => "Actas Dermosifiliogr. 2023;114:T784-T801"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731023003976"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.05.016"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3506"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "pgl"
    "cita" => "Actas Dermosifiliogr. 2023;114:802-11"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">DOCUMENTO DE CONSENSO</span>"
      "titulo" => "Recomendaciones del Grupo de Psoriasis de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a sobre el manejo del paciente de edad avanzada con psoriasis en placas moderada-grave"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "802"
          "paginaFinal" => "811"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Moderate to Severe Psoriasis in Older Adults&#58; Recommendations on Management from the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology &#40;AEDV&#41;"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46; Mataix, L&#46; Garc&#237;a, I&#46; Belinch&#243;n, J&#46;C&#46; Ruiz Carrascosa, P&#46; de la Cueva, J&#46;M&#46; Carrascosa"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Mataix"
            ]
            1 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Garc&#237;a"
            ]
            2 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Belinch&#243;n"
            ]
            3 => array:2 [
              "nombre" => "J&#46;C&#46;"
              "apellidos" => "Ruiz Carrascosa"
            ]
            4 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "de la Cueva"
            ]
            5 => array:2 [
              "nombre" => "J&#46;M&#46;"
              "apellidos" => "Carrascosa"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023003976?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023003976/v1_202310020456/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731023004969"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.06.012"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3553"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "rev"
    "cita" => "Actas Dermosifiliogr. 2023;114:784-801"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
      "titulo" => "Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:3 [
        0 => "en"
        1 => "en"
        2 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "784"
          "paginaFinal" => "801"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Perfil de seguridad a largo plazo y usos fuera de indicaci&#243;n de los inhibidores de JAK en dermatolog&#237;a"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0005"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 1085
              "Ancho" => 832
              "Tamanyo" => 133126
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "L&#46; Corbella-Bagot, C&#46; Riquelme-McLoughlin, D&#46; Morgado-Carrasco"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Corbella-Bagot"
            ]
            1 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Riquelme-McLoughlin"
            ]
            2 => array:2 [
              "nombre" => "D&#46;"
              "apellidos" => "Morgado-Carrasco"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0005"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004969?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023004969/v1_202310020456/en/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731023004969"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2023.06.012"
      "estado" => "S300"
      "fechaPublicacion" => "2023-10-01"
      "aid" => "3553"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "rev"
      "cita" => "Actas Dermosifiliogr. 2023;114:784-801"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:14 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
        "titulo" => "Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:3 [
          0 => "en"
          1 => "en"
          2 => "es"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "784"
            "paginaFinal" => "801"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Perfil de seguridad a largo plazo y usos fuera de indicaci&#243;n de los inhibidores de JAK en dermatolog&#237;a"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "es" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 1
          "multimedia" => array:5 [
            "identificador" => "fig0005"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => false
            "mostrarDisplay" => true
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "fx1.jpeg"
                "Alto" => 1085
                "Ancho" => 832
                "Tamanyo" => 133126
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "L&#46; Corbella-Bagot, C&#46; Riquelme-McLoughlin, D&#46; Morgado-Carrasco"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "L&#46;"
                "apellidos" => "Corbella-Bagot"
              ]
              1 => array:2 [
                "nombre" => "C&#46;"
                "apellidos" => "Riquelme-McLoughlin"
              ]
              2 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Morgado-Carrasco"
              ]
            ]
          ]
        ]
        "resumen" => array:1 [
          0 => array:3 [
            "titulo" => "Graphical abstract"
            "clase" => "graphical"
            "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0005"></elsevierMultimedia></p></span>"
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004969?idApp=UINPBA000044"
      "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023004969/v1_202310020456/en/main.assets"
    ]
  ]
  "es" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">REVISI&#211;N</span>"
    "titulo" => " Perfil de seguridad a largo plazo y usos fuera de indicaci&#243;n de los inhibidores de JAK en dermatolog&#237;a"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "T784"
        "paginaFinal" => "T801"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "L&#46; Corbella-Bagot, C&#46; Riquelme-McLoughlin, D&#46; Morgado-Carrasco"
        "autores" => array:3 [
          0 => array:3 [
            "nombre" => "L&#46;"
            "apellidos" => "Corbella-Bagot"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "C&#46;"
            "apellidos" => "Riquelme-McLoughlin"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          2 => array:4 [
            "nombre" => "D&#46;"
            "apellidos" => "Morgado-Carrasco"
            "email" => array:1 [
              0 => "morgadodaniel8@gmail.com"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital Cl&#237;nic de Barcelona&#44; Universitat de Barcelona&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital de Figueres&#44; Fundaci&#243; Salut Empord&#224;&#44; Figueres&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 1
      "multimedia" => array:5 [
        "identificador" => "fig0005"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 1085
            "Ancho" => 857
            "Tamanyo" => 134049
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Introducci&#243;n</span><p id="par0005" class="elsevierStylePara elsevierViewall">En los &#250;ltimos a&#241;os&#44; el campo de la dermatolog&#237;a ha experimentado avances significativos con el desarrollo de m&#250;ltiples f&#225;rmacos biol&#243;gicos y peque&#241;as mol&#233;culas que act&#250;an selectivamente sobre mol&#233;culas espec&#237;ficas del sistema inmunitario&#46; Una v&#237;a de se&#241;alizaci&#243;n especialmente notable&#44; implicada tanto en la inmunidad innata como en la adaptativa&#44; es la v&#237;a Janus quinasa&#47;transductor de se&#241;al y activador de la transcripci&#243;n &#40;JAK-STAT&#41;&#46; Esta &#250;ltima implica tirosina quinasas intracelulares denominadas Janus quinasas &#40;JAK&#41;&#44; que se componen de cuatro isoformas&#58; JAK1&#44; JAK2&#44; JAK3 y TYK2&#46; Los inhibidores de JAK act&#250;an suprimiendo de forma reversible la fosforilaci&#243;n de las JAK mediante la ocupaci&#243;n del sitio catal&#237;tico de uni&#243;n al ATP<a class="elsevierStyleCrossRef" href="#bib0525"><span class="elsevierStyleSup">1</span></a>&#46; Aunque los inhibidores de JAK m&#225;s selectivos pueden evitar los efectos adversos asociados a las isoformas JAK no bloqueadas&#44; las implicaciones de esta selectividad para la seguridad a largo plazo siguen sin estar claras<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">2</span></a>&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">El upadacitinib y el abrocitinib orales &#40;inhibidores selectivos de JAK 1&#41;&#44; as&#237; como el baricitinib oral y el ruxolitinib t&#243;pico &#40;inhibidores de JAK1&#47;2&#41; han sido aprobados por la Administraci&#243;n de Alimentos y Medicamentos de EE&#46; UU&#46; &#40;FDA&#41; y&#47;o la Agencia Europea de Medicamentos &#40;EMA&#41; para varias indicaciones dermatol&#243;gicas &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41;&#46; En este estudio&#44; pretendemos revisar el perfil de seguridad a largo plazo de estos inhibidores de JAK en dermatolog&#237;a y describir su uso fuera de ficha t&#233;cnica en diversos trastornos cut&#225;neos&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">M&#233;todos</span><p id="par0015" class="elsevierStylePara elsevierViewall">Se realiz&#243; una revisi&#243;n narrativa de la literatura&#46; Se efectuaron b&#250;squedas bibliogr&#225;ficas en PubMed y Google Scholar desde enero de 2000 hasta enero de 2023 utilizando las palabras clave &#171;<span class="elsevierStyleItalic">Janus kinase inhibitors</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">JAK inhibitors</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">off-label</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">dermatology</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">safety</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">adverse events</span>&#187;&#44; &#171;ruxolitinib&#187;&#44; &#171;upadacitinib&#187;&#44; &#171;abrocitinib&#187; y &#171;baricitinib&#187;&#46; Tambi&#233;n se incluyeron las enfermedades inflamatorias cut&#225;neas en la estrategia de b&#250;squeda&#58; &#171;<span class="elsevierStyleItalic">granuloma annulare</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">histiocytosis</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">sarcoidosis</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">morphea</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">livedoid vasculopathy</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">Sweet syndrome</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">VEXAS syndrome</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">hypereosinophilic syndrome</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">Kimura disease</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">acrodermatitis continua of Hallopeau</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">erythema multiforme</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">DRESS syndrome</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">Steven Johnson syndrome</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">toxic epidermal necrolysis</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">autoinflammatory diseases</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">panniculitis</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">cutaneous vasculitis</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">cutaneous lupus</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">lichen planus</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">graft versushost disease</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">Still disease</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">necrobiosis lipoidica</span>&#187; y &#171;<span class="elsevierStyleItalic">chronic nodular prurigo</span>&#187;&#46; La estrategia de b&#250;squeda incluy&#243; ensayos cl&#237;nicos&#44; metaan&#225;lisis&#44; estudios observacionales&#44; series y reportes de casos&#44; y se restringi&#243; a art&#237;culos en ingl&#233;s y espa&#241;ol&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Resultados</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Perfil de seguridad a largo plazo</span><p id="par0020" class="elsevierStylePara elsevierViewall">Los inhibidores de JAK suelen asociarse a diversos acontecimientos adversos&#46; Entre ellos&#44; se incluyen citopenias&#44; infecciones urinarias y del tracto respiratorio superior&#44; reactivaci&#243;n del virus del herpes&#44; n&#225;useas&#44; diarrea&#44; cefalea&#44; alteraci&#243;n de las pruebas de funci&#243;n hep&#225;tica&#44; hipercolesterolemia y aumento de la creatinfosfoquinasa &#40;CPK&#41;<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">3</span></a>&#46; Los acontecimientos adversos m&#225;s graves y poco frecuentes incluyen los eventos tromboemb&#243;licos&#44; la reactivaci&#243;n del virus de la hepatitis B &#40;VHB&#41;&#44; la tuberculosis diseminada&#44; la perforaci&#243;n gastrointestinal &#40;en particular el tofacitinib<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">4</span></a>&#41; y a los c&#225;nceres s&#243;lidos<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">3</span></a>&#46; Entre las reacciones adversas dermatol&#243;gicas poco comunes est&#225;n el c&#225;ncer de piel no melanoma&#44; el molusco contagioso diseminado y las reacciones cut&#225;neas adversas<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">5</span></a>&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">El primero de septiembre de 2021&#44; la FDA revis&#243; los resultados del ensayo de seguridad poscomercializaci&#243;n que comparaba el tofacitinib con los inhibidores del factor de necrosis tumoral alfa &#40;TNF-&#945;&#41; en la artritis reumatoide&#46; En el estudio participaron pacientes de &#8805; 50 a&#241;os tratados simult&#225;neamente con metotrexato y con factores de riesgo cardiovascular preexistentes&#46; Se concluy&#243; que el tofacitinib planteaba un mayor riesgo de eventos cardiovasculares mayores &#40;MACE&#41;&#44; acontecimientos tromboemb&#243;licos&#44; neoplasias malignas y la muerte&#46; Bas&#225;ndose en estos resultados&#44; la FDA emiti&#243; una advertencia &#40;<span class="elsevierStyleItalic">Boxed Warning</span>&#41;&#44; que tambi&#233;n se extendi&#243; a otros inhibidores de JAK que no hab&#237;an sido evaluados en ensayos cl&#237;nicos similares<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">6</span></a>&#46; Sin embargo&#44; un estudio que analiz&#243; un amplio conjunto de datos en 126&#46;815 informes de eventos adversos asociados al uso de inhibidores de JAK no logr&#243; identificar ning&#250;n aumento estad&#237;sticamente significativo de acontecimientos cardiovasculares graves<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">4</span></a>&#46; Adem&#225;s&#44; dos metaan&#225;lisis que investigaron los inhibidores de JAK en enfermedades inflamatorias y dermatitis at&#243;pica informaron de una incidencia similar de tromboembolismo venoso en comparaci&#243;n con los controles<a class="elsevierStyleCrossRefs" href="#bib0555"><span class="elsevierStyleSup">7&#44;8</span></a>&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Los datos procedentes de ensayos controlados aleatorizados &#40;ECA&#41; sugieren que ciertos eventos adversos pueden actuar de forma dependiente de la dosis&#44; debido al bloqueo de otras isoformas de JAK m&#225;s all&#225; de las diana<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">9</span></a>&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Abrocitinib</span><p id="par0035" class="elsevierStylePara elsevierViewall">En un estudio en el que se evaluaron las tasas de incidencia a largo plazo de los eventos adversos graves de una cohorte del estudio de an&#225;lisis integrado de seguridad para abrocitinib con 2&#46;856 pacientes y 1&#46;614 persona-a&#241;os &#40;pa&#41;&#44; el abrocitinib a dosis de 100 mg y 200 mg mostr&#243; 0&#44;6 y 0&#44;4 c&#225;nceres de piel no melanoma&#47;100 pa&#59; 0&#44;6 y 0&#44;2 eventos MACE&#47;100 pa&#44; y 0&#44;0 y 0&#44;4 acontecimientos tromboemb&#243;licos venosos &#40;TEV&#41;&#47;100 pa&#44; respectivamente&#46; Se produjeron otras neoplasias malignas &#40;excluido el c&#225;ncer de piel no melanoma&#41; a una tasa de 0&#44;2&#47;100 pa<a class="elsevierStyleCrossRefs" href="#bib0550"><span class="elsevierStyleSup">6&#44;10</span></a>&#46; Los eventos adversos relacionados con la dosis incluyeron principalmente n&#225;useas&#44; cefalea&#44; acn&#233; y trombocitopenia&#46; Las tasas de incidencia fueron de 2&#44;65&#47;100 pa y 2&#44;33&#47;100 pa para las infecciones graves&#44; 2&#44;04&#47;100 pa y 4&#44;34&#47;100 pa para el herpes z&#243;ster y 8&#44;73&#47;100 pa y 11&#44;83&#47;100 pa para el herpes simple en los grupos de 100 y 200 mg&#44; respectivamente&#46; Se notificaron tres muertes&#44; atribuidas a carcinoma g&#225;strico&#44; muerte s&#250;bita y COVID-19<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">10</span></a>&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">En adolescentes con dermatitis at&#243;pica&#44; la seguridad del abrocitinib oral se ha evaluado en un ECA de fase 3 controlado con placebo&#44; demostrando una menor incidencia de acontecimientos adversos graves en comparaci&#243;n con el grupo placebo<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">11</span></a>&#46; Un metan&#225;lisis en dermatitis at&#243;pica mostr&#243; que el abrocitinib a 100 mg estaba relacionado con m&#225;s efectos adversos graves que el dupilumab &#40;<span class="elsevierStyleItalic">odds ratio</span> &#91;OR&#93; 2&#44;6&#41;<a class="elsevierStyleCrossRef" href="#bib0580"><span class="elsevierStyleSup">12</span></a>&#46; Un an&#225;lisis de los recuentos plaquetarios a partir de datos obtenidos en cinco ensayos cl&#237;nicos de abrocitinib inform&#243; de un mayor riesgo de trombocitopenia en las primeras cuatro semanas de tratamiento en pacientes con recuentos plaquetarios basales bajos<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">13</span></a>&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Baricitinib</span><p id="par0045" class="elsevierStylePara elsevierViewall">La incidencia de los eventos adversos graves asociados al baricitinib est&#225; en consonancia con el riesgo inherente que plantea la poblaci&#243;n de la enfermedad espec&#237;fica que se est&#225; tratando&#46; Las enfermedades reumatol&#243;gicas suelen asociarse a una mayor prevalencia de MACE&#44; TEV&#44; neoplasias malignas&#44; infecciones graves y herpes z&#243;ster&#46; Por el contrario&#44; los casos de herpes simples son m&#225;s frecuentes entre los pacientes con dermatitis at&#243;pica<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">14</span></a>&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">En un an&#225;lisis de seguridad combinado de 8 ECA de baricitinib en 2&#46;531 sujetos con dermatitis at&#243;pica&#44; la tasa global de acontecimientos adversos emergentes del tratamiento &#40;EAET&#41; fue mayor en los pacientes tratados con baricitinib que en los que se manejaron con placebo&#46; La tasa de incidencia ajustada de infecciones graves fue de 3&#44;0&#47;100 pa y de 1&#44;5&#47;100 pa para baricitinib a 4 mg y 2 mg diarios&#44; respectivamente&#46; Se notificaron dos casos de MACE en personas que recibieron baricitinib 2 mg y se observaron dos casos de TEV en los que obtuvieron la dosis de 4 mg&#46; Hubo una muerte en el grupo de baricitinib a 4 mg&#44; debida a hemorragia gastrointestinal&#46; Los acontecimientos adversos comunes relacionados con alteraciones en la anal&#237;tica fueron el aumento de la CPK&#44; la hiperlipidemia y alteraciones hematol&#243;gicas&#44; hep&#225;ticas y renales leves<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">15</span></a>&#46; El an&#225;lisis de seguridad ampliado de baricitinib a 2 mg mostr&#243; resultados similares<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">16</span></a>&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Entre los 1&#46;303 pacientes con alopecia areata &#40;AA&#41; incluidos en un an&#225;lisis integrado de seguridad&#44; los EAET m&#225;s frecuentes fueron la infecci&#243;n de las v&#237;as respiratorias superiores&#44; la nasofaringitis&#44; la cefalea&#44; el acn&#233; y la elevaci&#243;n de la CPK&#46; El an&#225;lisis identific&#243; 34 casos de herpes z&#243;ster&#44; tres neoplasias malignas &#40;excluido el c&#225;ncer de piel no melanoma&#41;&#44; una infecci&#243;n oportunista&#44; un infarto de miocardio&#44; una embolia pulmonar y una perforaci&#243;n gastrointestinal<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">17</span></a>&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">En cuanto a la psoriasis&#44; el baricitinib se someti&#243; a un ensayo cl&#237;nico de fase 2 b &#40;n &#61; 271&#41;&#44; con informes de seguridad comparables<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">18</span></a>&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Upadacitinib</span><p id="par0065" class="elsevierStylePara elsevierViewall">Se realiz&#243; un metaan&#225;lisis de 2 ECA para evaluar las tasas de incidencia a largo plazo de acontecimientos adversos en pacientes con dermatitis at&#243;pica&#46; Los resultados indicaron que el upadacitinib en dosis de 15 mg y 30 mg presentaba tasas de neoplasias inferiores y similares&#44; respectivamente&#44; en comparaci&#243;n con la tasa de incidencia general de todas las neoplasias en la poblaci&#243;n de EE&#46; UU&#46; El upadacitinib tambi&#233;n mostr&#243; tasas bajas de c&#225;ncer de piel no melanoma &#40;0&#44;4 eventos&#47;100 a&#241;os&#41;&#44; MACE &#40;0&#44;0-0&#44;1 eventos&#47;100 a&#241;os&#41; y TEV &#40;0&#44;1 eventos&#47;100 a&#241;os&#41;<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">6</span></a>&#46; En ambos ECA&#44; la incidencia de eventos adversos graves fue similar entre los grupos&#46; Los EAET observados con mayor frecuencia incluyeron el acn&#233;&#44; una infecci&#243;n de las v&#237;as respiratorias superiores&#44; la elevaci&#243;n de los niveles de CPK y la dermatitis at&#243;pica<a class="elsevierStyleCrossRef" href="#bib0615"><span class="elsevierStyleSup">19</span></a>&#46; Otros ECA realizados en pacientes con dermatitis at&#243;pica informaron de un perfil de seguridad igualmente favorable<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">20</span></a>&#46; Un estudio revel&#243; tasas ligeramente superiores de infecciones graves &#40;1&#44;1 vs&#46; 0&#44;6&#37;&#41;&#44; eccema herp&#233;tico &#40;0&#44;3 vs&#46; 0&#37;&#41;&#44; herpes z&#243;ster &#40;2&#44;0 vs&#46; 0&#44;9&#37;&#41; y alteraciones anal&#237;ticas en sujetos que recibieron upadacitinib en comparaci&#243;n con los que obtuvieron dupilumab<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">20</span></a>&#46; Los ensayos controlados con placebo arrojaron resultados similares&#44; aunque el aumento del riesgo de herpes z&#243;ster e infecciones graves no fue constante en todos los estudios<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">21&#44;22</span></a>&#46; Un metaan&#225;lisis realizado en pacientes con artritis psori&#225;sica mostr&#243; que una dosis diaria de upadacitinib de 30 mg se asociaba a un riesgo relativo de acontecimientos adversos de 1&#44;20 en comparaci&#243;n con el placebo&#44; mientras que una dosis diaria de 15 mg no alcanz&#243; significaci&#243;n estad&#237;stica<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">23</span></a>&#46; Aunque otro metaan&#225;lisis sobre el perfil de seguridad del upadacitinib demostr&#243; tasas similares de eventos adversos emergentes con el tratamiento &#40;EAET&#41; en pacientes con dermatitis at&#243;pica y en aquellos con afecciones reumatol&#243;gicas&#44; los EAET graves&#44; el herpes z&#243;ster y las elevaciones de la creatinfosfoquinasa fueron menos frecuentes en personas con dermatitis at&#243;pica&#46; Sin embargo&#44; se observaron tasas m&#225;s elevadas de acn&#233; en aquellos con dermatitis at&#243;pica&#46; El mismo estudio concluy&#243; que el upadacitinib se vinculaba a un mayor riesgo de herpes z&#243;ster&#44; c&#225;ncer de piel no melanoma y elevaci&#243;n de la CPK en comparaci&#243;n con el metotrexato y el adalimumab<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">24</span></a>&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Ruxolitinib t&#243;pico</span><p id="par0070" class="elsevierStylePara elsevierViewall">En general&#44; el ruxolitinib t&#243;pico se tolera bien y sus efectos adversos se limitan principalmente a reacciones cut&#225;neas locales &#40;dolor en el lugar de aplicaci&#243;n&#44; eritema&#44; exfoliaci&#243;n&#44; foliculitis&#44; prurito&#41;<a class="elsevierStyleCrossRefs" href="#bib0645"><span class="elsevierStyleSup">25&#44;26</span></a>&#46; No se ha notificado toxicidad sist&#233;mica&#46; Curiosamente&#44; en un estudio doble ciego de ruxolitinib 0&#44;5 o 1&#44;0&#37; de crema diaria o 1&#44;5&#37; de crema dos veces al d&#237;a en la psoriasis&#44; no se observ&#243; inhibici&#243;n de transductor de se&#241;al y activador de la transcripci&#243;n 3 &#40;STAT3&#41; fosforilada en las c&#233;lulas sangu&#237;neas&#44; y se detectaron bajas concentraciones plasm&#225;ticas del f&#225;rmaco en estado estacionario<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">27</span></a>&#46; Un estudio en dermatitis at&#243;pica estim&#243; que la exposici&#243;n sist&#233;mica correspond&#237;a aproximadamente a 4-5&#37; de la dosis aplicada<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">28</span></a>&#46; En dos ECA de fase 3 en dermatitis at&#243;pica &#40;n &#61; 1&#46;251&#41;&#44; se notific&#243; una menor tasa de reacciones en el lugar de aplicaci&#243;n en comparaci&#243;n con el veh&#237;culo<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">29</span></a>&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Uso fuera de la ficha t&#233;cnica de los inhibidores de JAK en trastornos cut&#225;neos</span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Abrocitinib &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;</span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Alopecia areata</span><p id="par0075" class="elsevierStylePara elsevierViewall">Una adolescente con dermatitis at&#243;pica y AA <span class="elsevierStyleItalic">universalis</span> recibi&#243; abrocitinib 200 mg&#47;d&#237;a&#44; tras lo cual el cabello le volvi&#243; a crecer al cabo de 12 semanas&#46; Se observaron pelos terminales en varias zonas en la semana 52<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">30</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Dermatitis de contacto</span><p id="par0080" class="elsevierStylePara elsevierViewall">Un paciente adulto tratado con abrocitinib 100 mg&#47;d&#237;a para una dermatitis de contacto al&#233;rgica ocupacional transmitida por el aire alcanz&#243; la resoluci&#243;n completa despu&#233;s de ocho semanas<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">31</span></a>&#46;</p></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Baricitinib &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;</span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Trastornos autoinflamatorios con manifestaciones cut&#225;neas</span><p id="par0085" class="elsevierStylePara elsevierViewall">El baricitinib oral se ha probado en determinados trastornos autoinflamatorios&#46; Se observ&#243; mejor&#237;a cl&#237;nica en series y&#47;o reportes de pacientes con s&#237;ndrome de dermatosis neutrof&#237;lica at&#237;pica cr&#243;nica con lipodistrofia y elevaci&#243;n de la temperatura &#40;CANDLE&#41;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&#44; s&#237;ndrome de &#171;<span class="elsevierStyleItalic">CANDLE-like</span>&#187;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&#44; Aicardi-Gouti&#232;res<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&#44; vasculopat&#237;a asociada a la prote&#237;na STING de inicio en la infancia &#40;SAVI&#41;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&#44; mutaciones de ganancia de funci&#243;n &#40;GOF&#41; en STAT1<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&#44; s&#237;ndrome de Blau refractario<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">33</span></a> y artritis idiop&#225;tica juvenil sist&#233;mica<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">34</span></a>&#46; En el s&#237;ndrome de vacuolas&#44; enzima E-1&#44; ligado a x&#44; autoinflamatorio&#44; som&#225;tico &#40;VEXAS&#41;&#44; un estudio multic&#233;ntrico retrospectivo mostr&#243; que el baricitinib y el upadacitinib conduc&#237;an a peores resultados que el ruxolitinib oral<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">35</span></a>&#46; Dos series de casos &#40;n &#61; 3 y n &#61; 2&#41; de enfermedad de Still del adulto presentaron resoluci&#243;n completa &#40;40&#37;&#41; o parcial &#40;20&#37;&#41;<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">34</span></a> con el baricitinib 4 mg&#47;d&#237;a&#44; y se comunic&#243; un caso de remisi&#243;n cl&#237;nica tras asociar baricitinib a anakinra y corticoides<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">36</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Lupus eritematoso cut&#225;neo</span><p id="par0090" class="elsevierStylePara elsevierViewall">Encontramos una serie de casos y cuatro reportes de casos con baricitinib 4 mg&#47;d&#237;a&#46; En pacientes con lupus pernio familiar se observ&#243; una mejor&#237;a de las lesiones l&#250;picas cut&#225;neas al cabo de tres meses<a class="elsevierStyleCrossRef" href="#bib0705"><span class="elsevierStyleSup">37</span></a>&#46; En los reportes de casos se consigui&#243; una desaparici&#243;n completa con estabilizaci&#243;n concomitante de la alopecia frontal fibrosante<a class="elsevierStyleCrossRef" href="#bib0710"><span class="elsevierStyleSup">38</span></a>&#44; una mejor&#237;a de la alopecia asociada al lupus eritematoso sist&#233;mico<a class="elsevierStyleCrossRef" href="#bib0715"><span class="elsevierStyleSup">39</span></a> y una resoluci&#243;n casi completa de las lesiones de lupus eritematoso cut&#225;neo subagudo<a class="elsevierStyleCrossRefs" href="#bib0720"><span class="elsevierStyleSup">40&#44;41</span></a>&#46;</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Enfermedad cr&#243;nica de injerto contra hu&#233;sped &#40;EICHc&#41;</span><p id="par0095" class="elsevierStylePara elsevierViewall">Un ECA de fase 1&#47;2 de baricitinib en la enfermedad cr&#243;nica de injerto contra hu&#233;sped &#40;EICHc&#41; &#40;n &#61; 20&#41;&#44; que incluy&#243; 19 casos de EICHc escler&#243;tica&#44; demostr&#243; una respuesta global en el sexto mes de 63&#37;&#44; con 88&#37; de respuestas duraderas<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">42</span></a>&#46;</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Eccema cr&#243;nico de las manos</span><p id="par0100" class="elsevierStylePara elsevierViewall">Una serie de casos &#40;n &#61; 2&#41; con baricitinib 4 mg&#47;d&#237;a revel&#243; una resoluci&#243;n casi completa tras 16 semanas<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">43</span></a>&#46;</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Prurigo nodular cr&#243;nico</span><p id="par0105" class="elsevierStylePara elsevierViewall">Baricitinib 4 mg&#47;d&#237;a produjo una r&#225;pida mejor&#237;a del prurito y de las lesiones de prurigo en dos reportes de casos de pacientes con predisposici&#243;n at&#243;pica<a class="elsevierStyleCrossRefs" href="#bib0740"><span class="elsevierStyleSup">44&#44;45</span></a>&#44; y en uno con prurigo nodular cr&#243;nico no at&#243;pico<a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">46</span></a>&#46;</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Dermatomiositis &#40;forma adulta&#41;</span><p id="par0110" class="elsevierStylePara elsevierViewall">Un estudio abierto &#40;n &#61; 12&#41; demostr&#243; que baricitinib 2 mg&#47;12 h disminu&#237;a la actividad de la enfermedad y mejoraba la puntuaci&#243;n del &#205;ndice de Calidad de Vida en Dermatolog&#237;a &#40;DLQI&#41;<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">47</span></a>&#46; Una serie de casos &#40;n &#61; 3&#41;<a class="elsevierStyleCrossRef" href="#bib0760"><span class="elsevierStyleSup">48</span></a> y el reporte de un caso<a class="elsevierStyleCrossRef" href="#bib0765"><span class="elsevierStyleSup">49</span></a> de baricitinib 4 mg&#47;d&#237;a tambi&#233;n documentaron resultados prometedores&#46;</p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Fascitis eosinof&#237;lica</span><p id="par0115" class="elsevierStylePara elsevierViewall">En un var&#243;n adulto con fascitis eosinof&#237;lica refractaria&#44; el baricitinib redujo la induraci&#243;n cut&#225;nea y el uso de corticoides&#44; y mejor&#243; la elasticidad cut&#225;nea<a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">50</span></a>&#46;</p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Alopecia frontal fibrosante</span><p id="par0120" class="elsevierStylePara elsevierViewall">En un estudio retrospectivo &#40;n &#61; 5&#41;&#44; el baricitinib mejor&#243; a 60&#37; de los pacientes con alopecia fibrosante frontal<a class="elsevierStyleCrossRef" href="#bib0775"><span class="elsevierStyleSup">51</span></a>&#46;</p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Morfea generalizada</span><p id="par0125" class="elsevierStylePara elsevierViewall">Un var&#243;n con morfea generalizada refractaria fue tratado con baricitinib 2 mg&#47;d&#237;a&#44; con mejor&#237;a al cabo de seis meses<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">52</span></a>&#46;</p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Granuloma anular</span><p id="par0130" class="elsevierStylePara elsevierViewall">Todos los pacientes de una serie de casos &#40;n &#61; 2&#41; y dos informes de casos experimentaron mejor&#237;a o remisi&#243;n tras dos a ocho semanas de tratamiento con baricitinib 3-4 mg&#47;d&#237;a<a class="elsevierStyleCrossRefs" href="#bib0785"><span class="elsevierStyleSup">53&#8211;55</span></a>&#46;</p></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">S&#237;ndrome hipereosinof&#237;lico</span><p id="par0135" class="elsevierStylePara elsevierViewall">Una mujer de 39 a&#241;os con s&#237;ndrome hipereosinof&#237;lico que presentaba vasculitis eosinof&#237;lica en los dedos normaliz&#243; el recuento de eosin&#243;filos tras tres meses de baricitinib<a class="elsevierStyleCrossRef" href="#bib0800"><span class="elsevierStyleSup">56</span></a>&#46;</p></span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Enfermedades ampollosas inmunes</span><p id="par0140" class="elsevierStylePara elsevierViewall">Los reportes de casos han documentado el uso de baricitinib en el tratamiento de diversos trastornos&#44; como en la epiderm&#243;lisis bullosa pruriginosa&#44; en el penfigoide de la mucosa ocular&#44; el penfigoide ampolloso y en el liquen plano &#40;LP&#41; penfigoide&#46; Los resultados comunicados var&#237;an desde una mejor&#237;a significativa hasta la resoluci&#243;n completa<a class="elsevierStyleCrossRefs" href="#bib0805"><span class="elsevierStyleSup">57&#8211;59</span></a>&#46;</p></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Dermatomiositis juvenil</span><p id="par0145" class="elsevierStylePara elsevierViewall">El baricitinib &#40;4-8 mg&#47;d&#237;a&#41; redujo significativamente la actividad de la enfermedad en la dermatomiositis juvenil &#40;DMJ&#41; refractaria &#40;n &#61; 4&#41; a partir de la cuarta semana en un estudio prospectivo<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">60</span></a>&#46; Ensayos retrospectivos &#40;n &#61; 15 y n &#61; 3&#41; informaron de una mejor&#237;a cut&#225;nea en todos los pacientes con DMJ&#44; incluida la estabilizaci&#243;n de la calcinosis&#44; la regresi&#243;n parcial y la remisi&#243;n completa<a class="elsevierStyleCrossRefs" href="#bib0825"><span class="elsevierStyleSup">61&#44;62</span></a>&#46; Los reportes de casos demostraron una mejor&#237;a de los s&#237;ntomas cut&#225;neos y musculares<a class="elsevierStyleCrossRef" href="#bib0835"><span class="elsevierStyleSup">63</span></a>&#44; as&#237; como reducciones de la calcinosis<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">64</span></a>&#46;</p></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Liquen plano</span><p id="par0150" class="elsevierStylePara elsevierViewall">En un estudio retrospectivo &#40;n &#61; 7&#41;&#44; el uso de baricitinib demostr&#243; mejor&#237;a en 71&#37; de los pacientes con LP pilaris<a class="elsevierStyleCrossRef" href="#bib0775"><span class="elsevierStyleSup">51</span></a>&#46; Una mujer con LP ungueal grave<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">65</span></a> experiment&#243; una mejor&#237;a significativa y sostenida con el baricitinib&#46;</p></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Vasculopat&#237;a livedoide</span><p id="par0155" class="elsevierStylePara elsevierViewall">Una serie de casos &#40;n &#61; 8&#41; de baricitinib 2 mg&#47;d&#237;a para la vasculopat&#237;a livedoide refractaria hall&#243; una mejor&#237;a estad&#237;sticamente significativa de la actividad de la enfermedad&#46; Se alcanz&#243; la remisi&#243;n cl&#237;nica en seis casos<a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">66</span></a>&#46; Dos reportes de casos mostraron una mejor&#237;a r&#225;pida<a class="elsevierStyleCrossRef" href="#bib0855"><span class="elsevierStyleSup">67</span></a> y notable con el baricitinib 4 mg&#47;d&#237;a<a class="elsevierStyleCrossRef" href="#bib0860"><span class="elsevierStyleSup">68</span></a>&#46;</p></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Psoriasis</span><p id="par0160" class="elsevierStylePara elsevierViewall">En un ECA de fase 2 b de 12 semanas de duraci&#243;n &#40;n &#61; 271&#41;&#44; se logr&#243; una reducci&#243;n de 75&#37; en el &#237;ndice de &#225;rea y gravedad de la psoriasis &#40;PASI&#41; en 43-54&#37; de los pacientes tratados con baricitinib<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">18</span></a>&#46; Un metaan&#225;lisis mostr&#243; una menor eficacia de este f&#225;rmaco en comparaci&#243;n con el tofacitinib<a class="elsevierStyleCrossRef" href="#bib0865"><span class="elsevierStyleSup">69</span></a>&#46; Una mujer de 28 a&#241;os con acrodermatitis continua de Hallopeau present&#243; una remisi&#243;n r&#225;pida y mantenida de los s&#237;ntomas cut&#225;neos y articulares con baricitinib 2 mg&#47;d&#237;a<a class="elsevierStyleCrossRef" href="#bib0870"><span class="elsevierStyleSup">70</span></a>&#46;</p></span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Pioderma gangrenoso</span><p id="par0165" class="elsevierStylePara elsevierViewall">El baricitinib 4 mg&#47;d&#237;a condujo a una respuesta completa en una serie de casos &#40;n &#61; 2&#41; de pioderma gangrenoso refractario en la parte inferior de la pierna y el cuero cabelludo<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">71</span></a>&#46;</p></span><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0180">S&#237;ndrome de Sweet</span><p id="par0170" class="elsevierStylePara elsevierViewall">Una mujer de 59 a&#241;os con s&#237;ndrome de Sweet asociado a artritis reumatoide refractaria mejor&#243; sus s&#237;ntomas articulares y cut&#225;neos tras cuatro semanas con baricitinib<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">72</span></a>&#46;</p></span><span id="sec0165" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0185">Esclerosis sist&#233;mica</span><p id="par0175" class="elsevierStylePara elsevierViewall">Una serie de casos &#40;n &#61; 10&#41;<a class="elsevierStyleCrossRef" href="#bib0885"><span class="elsevierStyleSup">73</span></a> y dos reportes de casos investigaron el uso de baricitinib en la esclerosis sist&#233;mica<a class="elsevierStyleCrossRefs" href="#bib0890"><span class="elsevierStyleSup">74&#44;75</span></a>&#46; Se observ&#243; una respuesta cut&#225;nea significativa en nueve pacientes<a class="elsevierStyleCrossRef" href="#bib0900"><span class="elsevierStyleSup">76</span></a>&#46;</p></span><span id="sec0170" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0190">Vit&#237;ligo</span><p id="par0180" class="elsevierStylePara elsevierViewall">Un hombre de 67 a&#241;os con vit&#237;ligo en ambas manos y antebrazos recibi&#243; baricitinib 4 mg&#47;d&#237;a para la artritis reumatoide&#44; mostrando repigmentaci&#243;n al cabo de ocho meses<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">77</span></a>&#46;</p></span></span><span id="sec0175" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0195">Upadacitinib &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a>&#41;</span><span id="sec0180" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0200">Alopecia areata</span><p id="par0185" class="elsevierStylePara elsevierViewall">Cuatro informes de casos &#40;n &#61; 4&#41; demostraron que el cabello volv&#237;a a crecer con upadacitinib 15-30 mg&#47;d&#237;a&#46; En tres casos&#44; este r&#233;gimen tambi&#233;n mejor&#243; una dermatitis at&#243;pica grave concurrente<a class="elsevierStyleCrossRefs" href="#bib0910"><span class="elsevierStyleSup">78&#8211;81</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0185" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0205">Liquen plano oral erosivo</span><p id="par0190" class="elsevierStylePara elsevierViewall">Una mujer de 45 a&#241;os con LP erosivo oral y artritis psori&#225;sica<a class="elsevierStyleCrossRef" href="#bib0930"><span class="elsevierStyleSup">82</span></a>&#44; y otra de 59 a&#241;os con LP erosivo oral y esof&#225;gico refractario<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">83</span></a> recibieron upadacitinib 15 mg diarios&#46; En ambos casos se observ&#243; una mejor&#237;a dr&#225;stica y sostenida de las lesiones orales&#46;</p></span><span id="sec0190" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0210">Eritema multiforme</span><p id="par0195" class="elsevierStylePara elsevierViewall">Una mujer de 30 a&#241;os con eritema multiforme persistente mostr&#243; una mejor&#237;a significativa con upadacitinib 15 mg&#47;d&#237;a<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">84</span></a>&#46;</p></span><span id="sec0195" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0215">Granuloma anular</span><p id="par0200" class="elsevierStylePara elsevierViewall">Una mujer de 60 a&#241;os con granuloma anular refractario en placas present&#243; una remisi&#243;n casi completa con upadacitinib 15 mg&#47;d&#237;a<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">85</span></a>&#46;</p></span><span id="sec0200" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0220">Hidradenitis supurativa</span><p id="par0205" class="elsevierStylePara elsevierViewall">Un estudio retrospectivo &#40;n &#61; 20&#41; de hidradenitis supurativa de moderada a grave tratada con upadacitinib mostr&#243; una mejor&#237;a significativa de la respuesta cl&#237;nica de la hidradenitis supurativa &#40;HiSCR&#41;&#44; el DLQI y las puntuaciones de dolor a partir de la cuarta semana de tratamiento<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">86</span></a>&#46;</p></span></span><span id="sec0205" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0225">Ruxolitinib t&#243;pico &#40;<a class="elsevierStyleCrossRef" href="#tbl0025">tabla 5</a>&#41;</span><span id="sec0210" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0230">Alopecia areata</span><p id="par0210" class="elsevierStylePara elsevierViewall">En un ECA de fase 1 &#40;n &#61; 16&#41; en el que se compar&#243; pomada de ruxolitinib al 1&#37; con clobetasol 0&#44;05&#37; en individuos con AA <span class="elsevierStyleItalic">universalis</span>&#44; 31&#37; mostr&#243; un recrecimiento parcial del cabello en las zonas tratadas con ruxolitinib<a class="elsevierStyleCrossRef" href="#bib0955"><span class="elsevierStyleSup">87</span></a>&#46; Un estudio piloto abierto seguido de un ECA&#44; en el que participaron pacientes con 25-99&#37; de p&#233;rdida de cabello al inicio del estudio&#44; inform&#243; de que 50&#37; logr&#243; una reducci&#243;n &#62; 50&#37; en la <span class="elsevierStyleItalic">Severity of Alopecia Tool</span> &#40;SALT50&#41; en la semana 24 con crema de ruxolitinib al 1&#44;5&#37;&#46; Sin embargo&#44; el ECA no pudo demostrar una eficacia superior en comparaci&#243;n con el veh&#237;culo<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">26</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0025">tabla 5</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><p id="par0215" class="elsevierStylePara elsevierViewall">En una serie de casos pedi&#225;tricos &#40;n &#61; 2&#41;&#44; el ruxolitinib t&#243;pico al 1-2&#37; dos veces al d&#237;a hizo que volviera a crecer m&#225;s de 75&#37; del vello de las pesta&#241;as superiores en un paciente y en el otro no volvieron a salir las cejas<a class="elsevierStyleCrossRef" href="#bib0960"><span class="elsevierStyleSup">88</span></a>&#46; Dos informes de casos mostraron un crecimiento parcial del vello con ruxolitinib t&#243;pico<a class="elsevierStyleCrossRefs" href="#bib0965"><span class="elsevierStyleSup">89&#44;90</span></a>&#46; Otro caso no mostr&#243; eficacia con ruxolitinib al 0&#44;6&#37; dos veces al d&#237;a<a class="elsevierStyleCrossRef" href="#bib0975"><span class="elsevierStyleSup">91</span></a>&#46;</p></span><span id="sec0215" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0235">Enfermedad cr&#243;nica cut&#225;nea de injerto contra hu&#233;sped</span><p id="par0220" class="elsevierStylePara elsevierViewall">Un var&#243;n de 51 a&#241;os mostr&#243; una mejora de 6&#44;4&#37; en la superficie corporal total en las lesiones tratadas con ruxolitinib t&#243;pico al 1&#44;5&#37; en la sexta semana<a class="elsevierStyleCrossRef" href="#bib0980"><span class="elsevierStyleSup">92</span></a>&#46;</p></span><span id="sec0220" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0240">Lupus eritematoso cut&#225;neo</span><p id="par0225" class="elsevierStylePara elsevierViewall">Una mujer con lupus eritematoso discoide refractario present&#243; mejor&#237;a y le volvi&#243; a crecer pelo tras dos meses de crema de ruxolitinib al 1&#44;5&#37;<a class="elsevierStyleCrossRef" href="#bib0985"><span class="elsevierStyleSup">93</span></a>&#46;</p></span><span id="sec0225" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0245">Liquen plano</span><p id="par0230" class="elsevierStylePara elsevierViewall">Un estudio prospectivo de fase 2 abierto con ruxolitinib al 1&#44;5&#37; dos veces al d&#237;a en LP cut&#225;neo &#40;n &#61; 12&#41; mostr&#243; una reducci&#243;n estad&#237;sticamente significativa del n&#250;mero de lesiones y su gravedad al cabo de ocho semanas<a class="elsevierStyleCrossRef" href="#bib0990"><span class="elsevierStyleSup">94</span></a>&#46;</p></span><span id="sec0230" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0250">Necrobiosis lipoidea</span><p id="par0235" class="elsevierStylePara elsevierViewall">Una mujer con necrobiosis lipo&#237;dica refractaria observ&#243; una notable mejor&#237;a tras cambiar de crema de tofacitinib al 2&#37; a ruxolitinib al 1&#44;5&#37; dos veces al d&#237;a<a class="elsevierStyleCrossRef" href="#bib0995"><span class="elsevierStyleSup">95</span></a>&#46;</p></span><span id="sec0235" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0255">Psoriasis</span><p id="par0240" class="elsevierStylePara elsevierViewall">En un ECA de fase 2 &#40;n &#61; 29&#41; se observ&#243; que el ruxolitinib al 1 y al 1&#44;5&#37; reduc&#237;a las placas en 53 y 54&#37;<a class="elsevierStyleCrossRef" href="#bib1000"><span class="elsevierStyleSup">96</span></a>&#46; En un ensayo abierto de fase IIb se hall&#243; una mejora media del PASI de 40&#37; tras tres meses de tratamiento con crema de ruxolitinib al 1&#37;<a class="elsevierStyleCrossRef" href="#bib1005"><span class="elsevierStyleSup">97</span></a>&#46; Otro ensayo abierto en el que se compar&#243; la crema de ruxolitinib al 1&#37; y 1&#44;5&#37; aplicada una o dos veces al d&#237;a durante cuatro semanas mostr&#243; una reducci&#243;n media de la puntuaci&#243;n del eritema &#40;42-55&#37;&#41;&#44; la descamaci&#243;n &#40;46-78&#37;&#41; y el grosor &#40;50-65&#37;&#41; en todos los grupos<a class="elsevierStyleCrossRef" href="#bib1010"><span class="elsevierStyleSup">98</span></a>&#46; Un estudio abierto de fase 2 &#40;n &#61; 25&#41; de ruxolitinib al 1&#44;5&#37; dos veces al d&#237;a revel&#243; una mejora estad&#237;sticamente significativa en el d&#237;a 28<a class="elsevierStyleCrossRef" href="#bib1015"><span class="elsevierStyleSup">99</span></a>&#46;</p></span><span id="sec0240" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0260">Dermatitis seborreica</span><p id="par0245" class="elsevierStylePara elsevierViewall">Un hombre de 74 a&#241;os con ros&#225;cea concomitante mostr&#243; una resoluci&#243;n completa de la dermatitis seborreica y una mejor&#237;a parcial de la ros&#225;cea despu&#233;s de dos semanas con ruxolitinib al 1&#44;5&#37; dos veces al d&#237;a<a class="elsevierStyleCrossRef" href="#bib1020"><span class="elsevierStyleSup">100</span></a>&#46;</p></span></span></span></span><span id="sec0245" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0265">Discusi&#243;n</span><p id="par0250" class="elsevierStylePara elsevierViewall">La inclusi&#243;n de una advertencia &#40;<span class="elsevierStyleItalic">Boxed Warning</span>&#41; para los inhibidores de JAK ha suscitado preocupaci&#243;n entre los dermat&#243;logos en relaci&#243;n con la seguridad de estos medicamentos&#46; Sin embargo&#44; no debe sobrestimarse la magnitud de estas preocupaciones&#46; Los efectos secundarios a largo plazo que motivaron la advertencia se observaron en pacientes &#8805; 50 a&#241;os con artritis reumatoide&#44; en tratamiento concomitante con metotrexato y con factores de riesgo cardiovascular preexistentes<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">9</span></a>&#46; En las indicaciones dermatol&#243;gicas&#44; las poblaciones de pacientes suelen diferir en gran medida seg&#250;n el contexto cl&#237;nico en el que se realiz&#243; este estudio&#44; lo que puede influir en el perfil de seguridad&#46; Adem&#225;s&#44; un ensayo que comparaba la incidencia de efectos adversos entre las terapias sist&#233;micas tradicionales &#40;metotrexato&#44; ciclosporina y corticoesteroides sist&#233;micos&#41; y los inhibidores de JAK &#40;upadacitinib y abrocitinib&#41; hall&#243; tasas similares o superiores de malignidad&#44; MACE y TEV con los abordajes tradicionales<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">6</span></a>&#46; Esto sugiere que los inhibidores de JAK podr&#237;an ofrecer una alternativa m&#225;s segura en t&#233;rminos de efectos secundarios a largo plazo&#46; Para mitigar el riesgo de efectos graves&#44; un grupo de trabajo multidisciplinar public&#243; en 2021 unas recomendaciones consensuadas para el tratamiento de los pacientes manejados con inhibidores de JAK<a class="elsevierStyleCrossRef" href="#bib1025"><span class="elsevierStyleSup">101</span></a>&#46; En 2022&#44; la EMA respald&#243; las medidas recomendadas por el Comit&#233; de Evaluaci&#243;n de Riesgos en Farmacovigilancia elaboradas con el mismo fin<a class="elsevierStyleCrossRef" href="#bib1030"><span class="elsevierStyleSup">102</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0030">tabla 6</a>&#41;&#46; Antes de iniciar el tratamiento con inhibidores de JAK&#44; debe realizarse una anamnesis completa&#44; centr&#225;ndose en factores como antecedentes de MACE y TEV&#44; trombosis familiar y neoplasias malignas previas&#46; Debe efectuarse un examen f&#237;sico completo y an&#225;lisis de sangre&#44; incluyendo un hemograma&#44; pruebas de funci&#243;n hep&#225;tica y renal&#44; lipidograma&#44; CPK y cribado serol&#243;gico de virus de la inmunodeficiencia humana &#40;VIH&#41;&#44; VHB&#44; virus de la hepatitis C &#40;VHC&#41; y virus de la varicela zoster &#40;VVZ&#41;&#46; Tambi&#233;n debe llevarse a cabo un cribado de la tuberculosis&#46; Dado el elevado riesgo de herpes z&#243;ster&#44; debe ofrecerse a todos los pacientes la vacunaci&#243;n en funci&#243;n de su estado serol&#243;gico&#46; Shingrix&#44; una vacuna adyuvada recombinante contra el herpes z&#243;ster&#44; ha mostrado resultados prometedores en los datos iniciales de sujetos con artritis reumatoide&#44; con tan solo 0&#44;7&#37; de desarrollo de herpes z&#243;ster&#46; Sin embargo&#44; se necesitan m&#225;s estudios para confirmar su eficacia en prevenci&#243;n<a class="elsevierStyleCrossRef" href="#bib1035"><span class="elsevierStyleSup">103</span></a>&#46; El seguimiento y la monitorizaci&#243;n estrechos son vitales durante todo el tratamiento con inhibidores de JAK&#46; Los pacientes deben ser seguidos por profesionales expertos en estos medicamentos&#44; y deben realizarse an&#225;lisis de sangre peri&#243;dicos para controlar los posibles efectos adversos&#46; Las revisiones dermatol&#243;gicas son especialmente importantes en los sujetos de alto riesgo para detectar signos precoces de c&#225;ncer de piel&#46;</p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia><p id="par0255" class="elsevierStylePara elsevierViewall">Dado que los estudios cl&#237;nicos tienden a infrarrepresentar a los pacientes pedi&#225;tricos o mayores de 65 a&#241;os&#44; a los individuos con comorbilidades o en riesgo de malignidad o de eventos tromboemb&#243;licos y cardiovasculares&#44; es necesario que los ensayos cl&#237;nicos incluyan a estas poblaciones para evaluar de forma exhaustiva la seguridad de los inhibidores de JAK&#46; Se necesitan m&#225;s investigaciones para determinar si los riesgos pueden mitigarse mediante una cuidadosa selecci&#243;n de las dosis&#46;</p><p id="par0260" class="elsevierStylePara elsevierViewall">Nuestra revisi&#243;n incluye datos preliminares sobre la eficacia de los inhibidores de JAK en varias entidades dermatol&#243;gicas &#40;<a class="elsevierStyleCrossRef" href="#tbl0035">tabla 7</a>&#41;&#46; Sobre la base de los prometedores hallazgos examinados&#44; es razonable considerar a los inhibidores de JAK como una opci&#243;n terap&#233;utica potencial para enfermedades como la vasculopat&#237;a livedoide&#44; la EICHc&#44; las enfermedades autoinflamatorias&#44; el lupus eritematoso cut&#225;neo&#44; la dermatomiositis y la esclerosis sist&#233;mica&#46; Estas enfermedades suelen ser refractarias a los tratamientos convencionales o dependen en gran medida de los corticoesteroides&#44; por lo que urge encontrar terapias alternativas&#46;</p><elsevierMultimedia ident="tbl0035"></elsevierMultimedia><p id="par0265" class="elsevierStylePara elsevierViewall">La accesibilidad de los inhibidores de JAK como medicamentos fuera de ficha t&#233;cnica plantea preocupaciones&#46; Un estudio de cohorte prospectivo en cl&#237;nicas dermatol&#243;gicas alemanas revel&#243; tasas de aprobaci&#243;n m&#225;s bajas de inhibidores de JAK en comparaci&#243;n con los biol&#243;gicos &#40;OR 0&#44;16&#41;<a class="elsevierStyleCrossRef" href="#bib1040"><span class="elsevierStyleSup">104</span></a>&#46; Adem&#225;s&#44; considerando su alto coste&#44; un an&#225;lisis de coste-beneficio es esencial&#44; especialmente para afecciones que no amenazan la vida&#46;</p><p id="par0270" class="elsevierStylePara elsevierViewall">Nuestro estudio tiene varias limitaciones&#46; Es una revisi&#243;n narrativa y no sistem&#225;tica&#46; Los tama&#241;os de muestra eran en su mayor&#237;a peque&#241;os&#44; faltaban estudios prospectivos en muchas indicaciones fuera de ficha t&#233;cnica y hubo periodos de seguimiento cortos con metodolog&#237;as heterog&#233;neas&#44; lo que limit&#243; la generalizaci&#243;n de los hallazgos&#46; Muchos informes de casos y series que evaluaron la eficacia de los inhibidores de JAK enfrentaron desaf&#237;os al atribuir resultados positivos &#250;nicamente a estos medicamentos&#44; ya que numerosos casos involucraron tratamientos concomitantes que podr&#237;an haber influido en los hallazgos&#46;</p></span><span id="sec0250" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0270">Conclusi&#243;n</span><p id="par0275" class="elsevierStylePara elsevierViewall">Los inhibidores de JAK suponen un importante paso hacia la medicina de precisi&#243;n&#46; Su seguridad depende en gran medida de las caracter&#237;sticas del paciente&#44; la enfermedad que se est&#225; tratando&#44; la v&#237;a de administraci&#243;n&#44; el inhibidor espec&#237;fico de JAK y la dosis&#46; En comparaci&#243;n con las terapias inmunosupresoras tradicionales&#44; en general&#44; estos f&#225;rmacos demuestran mejores perfiles de seguridad&#46; Estos agentes son prometedores como tratamientos para diversas dermatosis inflamatorias que tienen un gran impacto en la calidad de vida&#46;</p></span><span id="sec0260" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0275">Financiaci&#243;n</span><p id="par0285" class="elsevierStylePara elsevierViewall">Ninguna&#46;</p></span><span id="sec0265" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0280">Conflicto de intereses</span><p id="par0280" class="elsevierStylePara elsevierViewall">Los autores declaran no tener conflicto de intereses&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:13 [
        0 => array:3 [
          "identificador" => "xres1979640"
          "titulo" => "Graphical abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:3 [
          "identificador" => "xres1979638"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        2 => array:2 [
          "identificador" => "xpalclavsec1702492"
          "titulo" => "Palabras clave"
        ]
        3 => array:3 [
          "identificador" => "xres1979639"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0015"
            ]
          ]
        ]
        4 => array:2 [
          "identificador" => "xpalclavsec1702491"
          "titulo" => "Keywords"
        ]
        5 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introducci&#243;n"
        ]
        6 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "M&#233;todos"
        ]
        7 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "Resultados"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Perfil de seguridad a largo plazo"
            ]
            1 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Abrocitinib"
            ]
            2 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Baricitinib"
            ]
            3 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Upadacitinib"
            ]
            4 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Ruxolitinib t&#243;pico"
            ]
            5 => array:3 [
              "identificador" => "sec0045"
              "titulo" => "Uso fuera de la ficha t&#233;cnica de los inhibidores de JAK en trastornos cut&#225;neos"
              "secciones" => array:4 [
                0 => array:3 [
                  "identificador" => "sec0050"
                  "titulo" => "Abrocitinib &#40;tabla 2&#41;"
                  "secciones" => array:2 [
                    0 => array:2 [
                      "identificador" => "sec0055"
                      "titulo" => "Alopecia areata"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0065"
                      "titulo" => "Dermatitis de contacto"
                    ]
                  ]
                ]
                1 => array:3 [
                  "identificador" => "sec0070"
                  "titulo" => "Baricitinib &#40;tabla 3&#41;"
                  "secciones" => array:20 [
                    0 => array:2 [
                      "identificador" => "sec0075"
                      "titulo" => "Trastornos autoinflamatorios con manifestaciones cut&#225;neas"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0080"
                      "titulo" => "Lupus eritematoso cut&#225;neo"
                    ]
                    2 => array:2 [
                      "identificador" => "sec0085"
                      "titulo" => "Enfermedad cr&#243;nica de injerto contra hu&#233;sped &#40;EICHc&#41;"
                    ]
                    3 => array:2 [
                      "identificador" => "sec0090"
                      "titulo" => "Eccema cr&#243;nico de las manos"
                    ]
                    4 => array:2 [
                      "identificador" => "sec0095"
                      "titulo" => "Prurigo nodular cr&#243;nico"
                    ]
                    5 => array:2 [
                      "identificador" => "sec0100"
                      "titulo" => "Dermatomiositis &#40;forma adulta&#41;"
                    ]
                    6 => array:2 [
                      "identificador" => "sec0105"
                      "titulo" => "Fascitis eosinof&#237;lica"
                    ]
                    7 => array:2 [
                      "identificador" => "sec0110"
                      "titulo" => "Alopecia frontal fibrosante"
                    ]
                    8 => array:2 [
                      "identificador" => "sec0115"
                      "titulo" => "Morfea generalizada"
                    ]
                    9 => array:2 [
                      "identificador" => "sec0120"
                      "titulo" => "Granuloma anular"
                    ]
                    10 => array:2 [
                      "identificador" => "sec0125"
                      "titulo" => "S&#237;ndrome hipereosinof&#237;lico"
                    ]
                    11 => array:2 [
                      "identificador" => "sec0130"
                      "titulo" => "Enfermedades ampollosas inmunes"
                    ]
                    12 => array:2 [
                      "identificador" => "sec0135"
                      "titulo" => "Dermatomiositis juvenil"
                    ]
                    13 => array:2 [
                      "identificador" => "sec0140"
                      "titulo" => "Liquen plano"
                    ]
                    14 => array:2 [
                      "identificador" => "sec0145"
                      "titulo" => "Vasculopat&#237;a livedoide"
                    ]
                    15 => array:2 [
                      "identificador" => "sec0150"
                      "titulo" => "Psoriasis"
                    ]
                    16 => array:2 [
                      "identificador" => "sec0155"
                      "titulo" => "Pioderma gangrenoso"
                    ]
                    17 => array:2 [
                      "identificador" => "sec0160"
                      "titulo" => "S&#237;ndrome de Sweet"
                    ]
                    18 => array:2 [
                      "identificador" => "sec0165"
                      "titulo" => "Esclerosis sist&#233;mica"
                    ]
                    19 => array:2 [
                      "identificador" => "sec0170"
                      "titulo" => "Vit&#237;ligo"
                    ]
                  ]
                ]
                2 => array:3 [
                  "identificador" => "sec0175"
                  "titulo" => "Upadacitinib &#40;tabla 4&#41;"
                  "secciones" => array:5 [
                    0 => array:2 [
                      "identificador" => "sec0180"
                      "titulo" => "Alopecia areata"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0185"
                      "titulo" => "Liquen plano oral erosivo"
                    ]
                    2 => array:2 [
                      "identificador" => "sec0190"
                      "titulo" => "Eritema multiforme"
                    ]
                    3 => array:2 [
                      "identificador" => "sec0195"
                      "titulo" => "Granuloma anular"
                    ]
                    4 => array:2 [
                      "identificador" => "sec0200"
                      "titulo" => "Hidradenitis supurativa"
                    ]
                  ]
                ]
                3 => array:3 [
                  "identificador" => "sec0205"
                  "titulo" => "Ruxolitinib t&#243;pico &#40;tabla 5&#41;"
                  "secciones" => array:7 [
                    0 => array:2 [
                      "identificador" => "sec0210"
                      "titulo" => "Alopecia areata"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0215"
                      "titulo" => "Enfermedad cr&#243;nica cut&#225;nea de injerto contra hu&#233;sped"
                    ]
                    2 => array:2 [
                      "identificador" => "sec0220"
                      "titulo" => "Lupus eritematoso cut&#225;neo"
                    ]
                    3 => array:2 [
                      "identificador" => "sec0225"
                      "titulo" => "Liquen plano"
                    ]
                    4 => array:2 [
                      "identificador" => "sec0230"
                      "titulo" => "Necrobiosis lipoidea"
                    ]
                    5 => array:2 [
                      "identificador" => "sec0235"
                      "titulo" => "Psoriasis"
                    ]
                    6 => array:2 [
                      "identificador" => "sec0240"
                      "titulo" => "Dermatitis seborreica"
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
        8 => array:2 [
          "identificador" => "sec0245"
          "titulo" => "Discusi&#243;n"
        ]
        9 => array:2 [
          "identificador" => "sec0250"
          "titulo" => "Conclusi&#243;n"
        ]
        10 => array:2 [
          "identificador" => "sec0260"
          "titulo" => "Financiaci&#243;n"
        ]
        11 => array:2 [
          "identificador" => "sec0265"
          "titulo" => "Conflicto de intereses"
        ]
        12 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2023-04-07"
    "fechaAceptado" => "2023-06-12"
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1702492"
          "palabras" => array:6 [
            0 => "Inhibidores de JAK"
            1 => "Inhibidores de Janus kinasa"
            2 => "Dermatolog&#237;a"
            3 => "Fuera de indicaci&#243;n"
            4 => "Seguridad"
            5 => "Eventos adversos"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1702491"
          "palabras" => array:6 [
            0 => "JAK inhibitors"
            1 => "Janus kinase inhibitors"
            2 => "Dermatology"
            3 => "Off-label"
            4 => "Safety"
            5 => "Adverse events"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Los inhibidores de Janus quinasa &#40;JAK&#41; act&#250;an bloqueando la acci&#243;n de ciertas citoquinas inflamatorias involucradas en varias enfermedades inflamatorias&#46; Cuatro mol&#233;culas han sido aprobadas para empleo en dermatolog&#237;a&#58; upadacitinib&#44; baricitinib&#44; abrocitinib y ruxolitinib t&#243;pico&#46; Se han reportado usos fuera de indicaci&#243;n para diferentes patolog&#237;as dermatol&#243;gicas&#46; Se realiz&#243; una revisi&#243;n narrativa de la literatura sobre la seguridad a largo plazo de los inhibidores de JAK aprobados y su utilizaci&#243;n fuera de indicaci&#243;n en enfermedades dermatol&#243;gicas&#44; mediante b&#250;squedas bibliogr&#225;ficas en PubMed y Google Scholar desde enero del 2000 hasta enero del 2023&#44; incluyendo las palabras clave&#58; &#171;<span class="elsevierStyleItalic">Janus kinase inhibitors</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">JAK inhibitors</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">off-label</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">dermatology</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">safety</span>&#187;&#44; &#171;<span class="elsevierStyleItalic">adverse events</span>&#187;&#44; &#171;ruxolitinib&#187;&#44; &#171;upadacitinib&#187;&#44; &#171;abrocitinib&#187; y &#171;baricitinib&#187;&#46; Se encontraron un total de 37 trastornos cut&#225;neos con estudios que respaldan el uso de estos f&#225;rmacos&#46; Los ensayos preliminares indican que los inhibidores de JAK tienen un perfil de seguridad generalmente favorable y pueden considerarse una opci&#243;n en muchas enfermedades dermatol&#243;gicas&#46;</p></span>"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0015" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">JAK inhibitors target specific inflammatory cytokines involved in various inflammatory diseases&#46; Four molecules have been approved for dermatological use&#58; upadacitinib&#44; baricitinib&#44; abrocitinib and topical ruxolitinib&#46; Off-label prescriptions for other dermatological conditions have been reported&#46; We conducted a narrative review of the literature to assess the long-term safety profile of currently approved JAK inhibitors in dermatology&#44; and their off-label use in skin disorders&#46; We performed literature searches with PubMed and Google Scholar from January 2000 to January 2023&#44; using the keywords &#8220;Janus kinase inhibitors&#8221;&#44; &#8220;JAK inhibitors&#8221;&#44;&#8220;off-label&#8221;&#44; &#8220;dermatology&#8221;&#44; &#8220;safety&#8221;&#44; &#8220;adverse events&#8221;&#44; &#8220;ruxolitinib&#8221;&#44; &#8220;upadacitinib&#8221;&#44;&#8220;abrocitinib&#8221; and &#8220;baricitinib&#8221;&#46; Our search yielded a total of 37 dermatological disorders with studies supporting the use of these JAK inhibitors&#46; Preliminary studies indicate that JAK inhibitors generally have a favorable safety profile and can be considered as an option in many dermatological disorders&#46;</p></span>"
      ]
    ]
    "multimedia" => array:8 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">EMA&#58; <span class="elsevierStyleItalic">European Medicines Agency</span>&#59; FDA&#58; <span class="elsevierStyleItalic">Food and Drugs Administration</span>&#59; JAK&#58; Janus quinasa&#59; TYK2&#58; tirosina quinasa 2&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Droga&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mecanismo de acci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaciones aprobadas por la FDA en Dermatolog&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaciones aprobadas por la EMA en Dermatolog&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abrocitinib &#40;oral&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor selectivo JAK 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis at&#243;pica moderada a severa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis at&#243;pica moderada a severa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib &#40;oral&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor JAK 1 y JAK 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia areata&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia areataDermatitis at&#243;pica moderada a severa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib &#40;oral&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor reversible JAK con mayor potencia inhibitoria para JAK1 que JAK2&#44; JAK3&#44; o TYK2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis at&#243;pica moderada a severa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis at&#243;pica moderada a severa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib &#40;t&#243;pico&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor JAK 1 y JAK 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis at&#243;pica leve a moderadaVit&#237;ligo no segmentario&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295034.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Mecanismo de acci&#243;n e indicaciones aprobadas para los inhibidores de JAK 1 en Dermatolog&#237;a</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mayor nivel de evidencia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dosificaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mediciones&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultados cl&#237;nicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Efectos adversos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia areata<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">30</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abrocitinib 200 mg diario&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reaparici&#243;n del vello en todas las zonas afectadas del cuerpo despu&#233;s de 12 semanas&#46; Se observan pelos gruesos terminales en varias zonas en la semana 52&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis de contacto<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">31</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abrocitinib 100 mg diario&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n completa tras ocho semanas de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295031.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Uso fuera de ficha t&#233;cnica de abrocitinib en Dermatolog&#237;a</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabla 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">AIJ&#58; artritis idiop&#225;tica juvenil&#59; CDASI-A&#58; &#237;ndice de actividad del &#225;rea y gravedad de la enfermedad de dermatomiositis cut&#225;nea&#59; CDASI&#58; &#237;ndice de &#225;rea y gravedad de la enfermedad cut&#225;nea&#59; DDS&#58; puntuaci&#243;n diaria&#59; DLQI&#58; &#237;ndice de calidad de vida dermatol&#243;gica&#59; EASI&#58; &#237;ndice de &#225;rea y gravedad del eccema&#59; EVA&#58; escala visual anal&#243;gica&#59; ECA&#58; ensayo controlado aleatorizado&#59; EICH&#58; enfermedad de injerto contra hu&#233;sped&#59; HAQ II<span class="elsevierStyleSmallCaps">&#58;</span> cuestionario de evaluaci&#243;n de la salud II&#59; HECSI&#58; &#237;ndice de gravedad del eccema de manos&#59; IGA&#58; escala de evaluaci&#243;n global del investigador&#59; JAK&#58; Janus quinasa&#59; LP&#58; liquen plano&#59; LPPAI&#58; &#237;ndice de actividad del liquen plano pilaris&#59; mRSS&#58; puntuaci&#243;n cut&#225;nea de Rodnan modificada&#59; NRS&#58; escala de clasificaci&#243;n num&#233;rica&#59; PAS&#58; puntuaci&#243;n de actividad del prurigo&#59; PASI&#58; puntuaci&#243;n del &#237;ndice de &#225;rea y gravedad de la psoriasis&#59; PGA&#58; actividad global del m&#233;dico&#59; QOLHE&#58; cuestionario de calidad de vida en el eccema de manos&#59; SAVI&#58; vasculopat&#237;a asociada a STING de inicio en la infancia&#59; LECS&#58; lupus eritematoso cut&#225;neo subagudo&#59; RCT&#58; ensayo cl&#237;nico aleatorizado&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mayor nivel de evidencia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dosificaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mediciones&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultados cl&#237;nicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Efectos adversos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Trastornos autoinflamatorios</span><a class="elsevierStyleCrossRefs" href="#bib0680"><span class="elsevierStyleSup">32&#8211;36</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Enfermedad de Still del adulto<a class="elsevierStyleCrossRefs" href="#bib0690"><span class="elsevierStyleSup">34&#44;36</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dos series de casos &#40;n &#61; 3 y n &#61; 2&#41;<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">34</span></a> y el reporte de un caso &#40;n &#61; 1&#41;<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">36</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Se consigui&#243; una resoluci&#243;n completa en tres casos &#40;50&#37;&#41;&#44; una remisi&#243;n parcial en un caso &#40;16&#44;7&#37;&#41; y ninguna remisi&#243;n en dos casos &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se produjeron acontecimientos adversos que condujeran a la reducci&#243;n de la dosis o a una interrupci&#243;n de la mediaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Aicardi-Gouti&#232;res<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a de la piel tras el tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Blau<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">33</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estabilizaci&#243;n de las manifestaciones cut&#225;neas&#44; oculares y articulares tras el cambio de tofacitinib a baricitinib 4 mg diarios debido a una linfopenia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Linfopenia transitoria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de CANDLE<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 11&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 0&#44;1&#8211;10 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Criterios de reducci&#243;n de la DDS&#44; tiempo de remisi&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">De los pacientes&#44; 83&#37; mostraron mejor&#237;a cl&#237;nica y en la DDS y&#47;o reducci&#243;n del uso de prednisona&#46; De ellos&#44; 36&#37; presentaron un aumento del tiempo de remisi&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infecciones frecuentes &#40;viremia del virus BK o infecciones respiratorias&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de CANDLE-like<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 0&#44;5&#8211;9 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Criterios de reducci&#243;n de la DDS&#44; disminuci&#243;n de la dosis de corticosteroides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a de la DDS&#58; 25&#37;Disminuci&#243;n de la dosis de corticoides&#58; 50&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infecciones &#40;incluida la sepsis&#41;&#44; trastorno cerebrovascular&#44; osteonecrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de mutaciones de GOF en STAT1<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a cut&#225;nea tras el tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>SAVI &#40;<span class="elsevierStyleItalic">n</span> &#61; 4&#41;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">32</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2&#8211;10 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Criterios de reducci&#243;n de la DDS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Solo un caso de cuatro de mejor&#237;a en DDS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infecciones de las v&#237;as respiratorias&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>AIJ sist&#233;mica<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">34</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4&#8211;8 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a parcial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome VEXAS<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">35</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&#44; niveles de prote&#237;na C reactiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib y upadacitinib fueron menos eficaces que el ruxolitinib oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infecciones y tromboembolismos venosos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Lupus eritematoso cut&#225;neo</span><a class="elsevierStyleCrossRefs" href="#bib0705"><span class="elsevierStyleSup">37&#8211;41</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Lupus pernio familiar<a class="elsevierStyleCrossRef" href="#bib0705"><span class="elsevierStyleSup">37</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#205;ndice revisado de &#225;rea y gravedad del lupus cut&#225;neo &#40;R-CLASI&#41;&#44; dolor evaluado mediante EVA&#44; firma de IFN tipo I en sangre&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Se alcanz&#243; el R-CLASI100 en dos de tres pacientes&#46; La EVA media disminuy&#243; 72&#37; en el d&#237;a 30&#46; La puntuaci&#243;n de IFN tipo I logr&#243; una reducci&#243;n estad&#237;sticamente significativa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notificaron reacciones adversas graves&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Lupus eritematoso cut&#225;neo subagudo<a class="elsevierStyleCrossRefs" href="#bib0710"><span class="elsevierStyleSup">38&#44;40&#44;41</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de casos &#40;n &#61; 3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica &#40;3&#47;3&#41;&#44; &#237;ndice revisado de &#225;rea y gravedad del lupus cut&#225;neo &#40;R-CLASI&#41; &#40;1&#47;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n casi completa de las lesiones cut&#225;neas activas &#40;2&#47;3&#41; &#40;incluido un descenso del R-CLASI de 21 a 3&#41;&#44; resoluci&#243;n completa del LECS &#40;1&#47;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Alopecia difusa no cicatricial por lupus eritematoso sist&#233;mico<a class="elsevierStyleCrossRef" href="#bib0715"><span class="elsevierStyleSup">39</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Interrupci&#243;n de la ca&#237;da del cabello seguida de un prominente recrecimiento del cabello al cabo de ocho semanas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Prurigo nodular cr&#243;nico</span><a class="elsevierStyleCrossRefs" href="#bib0740"><span class="elsevierStyleSup">44&#8211;46</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Prurigo nodular cr&#243;nico at&#243;pico<a class="elsevierStyleCrossRefs" href="#bib0740"><span class="elsevierStyleSup">44&#44;45</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Puntuaci&#243;n del EASI&#44; NRS del prurito &#40;2&#47;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">R&#225;pida mejor&#237;a del prurito y de las lesiones cut&#225;neas&#46; Se alcanz&#243; el EASI50 en la semana ocho &#40;1&#47;1&#41;La NRS de picor disminuy&#243; 66&#44;7&#37; en la semana ocho y 75&#37; al cabo de tres meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sequedad &#40;50&#37;&#41;&#44; ros&#225;cea &#40;50&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Prurigo nodular cr&#243;nico no at&#243;pico<a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">46</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IGA&#44; Escala visual anal&#243;gica &#40;EVA&#41;&#44; NRS&#44; PAS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">En la semana 12&#44; la IGA disminuy&#243; de 3 a 2&#44; la VAS disminuy&#243; de 8 a 1&#44; la NRS disminuy&#243; de 9 a 2&#44; y la PAS disminuy&#243; de 4 a 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dermatomiositis</span><a class="elsevierStyleCrossRefs" href="#bib0755"><span class="elsevierStyleSup">47&#44;60</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dermatomiositis juvenil<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">60</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudio prospectivo &#40;n &#61; 4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4&#8211;8 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Puntuaci&#243;n del CDASI&#44; actividad global seg&#250;n paciente&#47;cuidador&#44; actividad global extramuscular y PGA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Se logr&#243; una disminuci&#243;n estad&#237;sticamente significativa de todas las puntuaciones en la cuarta semana&#46; Se redujeron o suspendieron los corticoides orales y otros inmunosupresores&#46; No hubo cambios notables en la calcinosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notificaron reacciones adversas graves&#46; Infecciones del tracto respiratorio superior&#44; reactivaci&#243;n del virus BK&#44; anomal&#237;as hematol&#243;gicas y niveles elevados de creatina cinasa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dermatomiositis &#40;adulto&#41;<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">47</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudio abierto &#40;n &#61; 12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CDASI-A y puntuaci&#243;n del DLQI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a significativa en la puntuaci&#243;n del CDASI-A y del DLQI en la semana cuatro y 12&#44; respectivamenteEl eritema facial y el prurito mostraron una mejor&#237;a significativa tras el tratamientoLa prednisona se redujo en cinco de seis pacientes y se suspendi&#243; en un paciente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aumento transitorio de las plaquetas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Enfermedades ampollosas autoinmunes</span><a class="elsevierStyleCrossRefs" href="#bib0805"><span class="elsevierStyleSup">57&#8211;59</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Epiderm&#243;lisis ampollosa pruriginosa<a class="elsevierStyleCrossRef" href="#bib0805"><span class="elsevierStyleSup">57</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a sustancial tras dos semanas de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Penfigoide de mucosas<a class="elsevierStyleCrossRef" href="#bib0805"><span class="elsevierStyleSup">57</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a ocular significativa dos meses despu&#233;s del tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span> Penfigoide ampolloso<a class="elsevierStyleCrossRef" href="#bib0810"><span class="elsevierStyleSup">58</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Un paciente con psoriasis concomitante mostr&#243; una remisi&#243;n completa de ambas dermatosis en la semana 24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Liquen plano pemfigoide<a class="elsevierStyleCrossRef" href="#bib0815"><span class="elsevierStyleSup">59</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 3&#44;4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n casi completa al cabo de seis meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Otras dermatosis</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>EICH cr&#243;nica<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">42</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">RCT &#40;n &#61; 20&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg&#44; con escalada a 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Criterios de respuesta 2014 NIH cEICH&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respuesta global de 63&#37; al sexto mes&#46; Todos los &#243;rganos excepto los pulmones mostraron una respuesta significativa&#46; No se especific&#243; la respuesta cut&#225;nea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infecciones respiratorias altas &#40;13&#41;&#44; neutropenia &#40;6&#41;&#44; hipofosfatemia &#40;12&#41;&#44; hipertrigliceridemia &#40;5&#41;&#44; reactivaci&#243;n de CMV&#44; EBV o BK &#40;18&#44; ninguna requiri&#243; tratamiento&#41;&#44; infecciones graves &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Eccema cr&#243;nico de manos4<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">43</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HECSI&#44; QOLHEQ&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n casi completa en ambos casos&#44; con una reducci&#243;n media del HECSI de 88&#44;7&#37; en la semana 16&#44; cuando ambos casos ten&#237;an una calidad de vida &#171;en absoluto deteriorada&#187;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#218;lcera corneal bacteriana &#40;1&#47;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fascitis eosinof&#237;lica<a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">50</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib &#40;dosificaci&#243;n no especificada&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica y ecogr&#225;fica&#44; puntuaci&#243;n del HAQ II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reducci&#243;n de la dosis de corticosteroides&#44; mejora de la puntuaci&#243;n HAQ II de 2&#44;5 a 1&#44;0&#44; reducci&#243;n de la induraci&#243;n cut&#225;nea&#44; mejora de la elasticidad&#44; reducci&#243;n del grosor de la fascia del gastrocnemio superficial de 2 mm a 1 mm&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Alopecia frontal fibrosante<a class="elsevierStyleCrossRefs" href="#bib0775"><span class="elsevierStyleSup">51&#44;65</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudios retrospectivos &#40;n &#61; 5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 3&#44;4&#8211;6&#44;8 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LPPAI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a en la puntuaci&#243;n de actividad de la enfermedad en 60&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Elevaci&#243;n de las enzimas hep&#225;ticas &#40;1&#47;13&#41;&#44; hipercolesterolemia &#40;1&#47;13&#41;&#44; neutropenia &#40;1&#47;13&#41;&#44; fatiga &#40;1&#47;13&#41;<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Morfea generalizada<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">52</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n del eritema a los dos meses y mejor&#237;a subjetiva a los seis meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Granuloma anular<a class="elsevierStyleCrossRefs" href="#bib0785"><span class="elsevierStyleSup">53&#8211;55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Los casos no recidivaron&#44; mejoraron o remitieron tras dos semanas a dos meses con baricitinib&#46; Un caso no recay&#243; tras la interrupci&#243;n de baricitinib &#40;1&#47;2&#41;&#44; pero otro caso s&#237; &#40;1&#47;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome hipereosinof&#237;lico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 5 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recuento de eosin&#243;filos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Normalizaci&#243;n del recuento de eosin&#243;filos despu&#233;s de tres meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Liquen plano<a class="elsevierStyleCrossRefs" href="#bib0775"><span class="elsevierStyleSup">51&#44;65</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudios retrospectivos y reporte de casos &#40;n &#61; 8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 3&#44;4&#8211;6&#44;8 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LPPAI&#46; Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejora de la puntuaci&#243;n de actividad de la enfermedad en 71&#37;&#46; Mejor&#237;a significativa y mantenida del LP ungueal &#40;1&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Elevaci&#243;n de las enzimas hep&#225;ticas &#40;1&#47;13&#41;&#44; hipercolesterolemia &#40;1&#47;13&#41;&#44; neutropenia &#40;1&#47;13&#41;&#44; fatiga &#40;1&#47;13&#41;<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Vasculopat&#237;a livedoide<a class="elsevierStyleCrossRef" href="#bib0860"><span class="elsevierStyleSup">68</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Series de casos &#40;n &#61; 8&#41;<a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">66</span></a> y dos reportes de casos &#40;n &#61; 2&#41;<a class="elsevierStyleCrossRefs" href="#bib0855"><span class="elsevierStyleSup">67&#44;68</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2&#8211;4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Evaluaci&#243;n de la puntuaci&#243;n cl&#237;nica compuesta por tres dominios&#58; dolor &#40;0-3&#41;&#44; ulceraci&#243;n &#40;0-2&#41; y eritema &#40;0-3&#41;&#46; Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejora de las puntuaciones cl&#237;nicas medias tras el tratamiento con baricitinib &#40;7&#44;0 &#177; 1&#44;6 y 1&#44;4 &#177; 1&#44;2 antes y despu&#233;s&#44; respectivamente&#41;&#46; De los pacientes&#44; 75&#37; alcanzaron la remisi&#243;n cl&#237;nica<a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">66</span></a>Mejor&#237;a r&#225;pida y notable con el tratamiento<a class="elsevierStyleCrossRefs" href="#bib0855"><span class="elsevierStyleSup">67&#44;68</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Psoriasis<a class="elsevierStyleCrossRefs" href="#bib0610"><span class="elsevierStyleSup">18&#44;70</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Un ECA &#40;n &#61; 271&#41; y un reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2&#8211;10 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PASIExploraci&#243;n cl&#237;nica y radiogr&#225;fica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">En la semana 12&#44; lograron una reducci&#243;n de 75&#37; del PASI 43&#37; y 54&#37; de los pacientes tratados con baricitinib 8 mg y 10 mg diarios&#44; respectivamente&#44; frente a 17&#37; en el grupo placebo&#46; La eficacia se mantuvo hasta la semana 24 en m&#225;s de 81&#37; de los pacientes que respondieron<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">18</span></a>Mejor&#237;a dermatol&#243;gica y articular desde el quinto d&#237;a de tratamiento en un paciente con acrodermatitis continua de Hallopeau<a class="elsevierStyleCrossRef" href="#bib0870"><span class="elsevierStyleSup">70</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Neutropenia y anemia leves&#44; peque&#241;os aumentos de la creatinina y las lipoprote&#237;nas&#46; Una muerte en el grupo de baricitinib 4 mg&#44; debida a un c&#225;ncer de es&#243;fago&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pioderma gangrenoso<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">71</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serie de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Remisi&#243;n completa en cinco semanas- tres meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Sweet<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">72</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a articular y remisi&#243;n cut&#225;nea tras cuatro semanas&#44; sin m&#225;s reagudizaciones tras 10 meses de seguimiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Esclerosis sist&#233;mica<a class="elsevierStyleCrossRef" href="#bib0900"><span class="elsevierStyleSup">76</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Una serie de casos y dos reportes de casos &#40;n &#61; 12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 2&#8211;4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">mRSS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Se notific&#243; una respuesta cut&#225;nea significativa en 75&#37; de los pacientes&#44; con una reducci&#243;n media de la puntuaci&#243;n mRSS de 8&#44;75&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Herpes zoster &#40;1&#47;12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Vitiligo<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">77</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib 4 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Repigmentaci&#243;n casi completa de sus extremidades superiores tras ocho meses de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295028.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Un paciente requiri&#243; un ajuste de la dosis a baricitinib 8 mg diarios debido a un brote leve en la semana nueve&#44; y posteriormente se redujo a 6 mg diarios&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">En uno o m&#225;s pacientes&#44; la dosis de baricitinib se redujo a la mitad durante el seguimiento&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Los acontecimientos adversos de la alopecia frontal fibrosante y el liquen plano pilar se obtuvieron del mismo estudio&#44; por lo que la columna representa la suma de los acontecimientos adversos de ambas enfermedades&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Uso en Dermatolog&#237;a del baricitinib fuera de ficha t&#233;cnica</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabla 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">CPK&#58; creatinfosfoquinasa&#59; DLQI&#58; &#237;ndice de calidad de vida dermatol&#243;gica&#59; HiSCR&#58; respuesta cl&#237;nica de la hidradenitis supurativa&#59; LP&#58; liquen plano&#59; SALT&#58; herramienta de puntuaci&#243;n de la severidad de la alopecia&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M&#225;ximo grado de evidencia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dosificaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Medidas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultado cl&#237;nico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Efectos adversos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia areata<a class="elsevierStyleCrossRefs" href="#bib0910"><span class="elsevierStyleSup">78&#8211;81</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de casos &#40;n &#61; 4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib 15&#8211;30 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica &#40;4&#47;4&#41;&#44; tricoscopia &#40;1&#47;4&#41;&#44; herramienta de puntuaci&#243;n de la severidad de la alopecia SALT &#40;1&#47;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">El cabello volvi&#243; a crecer &#40;4&#47;4&#41;Se alcanz&#243; SALT100 en todas las regiones con pelo en el cuarto mes &#40;1&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Elevaci&#243;n transitoria de la lipasa y la amilasa s&#233;ricas &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Liquen plano oral erosivo<a class="elsevierStyleCrossRefs" href="#bib0930"><span class="elsevierStyleSup">82&#44;83</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de casos &#40;n &#61; 2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib 15 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica &#40;2&#47;2&#41;&#46; Esofagoscopia y ex&#225;menes histol&#243;gicos &#40;1&#47;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a completa y sostenida del LP oral &#40;2&#47;2&#41;&#46; Mejor&#237;a de la esofagitis en la semana 24 &#40;1&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Granuloma anular<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">85</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib 15 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n f&#237;sica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Marcada mejor&#237;a en la sexta semana&#46; Remisi&#243;n casi completa tras cuatro meses de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hidradenitis supurativa<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">86</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudio retrospectivo &#40;n &#61; 20&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib 15 mg diarios<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Proporci&#243;n de individuos que alcanzaron mejoras de 50&#44; 75 y 90&#37; en el criterio de valoraci&#243;n de la HiSCR&#46; DLQI y puntuaciones de dolor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Semana cuatro&#58;<span class="elsevierStyleHsp" style=""></span>- HiSCR50&#58; 75&#37;<span class="elsevierStyleHsp" style=""></span>- HiSCR75&#58; 30&#37;<span class="elsevierStyleHsp" style=""></span>- HiSCR90&#58; 20&#37;Semana 12&#58;<span class="elsevierStyleHsp" style=""></span>- HiSCR50&#58; 100&#37;<span class="elsevierStyleHsp" style=""></span>- HiSCR75&#58; 95&#37;<span class="elsevierStyleHsp" style=""></span>- HiSCR90&#58; 30&#37;El DLQI y el &#237;ndice de dolor se redujeron significativamente en la cuarta semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Elevaci&#243;n de CPK &#40;80&#37;&#41;&#44; COVID-19 &#40;15&#37;&#41;&#44; elevaci&#243;n transitoria de enzimas hep&#225;ticas &#40;10&#37;&#41;&#44; reactivaci&#243;n de herpes zoster &#40;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Eritema multiforme persistente<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">84</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib 15 mg diarios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Examen f&#237;sico e informe del paciente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Marcada mejor&#237;a de las manifestaciones orales y cut&#225;neas y respuesta sostenida tras 25 meses de seguimiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295032.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Upadacitinib 30 mg diarios se administr&#243; en individuos refractarios en la semana cuatro&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Uso fuera de ficha t&#233;cnica del upadacitinib en Dermatolog&#237;a</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Tabla 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">ECA&#58; ensayo controlado aleatorizado&#59; EICHc&#58; enfermedad cr&#243;nica del injerto contra el hu&#233;sped&#59; LP&#58; liquen plano&#59; mCAILS&#58; puntuaci&#243;n de la evaluaci&#243;n compuesta modificada del &#237;ndice de gravedad de las lesiones&#59; SALT&#58; herramienta de puntuaci&#243;n de la severidad de la alopecia&#59; SC&#58; superficie corporal&#59; EVA&#58; escala visual anal&#243;gica&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M&#225;ximo grado de evidencia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dosificaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Medidas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultados&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Acontecimientos adversos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia areata<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">26&#44;87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dos ECA &#40;n &#61; 16 y n &#61; 78&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pomada de ruxolitinib al 1-1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SALT<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">24</span></a>&#59; evaluaci&#243;n global del investigador y del paciente<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">86</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">De los pacientes&#44; 50&#37; alcanzaron SALT50 en la semana 24&#44; pero el ECA no pudo demostrar ninguna diferencia significativa en SALT en comparaci&#243;n con el veh&#237;culo<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">24</span></a>De los pacientes&#44; 31&#37; mostraron un recrecimiento parcial del vello en las zonas tratadas frente a 63&#37; con clobetasol al 0&#44;05&#37;<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">86</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se informaron de hallazgos significativos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Psoriasis<a class="elsevierStyleCrossRef" href="#bib1000"><span class="elsevierStyleSup">96</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ECA &#40;n &#61; 29&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 0&#44;5&#37; diarios a 1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Puntuaci&#243;n total de la lesi&#243;n&#58; eritema &#40;0-3&#41;&#44; descamaci&#243;n &#40;0-3&#41; y grosor &#40;0-3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib al 1&#37; aplicado a diario y al 1&#44;5&#37; aplicado dos veces al d&#237;a produjo una disminuci&#243;n no estad&#237;sticamente significativa de 53-54&#37; en la puntuaci&#243;n total de la lesi&#243;n&#44; frente a 32&#37; con el veh&#237;culo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Efectos adversos locales &#40;escozor&#44; picor&#44; irritaci&#243;n&#44; dolor&#44; sequedad&#44; exfoliaci&#243;n&#44; enrojecimiento&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatitis seborreica<a class="elsevierStyleCrossRef" href="#bib1020"><span class="elsevierStyleSup">100</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resoluci&#243;n completa tras dos semanas de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LP<a class="elsevierStyleCrossRef" href="#bib0990"><span class="elsevierStyleSup">94</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estudio abierto &#40;n &#61; 12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">mCAILS&#44; recuento total de lesiones&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">El recuento total de las lesiones disminuy&#243; en una mediana de 50 lesiones&#44; y el mCAILS disminuy&#243; en una diferencia media de 7&#44;6 entre las lesiones tratadas y las de control en la semana ocho&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notificaron acontecimientos adversos graves&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">EICHc cut&#225;neo<a class="elsevierStyleCrossRef" href="#bib0980"><span class="elsevierStyleSup">92</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N de un ensayo cl&#237;nico &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SC&#44; EVA del prurito&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejora de 6&#44;4&#37; en la SC de las lesiones tratadas&#44; frente a 3&#44;81&#37; de las lesiones tratadas con veh&#237;culo en la semana seis&#46; La mejor&#237;a del prurito no fue superior a la del placebo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ninguna atribuible a ruxolitinib t&#243;pico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lupus eritematoso cut&#225;neo<a class="elsevierStyleCrossRef" href="#bib0985"><span class="elsevierStyleSup">93</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 1&#44;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a en las placas tratadas y sutil recrecimiento del vello tras dos meses de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Necrobiosis lipoidica<a class="elsevierStyleCrossRef" href="#bib0995"><span class="elsevierStyleSup">95</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reporte de caso &#40;n &#61; 1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ruxolitinib 1&#44;5&#37; dos veces al d&#237;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exploraci&#243;n cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">El cambio de tofacitinib 2&#37; condujo a una marcada mejor&#237;a en el color y tama&#241;o despu&#233;s de tres meses de tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No se notific&#243; ninguno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295033.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Uso fuera de ficha t&#233;cnica del ruxolitinib t&#243;pico en dermatolog&#237;a</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0030"
        "etiqueta" => "Tabla 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at6"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">EMA&#58; Agencia Europea de Medicamentos&#59; JAK&#58; quinasa Janus&#59; PRAC&#58; Comit&#233; de Evaluaci&#243;n de Riesgos en Farmacovigilancia&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Propuesto por un grupo de trabajo multidisciplinar internacional de expertos en inhibidores de JAK en enfermedades inflamatorias<a class="elsevierStyleCrossRef" href="#bib1025"><span class="elsevierStyleSup">101</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Propuesto por el PRAC y aprobado por la EMA<a class="elsevierStyleCrossRef" href="#bib1030"><span class="elsevierStyleSup">102</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Ajustes de la dosis en situaciones especiales en pacientes tratados con inhibidores de JAK orales seg&#250;n el respectivo Resumen de las Caracter&#237;sticas del Producto de la EMA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Antes del tratamiento</span><span class="elsevierStyleHsp" style=""></span>&#8226; Historia cl&#237;nica completa<span class="elsevierStyleHsp" style=""></span>&#8226; Radiograf&#237;a de t&#243;rax<span class="elsevierStyleHsp" style=""></span>&#8226; Exploraci&#243;n basal de c&#225;ncer de piel<span class="elsevierStyleHsp" style=""></span>&#8226; An&#225;lisis de sangre completo &#40;hemograma&#44; enzimas hep&#225;ticas&#44; funci&#243;n renal&#44; niveles de l&#237;pidos y serolog&#237;as para VHB y VIH&#41;<span class="elsevierStyleHsp" style=""></span>&#8226; Detecci&#243;n de la tuberculosis<span class="elsevierStyleHsp" style=""></span>&#8226; Comprobaci&#243;n del estado vacunal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Restringir el uso de inhibidores de JAK a cuando no se disponga de otras opciones y preferiblemente a dosis m&#225;s bajas&#44; en pacientes con mayor riesgo de acontecimientos adversos graves&#58;<span class="elsevierStyleHsp" style=""></span>&#8226; Pacientes &#62; 65 a&#241;os<span class="elsevierStyleHsp" style=""></span>&#8226; Fumadores o exfumadores de larga duraci&#243;n<span class="elsevierStyleHsp" style=""></span>&#8226; Antecedentes de enfermedad cardiovascular<span class="elsevierStyleHsp" style=""></span>&#8226; Presencia de eventos tromboemb&#243;licos venosos o factores de riesgo de c&#225;ncer</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Baricitinib</span>La dosis recomendada para los trastornos dermatol&#243;gicos es de 4 mg diarios&#46; En pacientes de edad &#8805; 75 a&#241;os o con antecedentes de infecciones cr&#243;nicas o recurrentes&#44; debe considerarse una reducci&#243;n de la dosis a 2 mg diarios&#46; Baricitinib puede requerir ajustes de dosis en caso de insuficiencia renal<span class="elsevierStyleBold">Upadacitinib</span>La dosis recomendada para la dermatitis at&#243;pica es de 15-30 mg diarios&#46; La dosis de 15 mg diarios debe considerarse especialmente en adolescentes y pacientes de &#8805; 65 a&#241;os<span class="elsevierStyleBold">Abrocitinib</span>La dosis inicial recomendada para la dermatitis at&#243;pica es de 200 mg diarios&#46; Sin embargo&#44; la dosificaci&#243;n de 100 mg diarios debe considerarse especialmente en pacientes con insuficiencia renal moderada y pacientes de edad &#8805; 65 a&#241;os</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Durante el tratamiento</span><span class="elsevierStyleHsp" style=""></span>&#8226; Exploraci&#243;n peri&#243;dica de la piel<span class="elsevierStyleHsp" style=""></span>&#8226; Ex&#225;menes de sangre peri&#243;dicos &#40;primer y tercer mes&#44; luego peri&#243;dicamente como cada tres meses&#41;<span class="elsevierStyleHsp" style=""></span>&#8226; Vacunaci&#243;n antineumoc&#243;cica y antigripal<span class="elsevierStyleHsp" style=""></span>&#8226; Vacuna contra el virus del herpes z&#243;ster en caso de serolog&#237;a positiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295030.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Resumen de recomendaciones de pretratamiento y seguimiento del tratamiento en pacientes que reciben inhibidores de JAK</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0035"
        "etiqueta" => "Tabla 7"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at7"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">AIJ&#58; artitis idiop&#225;tica juvenil&#59; JAK&#58; Janus quinasa&#59; EICHc&#58; enfermedad cr&#243;nica del injerto contra el hu&#233;sped&#59; LP&#58; liquen plano&#59; SAVI&#58; vasculopat&#237;a asociada a STING de inicio en la infancia&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dermatosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No&#46; de estudios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No&#46; de pacientes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Inhibidores de JAK&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Acrodermatitis continua de Hallopeau</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0870"><span class="elsevierStyleSup">70</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Alopecia areata</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abrocitinib&#44;<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">30</span></a> upadacitinib<a class="elsevierStyleCrossRefs" href="#bib0910"><span class="elsevierStyleSup">78&#8211;81</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dermatitis de contacto</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abrocitinib<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">31</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dermatomiositis &#40;del adulto y juvenil&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0755"><span class="elsevierStyleSup">47&#8211;49&#44;60&#8211;64</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Fascitis eosinof&#237;lica</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">50</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Eritema multiforme</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">84</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Alopecia frontal fibrosante</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0710"><span class="elsevierStyleSup">38&#44;51</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Granuloma anular</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib&#44;<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">85</span></a> baricitinib<a class="elsevierStyleCrossRefs" href="#bib0785"><span class="elsevierStyleSup">53&#8211;55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">EICHc</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">42</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Eccema de manos &#40;cr&#243;nico&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">43</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hidradenitis supurativa</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">86</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">S&#237;ndrome hipereosinof&#237;lico</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0800"><span class="elsevierStyleSup">56</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">LP</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upadacitinib&#44;<a class="elsevierStyleCrossRefs" href="#bib0930"><span class="elsevierStyleSup">82&#44;83</span></a> baricitinib<a class="elsevierStyleCrossRefs" href="#bib0775"><span class="elsevierStyleSup">51&#44;65</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Vasculopat&#237;a livedoide</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0850"><span class="elsevierStyleSup">66&#8211;68</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Lupus eritematoso &#40;cut&#225;neo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0705"><span class="elsevierStyleSup">37&#8211;41</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Morfea &#40;generalizada&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">52</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Trastornos autoinflamatorios</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib&#44;<a class="elsevierStyleCrossRefs" href="#bib0680"><span class="elsevierStyleSup">32&#8211;36</span></a> upadacitinib<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">34</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Enfermedad de Still del adulto&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Aicardi-Gouti&#232;res&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Blau&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de Candle&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome CANDLE-like&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome de mutaciones de GOF en STAT1&#8217;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome SAVI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>AIJ sist&#233;mica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome VEXAS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Enfermedades ampollosas autoinmunes</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0805"><span class="elsevierStyleSup">57&#8211;59</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Penfigoide ampolloso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Epiderm&#243;lisis ampollosa pruriginosa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>LP penfigoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Penfigoide de la mucosa ocular&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Prurigo nodular cr&#243;nico</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0740"><span class="elsevierStyleSup">44&#8211;46</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Psoriasis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">271&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">18</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pioderma gangrenoso</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">71</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">S&#237;ndrome de Sweet</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">72</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Esclerosis sist&#233;mica</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRefs" href="#bib0885"><span class="elsevierStyleSup">73&#8211;76</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Vit&#237;ligo</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baricitinib<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">77</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295029.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Uso fuera de ficha t&#233;cnica en Dermatolog&#237;a de los inhibidores de JAK orales &#40;abrocitinib&#44; baricitinib y upadacitinib&#41;</p>"
        ]
      ]
      7 => array:5 [
        "identificador" => "fig0005"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 1085
            "Ancho" => 857
            "Tamanyo" => 134049
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:104 [
            0 => array:3 [
              "identificador" => "bib0525"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primer&#58; signal transduction in rheumatic disease &#8211; a clinician&#39;s guide"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/ncprheum0631"
                      "Revista" => array:7 [
                        "tituloSerie" => "Nat Clin Pract Rheumatol&#46;"
                        "fecha" => "2007"
                        "volumen" => "3"
                        "paginaInicial" => "651"
                        "paginaFinal" => "660"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0530"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "New-generation JAK inhibitors&#58; how selective can they be&#63;"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(18)31325-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet&#46;"
                        "fecha" => "2018"
                        "volumen" => "391"
                        "paginaInicial" => "2477"
                        "paginaFinal" => "2478"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0535"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Emerging topical and systemic JAK inhibitors in dermatology"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fimmu.2019.02847"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Immunol&#46;"
                        "fecha" => "2019"
                        "volumen" => "10"
                        "paginaInicial" => "2847"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0540"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adverse events associated with JAK inhibitors in 126&#44;815 reports from the WHO pharmacovigilance database"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/s41598-022-10777-w"
                      "Revista" => array:5 [
                        "tituloSerie" => "Sci Rep&#46;"
                        "fecha" => "2022"
                        "volumen" => "12"
                        "paginaInicial" => "7140"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0545"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Janus kinase inhibitors in dermatology&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2016.12.004"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "76"
                        "paginaInicial" => "745"
                        "paginaFinal" => "753&#46;e19"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0550"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK inhibitor safety compared to traditional systemic immunosuppressive therapies"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.36849/JDD.7187"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Drugs Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "21"
                        "paginaInicial" => "1298"
                        "paginaFinal" => "1303"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0555"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Venous thromboembolism risk with JAK inhibitors&#58; a meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.41580"
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Rheumatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "73"
                        "paginaInicial" => "779"
                        "paginaFinal" => "788"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0560"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2022.3516"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "158"
                        "paginaInicial" => "1254"
                        "paginaFinal" => "1261"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0565"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK in the &#91;black&#93; box&#58; a dermatology perspective on systemic JAK inhibitor safety"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40257-022-00701-3"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "23"
                        "paginaInicial" => "427"
                        "paginaFinal" => "431"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0570"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40257-021-00618-3"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "22"
                        "paginaInicial" => "693"
                        "paginaFinal" => "707"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0575"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis&#58; the JADE TEEN randomized clinical trial"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.2830"
                      "Revista" => array:7 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "157"
                        "paginaInicial" => "1165"
                        "paginaFinal" => "1173"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0580"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systemic immunomodulatory treatments for atopic dermatitis&#58; update of a living systematic review and network meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2022.0455"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "158"
                        "paginaInicial" => "523"
                        "paginaFinal" => "532"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0585"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Population pharmacokinetic&#8211;pharmacodynamic modelling of platelet time-courses following administration of abrocitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bcp.15334"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Clin Pharmacol&#46;"
                        "fecha" => "2022"
                        "volumen" => "88"
                        "paginaInicial" => "3856"
                        "paginaFinal" => "3871"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0590"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A review of safety outcomes from clinical trials of baricitinib in rheumatology&#44; dermatology and COVID-19"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12325-022-02281-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Adv Ther&#46;"
                        "fecha" => "2022"
                        "volumen" => "39"
                        "paginaInicial" => "4910"
                        "paginaFinal" => "4960"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0595"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.16948"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2021"
                        "volumen" => "35"
                        "paginaInicial" => "476"
                        "paginaFinal" => "485"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0600"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis&#58; an integrated analysis from eight randomized clinical trials"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40257-021-00602-x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "22"
                        "paginaInicial" => "395"
                        "paginaFinal" => "405"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0605"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/bjd/ljac059"
                      "Revista" => array:5 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2023"
                        "volumen" => "188"
                        "paginaInicial" => "218"
                        "paginaFinal" => "227"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0610"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A randomized phase 2 b trial of baricitinib&#44; an oral Janus kinase &#40;JAK&#41; 1&#47;JAK2 inhibitor&#44; in patients with moderate-to-severe psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.14403"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2016"
                        "volumen" => "174"
                        "paginaInicial" => "1266"
                        "paginaFinal" => "1276"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0615"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis &#40;Measure Up 1 and Measure Up 2&#41;&#58; results from two replicate double-blind&#44; randomised controlled phase 3 trials"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(21)00588-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet&#46;"
                        "fecha" => "2021"
                        "volumen" => "397"
                        "paginaInicial" => "2151"
                        "paginaFinal" => "2168"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0620"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis&#58; a randomized clinical trial"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.3023"
                      "Revista" => array:7 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "157"
                        "paginaInicial" => "1047"
                        "paginaFinal" => "1055"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0625"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis &#40;AD Up&#41;&#58; results from a randomised&#44; double-blind&#44; placebo-controlled&#44; phase 3 trial"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(21)00589-4"
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet&#46;"
                        "fecha" => "2021"
                        "volumen" => "397"
                        "paginaInicial" => "2169"
                        "paginaFinal" => "2181"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0630"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Upadacitinib in adults with moderate to severe atopic dermatitis&#58; 16-week results from a randomized&#44; placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaci.2019.11.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "145"
                        "paginaInicial" => "877"
                        "paginaFinal" => "884"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0635"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis&#63; A systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/1756-185X.14447"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Rheum Dis&#46;"
                        "fecha" => "2023"
                        "volumen" => "26"
                        "paginaInicial" => "31"
                        "paginaFinal" => "42"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0640"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis&#44; psoriatic arthritis&#44; ankylosing spondylitis and atopic dermatitis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/rmdopen-2022-002735"
                      "Revista" => array:5 [
                        "tituloSerie" => "RMD Open&#46;"
                        "fecha" => "2023"
                        "volumen" => "9"
                        "paginaInicial" => "e002735"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0645"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical Janus kinase inhibitors&#58; a review of applications in dermatology"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2018.04.018"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "79"
                        "paginaInicial" => "535"
                        "paginaFinal" => "544"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0650"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ruxolitinib cream for the treatment of patients with alopecia areata&#58; a 2-part&#44; double-blind&#44; randomized&#44; vehicle-controlled phase 2 study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2019.10.016"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "82"
                        "paginaInicial" => "412"
                        "paginaFinal" => "419"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0655"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Role of Janus kinase inhibitors in therapy of psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/jcm10194307"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Clin Med&#46;"
                        "fecha" => "2021"
                        "volumen" => "10"
                        "paginaInicial" => "4307"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0660"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of atopic dermatitis with ruxolitinib cream &#40;JAK1&#47;JAK2 inhibitor&#41; or triamcinolone cream"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaci.2019.08.042"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "145"
                        "paginaInicial" => "572"
                        "paginaFinal" => "582"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0665"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis&#58; results from 2 phase 3&#44; randomized&#44; double-blind studies"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2021.04.085"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "85"
                        "paginaInicial" => "863"
                        "paginaFinal" => "872"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0670"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2022.02.027"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAAD Case Rep&#46;"
                        "fecha" => "2022"
                        "volumen" => "22"
                        "paginaInicial" => "99"
                        "paginaFinal" => "100"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0675"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Occupational airborne allergic contact dermatitis to invasive compositae species treated with abrocitinib&#58; a reporte de caso"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cod.14204"
                      "Revista" => array:5 [
                        "tituloSerie" => "Contact Dermat&#46;"
                        "fecha" => "2022"
                        "volumen" => "87"
                        "paginaInicial" => "542"
                        "paginaFinal" => "544"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0680"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of Janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders&#58; a scoping review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s13555-021-00517-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Ther &#40;Heidelb&#41;&#46;"
                        "fecha" => "2021"
                        "volumen" => "11"
                        "paginaInicial" => "733"
                        "paginaFinal" => "750"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0685"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome&#58; reporte de caso and literature review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1759720X221093211"
                      "Revista" => array:3 [
                        "tituloSerie" => "Ther Adv Musculoskelet Dis&#46;"
                        "fecha" => "2022"
                        "volumen" => "14"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0690"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness and safety of JAK inhibitors in autoinflammatory diseases&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fmed.2022.930071"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Med &#40;Lausanne&#41;&#46;"
                        "fecha" => "2022"
                        "volumen" => "9"
                        "paginaInicial" => "930071"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0695"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome&#58; a retrospective multicenter study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood.2022016642"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "2022"
                        "volumen" => "140"
                        "paginaInicial" => "927"
                        "paginaFinal" => "931"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0700"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of refractory adult onset Still&#39;s disease with combination anakinra and baricitinib therapy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/key414"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2019"
                        "volumen" => "58"
                        "paginaInicial" => "736"
                        "paginaFinal" => "737"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0705"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessment of clinical response to Janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2018.5077"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "155"
                        "paginaInicial" => "342"
                        "paginaFinal" => "346"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0710"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.15044"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "47"
                        "paginaInicial" => "787"
                        "paginaFinal" => "788"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0715"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of JAK 1&#47;2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2019-216571"
                      "Revista" => array:7 [
                        "tituloSerie" => "Ann Rheum Dis&#46;"
                        "fecha" => "2020"
                        "volumen" => "79"
                        "paginaInicial" => "674"
                        "paginaFinal" => "675"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0720"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.15005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "47"
                        "paginaInicial" => "748"
                        "paginaFinal" => "750"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0725"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/kez442"
                      "Revista" => array:4 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2019"
                        "volumen" => "59"
                        "paginaInicial" => "1792"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0730"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease &#40;cGVHD&#41;&#58; preliminary analysis results of a phase 1&#47;2 study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2020-140392"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "2020"
                        "volumen" => "136"
                        "numero" => "Suppl&#46; 1"
                        "paginaInicial" => "1"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0735"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Baricitinib treatment of severe chronic hand eczema&#58; two reporte de casos"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cod.14039"
                      "Revista" => array:6 [
                        "tituloSerie" => "Contact Dermat&#46;"
                        "fecha" => "2022"
                        "volumen" => "86"
                        "paginaInicial" => "419"
                        "paginaFinal" => "421"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0740"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness of baricitinib in prurigo-type atopic dermatitis&#58; a reporte de caso"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.14878"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2021"
                        "volumen" => "34"
                        "paginaInicial" => "e14878"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0745"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Improvement of chronic nodular prurigo with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.17991"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2022"
                        "volumen" => "36"
                        "paginaInicial" => "e486"
                        "paginaFinal" => "e488"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0750"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment of refractory prurigo nodularis with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15642"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Therapy&#46;"
                        "fecha" => "2022"
                        "volumen" => "35"
                        "paginaInicial" => "e15642"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0755"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Baricitinib for the treatment of cutaneous dermatomyositis&#58; a prospective&#44; open-label study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2022.08.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "87"
                        "paginaInicial" => "1374"
                        "paginaFinal" => "1376"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0760"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.21252"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "187"
                        "paginaInicial" => "432"
                        "paginaFinal" => "435"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0765"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/keaa377"
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2020"
                        "volumen" => "59"
                        "paginaInicial" => "4003"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0770"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment with baricitinib in a patient with refractory eosinophilic fasciitis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3899/jrheum.200998"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "48"
                        "paginaInicial" => "948"
                        "paginaFinal" => "949"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0775"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of lichen planopilaris with baricitinib&#58; a retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2022.02.027"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "87"
                        "paginaInicial" => "663"
                        "paginaFinal" => "666"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0780"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Jak inhibition prevents bleomycin-induced fibrosis in mice and is effective in patients with morphea"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jid.2019.12.019"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Invest Dermatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "140"
                        "paginaInicial" => "1446"
                        "paginaFinal" => "1449&#46;e4"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0785"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rapid improvement of refractory generalized granuloma annulare with the Janus kinase inhibitor baricitinib in two patients"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ced/llac110"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2023"
                        "volumen" => "48"
                        "paginaInicial" => "375"
                        "paginaFinal" => "376"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0790"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Recalcitrant granuloma annulare induced by two different biologic agents resolved after Janus kinase inhibitor treatment"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15641"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2022"
                        "volumen" => "35"
                        "paginaInicial" => "e15641"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0795"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment of generalized granuloma annulare with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.18031"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2022"
                        "volumen" => "36"
                        "paginaInicial" => "e500"
                        "paginaFinal" => "e502"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0800"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hypereosinophilic syndrome &#8211; a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s10067-020-05134-z"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Rheumatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "39"
                        "paginaInicial" => "3507"
                        "paginaFinal" => "3510"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0805"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A literature review on Janus kinase &#40;JAK&#41; inhibitors for the treatment of immunobullous disorders"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.intimp.2022.108923"
                      "Revista" => array:5 [
                        "tituloSerie" => "Int Immunopharmacol&#46;"
                        "fecha" => "2022"
                        "volumen" => "110"
                        "paginaInicial" => "108923"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0810"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15754"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2022"
                        "volumen" => "35"
                        "paginaInicial" => "e15754"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0815"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effective treatment of refractory lichen planus pemphigoides with a Janus kinase-1&#47;2 inhibitor"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.15344"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "47"
                        "paginaInicial" => "2040"
                        "paginaFinal" => "2041"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0820"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Janus kinase &#40;JAK&#41; inhibition with baricitinib in refractory juvenile dermatomyositis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2020-218690"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis&#46;"
                        "fecha" => "2021"
                        "volumen" => "80"
                        "paginaInicial" => "406"
                        "paginaFinal" => "408"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0825"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The efficacy of baricitinib in real-world patients with refractory or severe juvenile dermatomyositis&#58; a monocentric retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.21203/rs.3.rs-1226720/v1"
                      "Revista" => array:3 [
                        "tituloSerie" => "Research Square&#46;"
                        "fecha" => "2022"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0830"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis&#58; a monocentric retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/keab116"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2021"
                        "volumen" => "60"
                        "paginaInicial" => "5801"
                        "paginaFinal" => "5808"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib0835"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Janus kinase 1&#47;2 inhibition with baricitinib in the treatment of juvenile dermatomyositis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/brain/awz005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Brain&#46;"
                        "fecha" => "2019"
                        "volumen" => "142"
                        "paginaInicial" => "e8"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib0840"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive&#44; bisphosphonate&#44; oral baricitinib and physical therapy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15960"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2022"
                        "volumen" => "35"
                        "paginaInicial" => "e15960"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib0845"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of severe nail lichen planus with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.5082"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2022"
                        "volumen" => "158"
                        "paginaInicial" => "107"
                        "paginaFinal" => "108"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib0850"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fimmu.2022.1008392"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Immunol&#46;"
                        "fecha" => "2022"
                        "volumen" => "13"
                        "paginaInicial" => "1008392"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib0855"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Refractory livedoid vasculopathy in a child successfully treated with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15659"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2022"
                        "volumen" => "35"
                        "paginaInicial" => "e15659"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib0860"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Refractory livedoid vasculopathy successfully treated with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ijd.16467"
                      "Revista" => array:2 [
                        "tituloSerie" => "Int J Dermatol&#46;"
                        "fecha" => "2022"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib0865"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The efficacy and safety of tofacitinib&#44; peficitinib&#44; solcitinib&#44; baricitinib&#44; abrocitinib and deucravacitinib in plaque psoriasis &#8211; a network meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.18263"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2022"
                        "volumen" => "36"
                        "paginaInicial" => "1937"
                        "paginaFinal" => "1946"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib0870"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inhibition of progression of acrodermatitis continua of hallopeau with baricitinib"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.0045"
                      "Revista" => array:7 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "157"
                        "paginaInicial" => "466"
                        "paginaFinal" => "468"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            70 => array:3 [
              "identificador" => "bib0875"
              "etiqueta" => "71"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment of ulcerated pyoderma gangrenosum with baricitinib&#44; a novel JAK inhibitor"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jtauto.2021.100099"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Transl Autoimmun&#46;"
                        "fecha" => "2021"
                        "volumen" => "4"
                        "paginaInicial" => "100099"
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            71 => array:3 [
              "identificador" => "bib0880"
              "etiqueta" => "72"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.14712"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "46"
                         …3
                      ]
                    ]
                  ]
                ]
              ]
            ]
            72 => array:3 [
              "identificador" => "bib0885"
              "etiqueta" => "73"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK1&#47;2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fmed.2022.859330"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            73 => array:3 [
              "identificador" => "bib0890"
              "etiqueta" => "74"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib&#58; A Novel Case Report"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1155/2019/5293981"
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            74 => array:3 [
              "identificador" => "bib0895"
              "etiqueta" => "75"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.55563/clinexprheumatol/gu1ac8"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            75 => array:3 [
              "identificador" => "bib0900"
              "etiqueta" => "76"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK inhibitors and systemic sclerosis&#58; A systematic review of the literature"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.autrev.2022.103168"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            76 => array:3 [
              "identificador" => "bib0905"
              "etiqueta" => "77"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Repigmentation of vitiligo with oral baricitinib"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ajd.13348"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            77 => array:3 [
              "identificador" => "bib0910"
              "etiqueta" => "78"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Upadacitinib improved alopecia areata in a patient with atopic dermatitis&#58; A case report"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15346"
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            78 => array:3 [
              "identificador" => "bib0915"
              "etiqueta" => "79"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient&#58; A case report"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/2050313X221138452"
                      "Revista" => array:3 [ …3]
                    ]
                  ]
                ]
              ]
            ]
            79 => array:3 [
              "identificador" => "bib0920"
              "etiqueta" => "80"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ijd.16316"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            80 => array:3 [
              "identificador" => "bib0925"
              "etiqueta" => "81"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effective treatment of alopecia universalis with oral upadacitinib"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2022.08.014"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            81 => array:3 [
              "identificador" => "bib0930"
              "etiqueta" => "82"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of Oral Erosive Lichen Planus With Upadacitinib"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2022.0147"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            82 => array:3 [
              "identificador" => "bib0935"
              "etiqueta" => "83"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK inhibitors in lichen planus&#58; a review of pathogenesis and treatments"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546634.2022.2116926"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            83 => array:3 [
              "identificador" => "bib0940"
              "etiqueta" => "84"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.4084"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            84 => array:3 [
              "identificador" => "bib0945"
              "etiqueta" => "85"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful therapy of disseminated patch-type granuloma annulare with upadacitinib in a patient with rheumatoid arthritis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.15211"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            85 => array:3 [
              "identificador" => "bib0950"
              "etiqueta" => "86"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "AbbVie&#46; A phase 2&#44; multicenter&#44; randomized&#44; placebo-controlled&#44; double-blind study to evaluate upadacitinib in adult subjects with moderate to severe hidradenitis suppurativa&#46; clinicaltrials&#46;gov&#59; 2023&#46; &#91;Internet&#93;&#44; &#91;consultado 29 Mar 2023&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT04430855">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT04430855</a>"
                ]
              ]
            ]
            86 => array:3 [
              "identificador" => "bib0955"
              "etiqueta" => "87"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of alopecia universalis with topical Janus kinase inhibitors &#8211; a double blind&#44; placebo&#44; and active controlled pilot study"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ijd.14192"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            87 => array:3 [
              "identificador" => "bib0960"
              "etiqueta" => "88"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2017.03.024"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            88 => array:3 [
              "identificador" => "bib0965"
              "etiqueta" => "89"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.15383"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            89 => array:3 [
              "identificador" => "bib0970"
              "etiqueta" => "90"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical Ruxolitinib for the Treatment of Alopecia Universalis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2015.4445"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            90 => array:3 [
              "identificador" => "bib0975"
              "etiqueta" => "91"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A case of Topical Ruxolitinib Treatment Failure in Alopecia Areata"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1203475417716363"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            91 => array:3 [
              "identificador" => "bib0980"
              "etiqueta" => "92"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Cowen E&#44; Phase II study of topical ruxolitinib for cutaneous chronic graft versus host disease &#40;CGVHD&#41;&#46; clinicaltrials&#46;gov&#59; 2022&#46; &#91;Internet&#93;&#44; &#91;consultado 29 Mar 2023&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/study/NCT03395340">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;study&#47;NCT03395340</a>"
                ]
              ]
            ]
            92 => array:3 [
              "identificador" => "bib0985"
              "etiqueta" => "93"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of cutaneous lupus with topical ruxolitinib cream"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2022.08.038"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            93 => array:3 [
              "identificador" => "bib0990"
              "etiqueta" => "94"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus&#58; A Prospective&#44; Open-Label Study"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jid.2022.01.015"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            94 => array:3 [
              "identificador" => "bib0995"
              "etiqueta" => "95"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2022.08.028"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            95 => array:3 [
              "identificador" => "bib1000"
              "etiqueta" => "96"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Preliminary clinical activity of a topical JAK1&#47;2 inhibitor in the treatment of psoriasis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2011.12.018"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            96 => array:3 [
              "identificador" => "bib1005"
              "etiqueta" => "97"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Downmodulation of key inflammatory cell markers with a topical Janus kinase 1&#47;2 inhibitor"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.13994"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            97 => array:3 [
              "identificador" => "bib1010"
              "etiqueta" => "98"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Incyte Corporation&#46; A double-blind&#44; randomized&#44; vehicle-controlled dose ranging study of the effect of INCB018424 phosphate cream when applied to patients with plaque psoriasis&#46; clinicaltrials&#46;gov&#59; 2022&#46; &#91;Internet&#93;&#44; &#91;consultado 29 Mar 2023&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT00778700">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT00778700</a>"
                ]
              ]
            ]
            98 => array:3 [
              "identificador" => "bib1015"
              "etiqueta" => "99"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Incyte Corporation&#46; An open label&#44; safety&#44; tolerability&#44; pharmacokinetic &#40;PK&#41;&#44; pharmacodynamic &#40;PD&#41; and preliminary efficacy study of ruxolitinib when applied to patients with plaque psoriasis involving 2&#8211;20&#37; body surface area &#40;BSA&#41;&#46; clinicaltrials&#46;gov&#59; 2022&#46; &#91;Internet&#93;&#44; &#91;consultado 29 Mar 2023&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT00617994">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT00617994</a>"
                ]
              ]
            ]
            99 => array:3 [
              "identificador" => "bib1020"
              "etiqueta" => "100"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2022.04.003"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            100 => array:3 [
              "identificador" => "bib1025"
              "etiqueta" => "101"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors&#58; a consensus statement"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2020-218398"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            101 => array:3 [
              "identificador" => "bib1030"
              "etiqueta" => "102"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "EMA&#46; EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders&#46; European Medicines Agency&#46; &#91;Internet&#93;&#44; &#91;consultado 30 Mar 2023&#93;&#46; Disponible en&#58; <a target="_blank" href="https://www.ema.europa.eu/en/news/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic">https&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;en&#47;news&#47;ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic</a>"
                ]
              ]
            ]
            102 => array:3 [
              "identificador" => "bib1035"
              "etiqueta" => "103"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Herpes zoster subunit vaccine for patients initiating a Janus kinase inhibitor"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2022.08.040"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            103 => array:3 [
              "identificador" => "bib1040"
              "etiqueta" => "104"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impact of off-label use regulations on patient care in dermatology &#8211; a prospective study of cost-coverage applications filed by tertiary dermatology clinics throughout Germany"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.18357"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023006397/v1_202310020456/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6158"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Revisiones"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011400000009/v1_202310020456/S0001731023006397/v1_202310020456/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023006397?idApp=UINPBA000044"
]
Información del artículo
ISSN: 00017310
Idioma original: Español
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 33 14 47
2024 Octubre 361 98 459
2024 Septiembre 340 79 419
2024 Agosto 445 135 580
2024 Julio 411 88 499
2024 Junio 440 92 532
2024 Mayo 432 90 522
2024 Abril 344 77 421
2024 Marzo 349 74 423
2024 Febrero 283 67 350
2024 Enero 261 73 334
2023 Diciembre 261 86 347
2023 Noviembre 280 116 396
2023 Octubre 299 155 454
2023 Septiembre 201 90 291
2023 Agosto 183 136 319
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?